



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ :		A1	(11) International Publication Number:	WO 99/26961					
C07H 21/04, 21/02, C12N 15/11, 15/00, 1/21, 15/63, C07K 14/00, A61K 38/00, C12P 19/34			(43) International Publication Date:	3 June 1999 (03.06.99)					
(21) International Application Number:		PCT/US98/25149	(72) Inventors:						
(22) International Filing Date:		24 November 1998 (24.11.98)	JACOBS, Kenneth; 151 Beaumont Avenue, Newton, MA 02160 (US). MCCOY, John, M.; 56 Howard Street, Reading, MA 01867 (US). LAVALLIE, Edward, R.; 113 Ann Lee Road, Harvard, MA 01451 (US). COLLINS-RACIE, Lisa, A.; 124 School Street, Acton, MA 01720 (US). EVANS, Cheryl; 307 Brighton Drive, Beverly, MA 01915 (US). MERBERG, David; 2 Orchard Drive, Acton, MA 01720 (US). TREACY, Maurice; 93 Walcott Road, Chestnut Hill, MA 02167 (US). AGOSTINO, Michael, J.; 26 Wolcott Avenue, Andover, MA 01810 (US). STEININGER, Robert, J., II; 100 Reed Street, Cambridge, MA 02140 (US). WONG, Gordon, G.; 239 Clark Road, Brookline, MA 02146 (US). CLARK, Hilary, F.; 146 Webster Avenue #2, Cambridge, MA 02141 (US). FECHTEL, Kim; 46 Marion Road, Arlington, MA 02174 (US).						
(30) Priority Data:		26 November 1997 (26.11.97) US 23 November 1998 (23.11.98) US	(74) Agent:						
(71) Applicant:		GENETICS INSTITUTE, INC. [US/US]; 87 CambridgePark Drive, Cambridge, MA 02140 (US).	SPRUNGER, Suzanne, A.; Genetics Institute, Inc., 87 CambridgePark Drive, Cambridge, MA 02140 (US).						
(81) Designated States:		AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).							
(54) Title:		Published <i>With international search report.</i>							
(57) Abstract									
Novel polynucleotides and the proteins encoded thereby are disclosed.									

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		

SECRETED PROTEINS AND POLYNUCLEOTIDES ENCODING THEM

5 This application is a continuation-in-part of provisional application Ser. No. 60/066,804, filed November 26, 1997, which is incorporated by reference herein.

FIELD OF THE INVENTION

10 The present invention provides novel polynucleotides and proteins encoded by such polynucleotides, along with therapeutic, diagnostic and research utilities for these polynucleotides and proteins.

BACKGROUND OF THE INVENTION

15 Technology aimed at the discovery of protein factors (including e.g., cytokines, such as lymphokines, interferons, CSFs and interleukins) has matured rapidly over the past decade. The now routine hybridization cloning and expression cloning techniques clone novel polynucleotides "directly" in the sense that they rely on information directly related to the discovered protein (i.e., partial DNA/amino acid sequence of the protein in the case of hybridization cloning; activity of the protein in the case of expression cloning). More recent "indirect" cloning techniques such as signal sequence cloning, which isolates DNA sequences based on the presence of a now well-recognized secretory leader sequence motif, as well as various PCR-based or low stringency hybridization cloning techniques, have advanced the state of the art by making available large numbers of DNA/amino acid sequences for proteins that are known to have biological activity by virtue of their secreted nature in the case of leader sequence cloning, or by virtue of the cell or tissue source in the case of PCR-based techniques. It is to these proteins and the polynucleotides encoding them that the present invention is directed.

SUMMARY OF THE INVENTION

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1;
- 5 (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide 63 to nucleotide 1265;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide 132 to nucleotide 1265;
- 10 (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone bd306_7 deposited under accession number ATCC 98599;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone bd306_7 deposited under accession number ATCC 98599;
- 15 (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone bd306_7 deposited under accession number ATCC 98599;
- (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone bd306_7 deposited under accession number ATCC 98599;
- 20 (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:2;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:2;
- 25 (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and
- 30 (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i).

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:1 from nucleotide 63 to nucleotide 1265; the nucleotide sequence of SEQ ID NO:1 from nucleotide 132 to nucleotide 1265; the nucleotide sequence of the full-length protein coding sequence of clone bd306_7 deposited under accession number ATCC 98599; or the

nucleotide sequence of a mature protein coding sequence of clone bd306_7 deposited under accession number ATCC 98599. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone bd306_7 deposited under accession number ATCC 98599. In yet other preferred 5 embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:2 from amino acid 148 to amino acid 189. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment preferably comprising eight (more preferably 10 twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:2, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment comprising the amino acid sequence from amino acid 195 to amino acid 204 of SEQ ID NO:2.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ 15 ID NO:1.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- (a) a process comprising the steps of:
 - (i) preparing one or more polynucleotide probes that hybridize 20 in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - (aa) SEQ ID NO:1, but excluding the poly(A) tail at the 3' end of SEQ ID NO:1; and
 - (ab) the nucleotide sequence of the cDNA insert of clone bd306_7 deposited under accession number ATCC 98599; and
 - (ii) hybridizing said probe(s) to human DNA; and
 - (iii) isolating the DNA polynucleotide detected with the probe(s);

and

- 30 (b) a process comprising the steps of:
 - (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:1, but excluding the poly(A) tail at the 3' end of SEQ ID NO:1; and

(bb) the nucleotide sequence of the cDNA insert of clone bd306_7 deposited under accession number ATCC 98599; and

5 (ii) hybridizing said primer(s) to human DNA;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide product of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:1, and extending 10 contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:1 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:1 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:1. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:1 from nucleotide 63 to nucleotide 1265, and extending 15 contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:1 from nucleotide 63 to nucleotide 1265, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:1 from nucleotide 63 to nucleotide 1265. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID 20 NO:1 from nucleotide 132 to nucleotide 1265, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:1 from nucleotide 132 to nucleotide 1265, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:1 from nucleotide 132 to nucleotide 1265.

In other embodiments, the present invention provides a composition comprising 25 a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:2;

(b) the amino acid sequence of SEQ ID NO:2 from amino acid 148 to amino acid 189;

30 (c) fragments of the amino acid sequence of SEQ ID NO:2 comprising eight consecutive amino acids of SEQ ID NO:2; and

(d) the amino acid sequence encoded by the cDNA insert of clone bd306_7 deposited under accession number ATCC 98599;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:2 or the amino acid sequence of SEQ ID NO:2 from amino acid 148 to amino acid 189. In further preferred embodiments, the present invention provides a protein comprising a fragment of the 5 amino acid sequence of SEQ ID NO:2 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:2, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment comprising the amino acid sequence from amino acid 195 to amino acid 204 of SEQ ID NO:2.

10 In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3 from nucleotide 719 to nucleotide 1855;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3 from nucleotide 779 to nucleotide 1855;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone fJ283_11 deposited under accession number ATCC 98599;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone fJ283_11 deposited under accession number ATCC 98599;
- (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone fJ283_11 deposited under accession number ATCC 98599;
- (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone fJ283_11 deposited under accession number ATCC 98599;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:4;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:4;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i).

- 5 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:3 from nucleotide 719 to nucleotide 1855; the nucleotide sequence of SEQ ID NO:3 from nucleotide 779 to nucleotide 1855; the nucleotide sequence of the full-length protein coding sequence of clone fj283_11 deposited under accession number ATCC 98599; or the nucleotide sequence of a mature protein coding sequence of clone fj283_11 deposited 10 under accession number ATCC 98599. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone fj283_11 deposited under accession number ATCC 98599. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:4 from amino acid 1 to amino acid 27.
- 15 In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:4, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of 20 SEQ ID NO:4 having biological activity, the fragment comprising the amino acid sequence from amino acid 184 to amino acid 193 of SEQ ID NO:4.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:3.

- Further embodiments of the invention provide isolated polynucleotides produced 25 according to a process selected from the group consisting of:

- (a) a process comprising the steps of:
- (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
- 30 (aa) SEQ ID NO:3, but excluding the poly(A) tail at the 3' end of SEQ ID NO:3; and
- (ab) the nucleotide sequence of the cDNA insert of clone fj283_11 deposited under accession number ATCC 98599; and
- (ii) hybridizing said probe(s) to human DNA; and

(iii) isolating the DNA polynucleotide detected with the probe(s);

and

(b) a process comprising the steps of:

5 (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

10 (ba) SEQ ID NO:3, but excluding the poly(A) tail at the 3' end of SEQ ID NO:3; and

(bb) the nucleotide sequence of the cDNA insert of clone fJ283_11 deposited under accession number ATCC 98599; and

(ii) hybridizing said primer(s) to human DNA;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide product of step (b)(iii).

15 Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:3, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:3 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:3 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:3. Also preferably the polynucleotide isolated

20 according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:3 from nucleotide 719 to nucleotide 1855, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:3 from nucleotide 719 to nucleotide 1855, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:3 from nucleotide 719 to

25 nucleotide 1855. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:3 from nucleotide 779 to nucleotide 1855, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:3 from nucleotide 779 to nucleotide 1855, to a nucleotide sequence corresponding to the 3' end

30 of said sequence of SEQ ID NO:3 from nucleotide 779 to nucleotide 1855.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:4;

(b) the amino acid sequence of SEQ ID NO:4 from amino acid 1 to amino acid 27;

(c) fragments of the amino acid sequence of SEQ ID NO:4 comprising eight consecutive amino acids of SEQ ID NO:4;

5 (d) the amino acid sequence encoded by the cDNA insert of clone fj283_11 deposited under accession number ATCC 98599; and

(e) the amino acid sequence encoded by the cDNA insert of clone fj283_6 deposited under accession number ATCC xxxx;

the protein being substantially free from other mammalian proteins. Preferably such 10 protein comprises the amino acid sequence of SEQ ID NO:4 or the amino acid sequence of SEQ ID NO:4 from amino acid 1 to amino acid 27. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID 15 NO:4, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment comprising the amino acid sequence from amino acid 184 to amino acid 193 of SEQ ID NO:4.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

20 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:32;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:32 from nucleotide 982 to nucleotide 2118;

25 (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:32 from nucleotide 1042 to nucleotide 2118;

(d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:32 from nucleotide 621 to nucleotide 1248;

30 (e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone fj283_6 deposited under accession number ATCC xxxx;

(f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone fj283_6 deposited under accession number ATCC xxxx;

- (g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone fj283_6 deposited under accession number ATCC xxxxx;
- 5 (h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone fj283_6 deposited under accession number ATCC xxxxx;
- (i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:4;
- 10 (j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:4;
- (k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;
- (l) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ; and
- 15 (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j).
- Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:32 from nucleotide 982 to nucleotide 2118; the nucleotide sequence of SEQ ID NO:32 from nucleotide 1042 to nucleotide 2118; the nucleotide sequence of SEQ ID NO:32 from nucleotide 621 to nucleotide 1248; the nucleotide sequence of the full-length protein coding sequence of clone fj283_6 deposited under accession number ATCC xxxxx; or the nucleotide sequence of a mature protein coding sequence of clone fj283_6 deposited under accession number ATCC xxxxx. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone fj283_6 deposited under accession number ATCC xxxxx. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:4, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment comprising the amino acid sequence from amino acid 184 to amino acid 193 of SEQ ID NO:4.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:32.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- (a) a process comprising the steps of:
- (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
- (aa) SEQ ID NO:32, but excluding the poly(A) tail at the 3' end of SEQ ID NO:32; and
- (ab) the nucleotide sequence of the cDNA insert of clone fJ283_6 deposited under accession number ATCC xxxxx; and
- (ii) hybridizing said probe(s) to human DNA; and
- (iii) isolating the DNA polynucleotide detected with the probe(s);
- and
- (b) a process comprising the steps of:
- (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
- (ba) SEQ ID NO:32, but excluding the poly(A) tail at the 3' end of SEQ ID NO:32; and
- (bb) the nucleotide sequence of the cDNA insert of clone fJ283_6 deposited under accession number ATCC xxxxx; and
- (ii) hybridizing said primer(s) to human DNA;
- (iii) amplifying human DNA sequences; and
- (iv) isolating the polynucleotide product of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:32, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:32 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:32, but excluding the poly(A) tail at the 3' end of SEQ ID NO:32. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:32 from nucleotide 982 to nucleotide 2118, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:32 from nucleotide 982 to nucleotide 2118, to a nucleotide

sequence corresponding to the 3' end of said sequence of SEQ ID NO:32 from nucleotide 982 to nucleotide 2118. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:32 from nucleotide 1042 to nucleotide 2118, and extending contiguously from a 5 nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:32 from nucleotide 1042 to nucleotide 2118, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:32 from nucleotide 1042 to nucleotide 2118. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:32 from 10 nucleotide 621 to nucleotide 1248, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:32 from nucleotide 621 to nucleotide 1248, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:32 from nucleotide 621 to nucleotide 1248.

In one embodiment, the present invention provides a composition comprising an 15 isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:5;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:5 from nucleotide 259 to nucleotide 624;
- 20 (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone fk317_3 deposited under accession number ATCC 98599;
- (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone fk317_3 deposited under accession number ATCC 98599;
- 25 (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone fk317_3 deposited under accession number ATCC 98599;
- (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone fk317_3 deposited under accession number ATCC 98599;
- 30 (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:6;
- (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:6;

- (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
- (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ; and
- 5 (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h).

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:5 from nucleotide 259 to nucleotide 624; the nucleotide sequence of the full-length protein coding sequence of clone fk317_3 deposited under accession number ATCC 98599; 10 or the nucleotide sequence of a mature protein coding sequence of clone fk317_3 deposited under accession number ATCC 98599. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone fk317_3 deposited under accession number ATCC 98599. In yet other preferred 15 embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:6 from amino acid 1 to amino acid 72. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:6, or a 20 polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having biological activity, the fragment comprising the amino acid sequence from amino acid 56 to amino acid 65 of SEQ ID NO:6.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:5.

25 Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- (a) a process comprising the steps of:
 - (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group 30 consisting of:
 - (aa) SEQ ID NO:5, but excluding the poly(A) tail at the 3' end of SEQ ID NO:5; and
 - (ab) the nucleotide sequence of the cDNA insert of clone fk317_3 deposited under accession number ATCC 98599; and

- (ii) hybridizing said probe(s) to human DNA; and
- (iii) isolating the DNA polynucleotide detected with the probe(s);

and

- 5 (b) a process comprising the steps of:
 - (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - (ba) SEQ ID NO:5, but excluding the poly(A) tail at the 10 3' end of SEQ ID NO:5; and
 - (bb) the nucleotide sequence of the cDNA insert of clone fk317_3 deposited under accession number ATCC 98599; and
 - (ii) hybridizing said primer(s) to human DNA;
 - (iii) amplifying human DNA sequences; and
 - (iv) isolating the polynucleotide product of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:5, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:5 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:5 , but excluding the 20 poly(A) tail at the 3' end of SEQ ID NO:5. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:5 from nucleotide 259 to nucleotide 624, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:5 from nucleotide 259 to nucleotide 624, to a nucleotide sequence 25 corresponding to the 3' end of said sequence of SEQ ID NO:5 from nucleotide 259 to nucleotide 624.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- 30 (a) the amino acid sequence of SEQ ID NO:6;
- (b) the amino acid sequence of SEQ ID NO:6 from amino acid 1 to amino acid 72;
- (c) fragments of the amino acid sequence of SEQ ID NO:6 comprising eight consecutive amino acids of SEQ ID NO:6; and

(d) the amino acid sequence encoded by the cDNA insert of clone fk317_3 deposited under accession number ATCC 98599; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:6 or the amino acid sequence 5 of SEQ ID NO:6 from amino acid 1 to amino acid 72. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:6, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 10 having biological activity, the fragment comprising the amino acid sequence from amino acid 56 to amino acid 65 of SEQ ID NO:6.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID 15 NO:7;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:7 from nucleotide 357 to nucleotide 578;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:7 from nucleotide 471 to nucleotide 578;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone k213_2x deposited under accession 20 number ATCC 98599;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone k213_2x deposited under accession number ATCC 98599;
- (f) a polynucleotide comprising the nucleotide sequence of a mature 25 protein coding sequence of clone k213_2x deposited under accession number ATCC 98599;
- (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone k213_2x deposited under accession number ATCC 98599;
- (h) a polynucleotide encoding a protein comprising the amino acid 30 sequence of SEQ ID NO:8;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:8;

- (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and
- 5 (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i).

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:7 from nucleotide 357 to nucleotide 578; the nucleotide sequence of SEQ ID NO:7 from nucleotide 471 to nucleotide 578; the nucleotide sequence of the full-length protein coding sequence of clone k213_2x deposited under accession number ATCC 98599; or the nucleotide sequence of a mature protein coding sequence of clone k213_2x deposited under accession number ATCC 98599. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone k213_2x deposited under accession number ATCC 98599. In further preferred 15 embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:8, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having 20 biological activity, the fragment comprising the amino acid sequence from amino acid 32 to amino acid 41 of SEQ ID NO:8.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:7.

Further embodiments of the invention provide isolated polynucleotides produced 25 according to a process selected from the group consisting of:

- (a) a process comprising the steps of:
 - (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - 30 (aa) SEQ ID NO:7, but excluding the poly(A) tail at the 3' end of SEQ ID NO:7; and
 - (ab) the nucleotide sequence of the cDNA insert of clone k213_2x deposited under accession number ATCC 98599; and
 - (ii) hybridizing said probe(s) to human DNA; and

(iii) isolating the DNA polynucleotide detected with the probe(s);

and

(b) a process comprising the steps of:

5 (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

10 (ba) SEQ ID NO:7, but excluding the poly(A) tail at the 3' end of SEQ ID NO:7; and

15 (bb) the nucleotide sequence of the cDNA insert of clone k213_2x deposited under accession number ATCC 98599; and

(ii) hybridizing said primer(s) to human DNA;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide product of step (b)(iii).

15 Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:7, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:7 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:7 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:7. Also preferably the polynucleotide isolated
20 according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:7 from nucleotide 357 to nucleotide 578, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:7 from nucleotide 357 to nucleotide 578, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:7 from nucleotide 357 to
25 nucleotide 578. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:7 from nucleotide 471 to nucleotide 578, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:7 from nucleotide 471 to nucleotide 578, to a nucleotide sequence corresponding to the 3' end of
30 said sequence of SEQ ID NO:7 from nucleotide 471 to nucleotide 578.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:8;

- (b) fragments of the amino acid sequence of SEQ ID NO:8 comprising eight consecutive amino acids of SEQ ID NO:8; and
 - (c) the amino acid sequence encoded by the cDNA insert of clone k213_2x deposited under accession number ATCC 98599;
- 5 the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:8. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:8, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment comprising the amino acid sequence from amino acid 32 to amino acid 41 of SEQ ID NO:8.
- 10

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- 15 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:9;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:9 from nucleotide 332 to nucleotide 598;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:9 from nucleotide 458 to nucleotide 598;
- 20 (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone na316_1 deposited under accession number ATCC 98599;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone na316_1 deposited under accession number ATCC 98599;
- 25 (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone na316_1 deposited under accession number ATCC 98599;
- (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone na316_1 deposited under accession number ATCC 98599;
- 30 (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:10;

- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:10;
- 5 (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and
- (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i).

10 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:9 from nucleotide 332 to nucleotide 598; the nucleotide sequence of SEQ ID NO:9 from nucleotide 458 to nucleotide 598; the nucleotide sequence of the full-length protein coding sequence of clone na316_1 deposited under accession number ATCC 98599; or the nucleotide sequence of a mature protein coding sequence of clone na316_1 deposited 15 under accession number ATCC 98599. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone na316_1 deposited under accession number ATCC 98599. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological 20 activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:10, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological activity, the fragment comprising the amino acid sequence from amino acid 39 to amino acid 48 of SEQ ID NO:10.

25 Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:9.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- (a) a process comprising the steps of:
 - 30 (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - (aa) SEQ ID NO:9, but excluding the poly(A) tail at the 3' end of SEQ ID NO:9; and

(ab) the nucleotide sequence of the cDNA insert of clone
na316_1 deposited under accession number ATCC 98599; and
(ii) hybridizing said probe(s) to human DNA; and
(iii) isolating the DNA polynucleotide detected with the
5 probe(s);

and

- (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
10 the group consisting of:
(ba) SEQ ID NO:9, but excluding the poly(A) tail at the
3' end of SEQ ID NO:9; and
(bb) the nucleotide sequence of the cDNA insert of clone
na316_1 deposited under accession number ATCC 98599; and
15 (ii) hybridizing said primer(s) to human DNA;
(iii) amplifying human DNA sequences; and
(iv) isolating the polynucleotide product of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:9, and extending
20 contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:9 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:9 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:9. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:9 from nucleotide 332 to nucleotide 598, and extending
25 contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:9 from nucleotide 332 to nucleotide 598, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:9 from nucleotide 332 to nucleotide 598. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID
30 NO:9 from nucleotide 458 to nucleotide 598, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:9 from nucleotide 458 to nucleotide 598, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:9 from nucleotide 458 to nucleotide 598.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:10;
- 5 (b) fragments of the amino acid sequence of SEQ ID NO:10 comprising eight consecutive amino acids of SEQ ID NO:10; and
- (c) the amino acid sequence encoded by the cDNA insert of clone na316_1 deposited under accession number ATCC 98599;

the protein being substantially free from other mammalian proteins. Preferably such 10 protein comprises the amino acid sequence of SEQ ID NO:10. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:10, or a protein comprising a fragment of the amino acid sequence of 15 SEQ ID NO:10 having biological activity, the fragment comprising the amino acid sequence from amino acid 39 to amino acid 48 of SEQ ID NO:10.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID 20 NO:11;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:11 from nucleotide 354 to nucleotide 986;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:11 from nucleotide 408 to nucleotide 986;
- 25 (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone nf93_20 deposited under accession number ATCC 98599;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone nf93_20 deposited under accession number ATCC 98599;
- 30 (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone nf93_20 deposited under accession number ATCC 98599;
- (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone nf93_20 deposited under accession number ATCC 98599;

- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:12;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:12;
- 5 (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and
- 10 (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i).

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:11 from nucleotide 354 to nucleotide 986; the nucleotide sequence of SEQ ID NO:11 from nucleotide 408 to nucleotide 986; the nucleotide sequence of the full-length protein coding sequence of clone nf93_20 deposited under accession number ATCC 98599; or the nucleotide sequence of a mature protein coding sequence of clone nf93_20 deposited under accession number ATCC 98599. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone nf93_20 deposited under accession number ATCC 98599. In further preferred 15 embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:12, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12 having 20 biological activity, the fragment comprising the amino acid sequence from amino acid 100 to amino acid 109 of SEQ ID NO:12.

25

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:11.

Further embodiments of the invention provide isolated polynucleotides produced 30 according to a process selected from the group consisting of:

- (a) a process comprising the steps of:
- (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:11, but excluding the poly(A) tail at the 3' end of SEQ ID NO:11; and

(ab) the nucleotide sequence of the cDNA insert of clone nf93_20 deposited under accession number ATCC 98599; and

5 (ii) hybridizing said probe(s) to human DNA; and

(iii) isolating the DNA polynucleotide detected with the probe(s);

and

(b) a process comprising the steps of:

10 (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:11, but excluding the poly(A) tail at the 3' end of SEQ ID NO:11; and

15 (bb) the nucleotide sequence of the cDNA insert of clone nf93_20 deposited under accession number ATCC 98599; and

(ii) hybridizing said primer(s) to human DNA;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide product of step (b)(iii).

20 Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:11, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:11 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:11, but excluding the poly(A) tail at the 3' end of SEQ ID NO:11. Also preferably the

25 polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:11 from nucleotide 354 to nucleotide 986, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:11 from nucleotide 354 to nucleotide 986, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:11 from nucleotide

30 354 to nucleotide 986. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:11 from nucleotide 408 to nucleotide 986, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:11 from

nucleotide 408 to nucleotide 986, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:11 from nucleotide 408 to nucleotide 986.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:12;
- (b) fragments of the amino acid sequence of SEQ ID NO:12 comprising eight consecutive amino acids of SEQ ID NO:12; and
- (c) the amino acid sequence encoded by the cDNA insert of clone nf93_20 deposited under accession number ATCC 98599;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:12. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:12, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12 having biological activity, the fragment comprising the amino acid sequence from amino acid 100 to amino acid 109 of SEQ ID NO:12.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:13;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:13 from nucleotide 301 to nucleotide 1821;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:13 from nucleotide 1381 to nucleotide 1821;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone np164_1 deposited under accession number ATCC 98599;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone np164_1 deposited under accession number ATCC 98599;
- (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone np164_1 deposited under accession number ATCC 98599;

- (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone np164_1 deposited under accession number ATCC 98599;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:14;
- 5 (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:14 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:14;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- 10 (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and
- (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i).
- Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
- 15 NO:13 from nucleotide 301 to nucleotide 1821; the nucleotide sequence of SEQ ID NO:13 from nucleotide 1381 to nucleotide 1821; the nucleotide sequence of the full-length protein coding sequence of clone np164_1 deposited under accession number ATCC 98599; or the nucleotide sequence of a mature protein coding sequence of clone np164_1 deposited under accession number ATCC 98599. In other preferred embodiments, the
- 20 polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone np164_1 deposited under accession number ATCC 98599. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:14 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:14, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:14 having biological activity, the fragment comprising the amino acid sequence from amino acid 248 to amino acid 257 of SEQ ID NO:14.
- 25

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:13.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- (a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:13, but excluding the poly(A) tail at the

5 3' end of SEQ ID NO:13; and

(ab) the nucleotide sequence of the cDNA insert of clone np164_1 deposited under accession number ATCC 98599; and

(ii) hybridizing said probe(s) to human DNA; and

(iii) isolating the DNA polynucleotide detected with the
10 probe(s);

and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:13, but excluding the poly(A) tail at the 3' end of SEQ ID NO:13; and

(bb) the nucleotide sequence of the cDNA insert of clone np164_1 deposited under accession number ATCC 98599; and

15 (ii) hybridizing said primer(s) to human DNA;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide product of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:13, and
25 extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:13 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:13, but excluding the poly(A) tail at the 3' end of SEQ ID NO:13. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:13 from nucleotide 301 to nucleotide 30
30 1821, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:13 from nucleotide 301 to nucleotide 1821, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:13 from nucleotide 301 to nucleotide 1821. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID

NO:13 from nucleotide 1381 to nucleotide 1821, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:13 from nucleotide 1381 to nucleotide 1821, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:13 from nucleotide 1381 to nucleotide 1821.

5 In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:14;
- (b) fragments of the amino acid sequence of SEQ ID NO:14 comprising
10 eight consecutive amino acids of SEQ ID NO:14; and
- (c) the amino acid sequence encoded by the cDNA insert of clone np164_1 deposited under accession number ATCC 98599;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:14. In further preferred
15 embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:14 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:14, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:14 having biological activity, the fragment comprising the amino acid sequence from amino acid 248 to amino acid 257 of SEQ ID NO:14.
20

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:15;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:15 from nucleotide 148 to nucleotide 537;
25
- (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone pe204_1 deposited under accession number ATCC 98599;
- (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone pe204_1 deposited under accession number ATCC 98599;
30
- (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone pe204_1 deposited under accession number ATCC 98599;

- (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone pe204_1 deposited under accession number ATCC 98599;
 - (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:16;
 - 5 (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:16 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:16;
 - (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;
 - 10 (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ; and
 - (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h).
- Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:15 from nucleotide 148 to nucleotide 537; the nucleotide sequence of the full-length protein coding sequence of clone pe204_1 deposited under accession number ATCC 98599; or the nucleotide sequence of a mature protein coding sequence of clone pe204_1 deposited under accession number ATCC 98599. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone pe204_1 deposited under accession number ATCC 98599. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:16 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:16, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:16 having biological activity, the fragment comprising the amino acid sequence from amino acid 60 to amino acid 69 of SEQ ID NO:16.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:15.

30 Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- (a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:15, but excluding the poly(A) tail at the

5 3' end of SEQ ID NO:15; and

(ab) the nucleotide sequence of the cDNA insert of clone
pe204_1 deposited under accession number ATCC 98599; and

(ii) hybridizing said probe(s) to human DNA; and

(iii) isolating the DNA polynucleotide detected with the
10 probe(s);

and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
15 the group consisting of:

(ba) SEQ ID NO:15, but excluding the poly(A) tail at the
3' end of SEQ ID NO:15; and

(bb) the nucleotide sequence of the cDNA insert of clone
pe204_1 deposited under accession number ATCC 98599; and

20 (ii) hybridizing said primer(s) to human DNA;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide product of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:15, and
25 extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ
ID NO:15 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:15 , but
excluding the poly(A) tail at the 3' end of SEQ ID NO:15. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide sequence
corresponding to the cDNA sequence of SEQ ID NO:15 from nucleotide 148 to nucleotide
30 537, and extending contiguously from a nucleotide sequence corresponding to the 5' end
of said sequence of SEQ ID NO:15 from nucleotide 148 to nucleotide 537, to a nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID NO:15 from nucleotide
148 to nucleotide 537.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- 5 (a) the amino acid sequence of SEQ ID NO:16;
- (b) fragments of the amino acid sequence of SEQ ID NO:16 comprising eight consecutive amino acids of SEQ ID NO:16; and
- (c) the amino acid sequence encoded by the cDNA insert of clone pe204_1 deposited under accession number ATCC 98599;

the protein being substantially free from other mammalian proteins. Preferably such 10 protein comprises the amino acid sequence of SEQ ID NO:16. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:16 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:16, or a protein comprising a fragment of the amino acid sequence of 15 SEQ ID NO:16 having biological activity, the fragment comprising the amino acid sequence from amino acid 60 to amino acid 69 of SEQ ID NO:16.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- 20 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:17;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:17 from nucleotide 24 to nucleotide 1109;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:17 from nucleotide 1050 to nucleotide 1109;
- 25 (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone ya1_1 deposited under accession number ATCC 98599;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone ya1_1 deposited under accession number ATCC 98599;
- 30 (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone ya1_1 deposited under accession number ATCC 98599;
- (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone ya1_1 deposited under accession number ATCC 98599;

- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:18;
- 5 (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:18 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:18;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and
- 10 (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i).

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:17 from nucleotide 24 to nucleotide 1109; the nucleotide sequence of SEQ ID NO:17 from nucleotide 1050 to nucleotide 1109; the nucleotide sequence of the full-length 15 protein coding sequence of clone ya1_1 deposited under accession number ATCC 98599; or the nucleotide sequence of a mature protein coding sequence of clone ya1_1 deposited under accession number ATCC 98599. In other preferred embodiments, the polynucleotide encodes the full length or a mature protein encoded by the cDNA insert of clone ya1_1 deposited under accession number ATCC 98599. In further preferred 20 embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:18 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:18, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:18 having 25 biological activity, the fragment comprising the amino acid sequence from amino acid 176 to amino acid 185 of SEQ ID NO:18.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:17.

Further embodiments of the invention provide isolated polynucleotides produced 30 according to a process selected from the group consisting of:

- (a) a process comprising the steps of:
 - (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

- (aa) SEQ ID NO:17, but excluding the poly(A) tail at the
3' end of SEQ ID NO:17; and
- (ab) the nucleotide sequence of the cDNA insert of clone
ya1_1 deposited under accession number ATCC 98599; and
- 5 (ii) hybridizing said probe(s) to human DNA; and
- (iii) isolating the DNA polynucleotide detected with the
probe(s);
- and
- (b) a process comprising the steps of:
- 10 (i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
- (ba) SEQ ID NO:17, but excluding the poly(A) tail at the
3' end of SEQ ID NO:17; and
- 15 (bb) the nucleotide sequence of the cDNA insert of clone
ya1_1 deposited under accession number ATCC 98599; and
- (ii) hybridizing said primer(s) to human DNA;
- (iii) amplifying human DNA sequences; and
- (iv) isolating the polynucleotide product of step (b)(iii).
- 20 Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:17, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:17 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:17, but excluding the poly(A) tail at the 3' end of SEQ ID NO:17. Also preferably the
- 25 polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:17 from nucleotide 24 to nucleotide 1109, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:17 from nucleotide 24 to nucleotide 1109, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:17 from nucleotide
- 30 24 to nucleotide 1109. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:17 from nucleotide 1050 to nucleotide 1109, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:17 from

nucleotide 1050 to nucleotide 1109, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:17 from nucleotide 1050 to nucleotide 1109.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group 5 consisting of:

- (a) the amino acid sequence of SEQ ID NO:18;
- (b) fragments of the amino acid sequence of SEQ ID NO:18 comprising eight consecutive amino acids of SEQ ID NO:18; and
- (c) the amino acid sequence encoded by the cDNA insert of clone 10 ya1_1 deposited under accession number ATCC 98599;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:18. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:18 having biological activity, the fragment preferably 15 comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:18, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:18 having biological activity, the fragment comprising the amino acid sequence from amino acid 176 to amino acid 185 of SEQ ID NO:18.

In one embodiment, the present invention provides a composition comprising an 20 isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:19;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:19 from nucleotide 27 to nucleotide 734;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:19 from nucleotide 270 to nucleotide 734;
- (d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:19 from nucleotide 85 to nucleotide 1604;
- (e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone yb8_1 deposited under accession number 30 ATCC 98599;
- (f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone yb8_1 deposited under accession number ATCC 98599;

- (g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone yb8_1 deposited under accession number ATCC 98599;
- 5 (h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone yb8_1 deposited under accession number ATCC 98599;
- (i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:20;
- 10 (j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:20 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:20;
- (k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;
- (l) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ; and
- 15 (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j).

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:19 from nucleotide 27 to nucleotide 734; the nucleotide sequence of SEQ ID NO:19 from nucleotide 270 to nucleotide 734; the nucleotide sequence of SEQ ID NO:19 from nucleotide 85 to nucleotide 1604; the nucleotide sequence of the full-length protein coding sequence of clone yb8_1 deposited under accession number ATCC 98599; or the nucleotide sequence of a mature protein coding sequence of clone yb8_1 deposited under accession number ATCC 98599. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone yb8_1 deposited under accession number ATCC 98599. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:20 from amino acid 70 to amino acid 236. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:20 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:20, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:20 having biological activity, the fragment comprising the amino acid sequence from amino acid 113 to amino acid 122 of SEQ ID NO:20.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:19.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- 5 (a) a process comprising the steps of:
 (i) preparing one or more polynucleotide probes that hybridize
 in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
 consisting of:
 (aa) SEQ ID NO:19, but excluding the poly(A) tail at the
10 3' end of SEQ ID NO:19; and
 (ab) the nucleotide sequence of the cDNA insert of clone
 yb8_1 deposited under accession number ATCC 98599; and
 (ii) hybridizing said probe(s) to human DNA; and
 (iii) isolating the DNA polynucleotide detected with the
15 probe(s);
 and
 (b) a process comprising the steps of:
 (i) preparing one or more polynucleotide primers that
 hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
 the group consisting of:
 (ba) SEQ ID NO:19, but excluding the poly(A) tail at the
20 3' end of SEQ ID NO:19; and
 (bb) the nucleotide sequence of the cDNA insert of clone
 yb8_1 deposited under accession number ATCC 98599; and
 (ii) hybridizing said primer(s) to human DNA;
 (iii) amplifying human DNA sequences; and
 (iv) isolating the polynucleotide product of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:19, and
30 extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:19 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:19, but excluding the poly(A) tail at the 3' end of SEQ ID NO:19. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:19 from nucleotide 27 to nucleotide

734, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:19 from nucleotide 27 to nucleotide 734, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:19 from nucleotide 27 to nucleotide 734. Also preferably the polynucleotide isolated according to the above 5 process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:19 from nucleotide 270 to nucleotide 734, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:19 from nucleotide 270 to nucleotide 734, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:19 from nucleotide 270 to nucleotide 734. Also preferably 10 the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:19 from nucleotide 85 to nucleotide 1604, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:19 from nucleotide 85 to nucleotide 1604, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:19 from 15 nucleotide 85 to nucleotide 1604.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:20;
- 20 (b) the amino acid sequence of SEQ ID NO:20 from amino acid 70 to amino acid 236;
- (c) fragments of the amino acid sequence of SEQ ID NO:20 comprising eight consecutive amino acids of SEQ ID NO:20; and
- (d) the amino acid sequence encoded by the cDNA insert of clone 25 yb8_1 deposited under accession number ATCC 98599;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:20 or the amino acid sequence of SEQ ID NO:20 from amino acid 70 to amino acid 236. In further preferred embodiments, the present invention provides a protein comprising a fragment of the 30 amino acid sequence of SEQ ID NO:20 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:20, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:20 having biological activity, the fragment comprising the amino acid sequence from amino acid 113 to amino acid 122 of SEQ ID NO:20.

In certain preferred embodiments, the polynucleotide is operably linked to an expression control sequence. The invention also provides a host cell, including bacterial, yeast, insect and mammalian cells, transformed with such polynucleotide compositions. Also provided by the present invention are organisms that have enhanced, reduced, or 5 modified expression of the gene(s) corresponding to the polynucleotide sequences disclosed herein.

Processes are also provided for producing a protein, which comprise:

- (a) growing a culture of the host cell transformed with such polynucleotide compositions in a suitable culture medium; and
10
- (b) purifying the protein from the culture.

The protein produced according to such methods is also provided by the present invention.

Protein compositions of the present invention may further comprise a pharmaceutically acceptable carrier. Compositions comprising an antibody which 15 specifically reacts with such protein are also provided by the present invention.

Methods are also provided for preventing, treating or ameliorating a medical condition which comprises administering to a mammalian subject a therapeutically effective amount of a composition comprising a protein of the present invention and a pharmaceutically acceptable carrier.

20

BRIEF DESCRIPTION OF THE DRAWINGS

Figures 1A and 1B are schematic representations of the pED6 and pNOTs vectors, respectively, used for deposit of clones disclosed herein.

25

DETAILED DESCRIPTION

ISOLATED PROTEINS AND POLYNUCLEOTIDES

Nucleotide and amino acid sequences, as presently determined, are reported below for each clone and protein disclosed in the present application. The nucleotide sequence of each clone can readily be determined by sequencing of the deposited clone 30 in accordance with known methods. The predicted amino acid sequence (both full-length and mature forms) can then be determined from such nucleotide sequence. The amino acid sequence of the protein encoded by a particular clone can also be determined by expression of the clone in a suitable host cell, collecting the protein and determining its sequence. For each disclosed protein applicants have identified what they have

determined to be the reading frame best identifiable with sequence information available at the time of filing.

As used herein a "secreted" protein is one which, when expressed in a suitable host cell, is transported across or through a membrane, including transport as a result of signal sequences in its amino acid sequence. "Secreted" proteins include without limitation proteins secreted wholly (e.g., soluble proteins) or partially (e.g., receptors) from the cell in which they are expressed. "Secreted" proteins also include without limitation proteins which are transported across the membrane of the endoplasmic reticulum.

10 Clone "bd306_7"

A polynucleotide of the present invention has been identified as clone "bd306_7". bd306_7 was isolated from a human fetal kidney cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. bd306_7 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "bd306_7 protein").

The nucleotide sequence of bd306_7 as presently determined is reported in SEQ ID NO:1, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the bd306_7 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:2. Amino acids 11 to 23 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 24. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the bd306_7 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone bd306_7 should be approximately 3700 bp.

The nucleotide sequence disclosed herein for bd306_7 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and 30 FASTA search protocols. bd306_7 demonstrated at least some similarity with sequences identified as AA027096 (zk04d03.s1 Soares pregnant uterus NbHPU Homo sapiens cDNA clone 469541 3'), AA027135 (zk04d03.r1 Soares pregnant uterus NbHPU Homo sapiens cDNA clone 469541 5'), AA166312 (ms42g11.r1 Life Tech mouse embryo 13 5dpc 10666014 Mus musculus cDNA clone 614276 5' similar to TR E238793 E238793 DUALIN), AA535890

(nf94a03.s1 NCI_CGAP_Co3 Homo sapiens cDNA clone IMAGE:927532), H14467 (yl25g07.r1 Homo sapiens cDNA clone 159324 5' similar to contains HGR repetitive element), T21281 (Human gene signature HUMGS02637), T61016 (Total DNA sequence from cosmid clones LP(2)127 and LP(2)128), U47621 (Human nucleolar autoantigen No55 mRNA, complete cds), W51808 (zc48g04.r1 Soares senescent fibroblasts NbHSF Homo sapiens cDNA clone 325590 5' similar to PIR:S20742 S20742 synaptonemal complex protein Sc65 - rat; contains Alu repetitive element; mRNA sequence), and X97607 (G.gallus mRNA for cartilage associated protein). The predicted amino acid sequence disclosed herein for bd306_7 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted bd306_7 protein demonstrated at least some similarity to sequences identified as R95913 (Neural thread protein [Homo sapiens]), U47621 (nucleolar autoantigen No55 [Homo sapiens]), and X97607 (cartilage associated protein [Gallus gallus]). Two regions of bd306_7 protein (amino acids 148-217 and 298-367 of SEQ ID NO:2) align with the same region, amino acids 145-214, of cartilage associated protein. The homology between bd306_7 protein and nucleolar autoantigen No55 is also good, but in this case it appears that bd306_7 amino acids 148-189 is similar to two regions of No55 (amino acids 145-186 and 296-337), and bd306_7 amino acids 298-367 are also similar to nearly the same two regions of No55 (amino acids 145-214 and 296-365). This implies that two regions in bd306_7 (roughly 148-189 and 298-367) are similar to each other, and one copy of this region is found in cartilage associated protein, but both are present in No55. Cartilage associated protein is reported to be localized to the extracellular matrix {J. Cell Sci 1997 110(Pt 12):1351-1359}, while No55 is found in the granular component of the nucleolus {Mol Biol Cell 1996 7(7):1015-1024}. Based upon sequence similarity, bd306_7 proteins and each similar protein or peptide may share at least some activity. The nucleotide sequence of bd306_7 also indicates that it may contain an Alu repetitive element.

Clone "fj283_11" and Clone "fj283_6"

Polynucleotides of the present invention have been identified as clone "fj283_11" and clone "fj283_6". fj283_11 and fj283_6 were isolated from a human adult lung carcinoma cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or were identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of

the encoded protein. fj283_11 and fj283_6 are full-length clones, including the entire coding sequence of a secreted protein (also referred to herein as "fj283 protein").

The nucleotide sequence of fj283_11 as presently determined is reported in SEQ ID NO:3, and includes a poly(A) tail. The nucleotide sequence of fj283_6 as presently determined is reported in SEQ ID NO:32, and includes a poly(A) tail. Although cDNA clones fj283_11 and fj283_6 have different nucleotide sequences, perhaps as a result of alternative splicing of a common primary mRNA transcript (particularly between nucleotide 402 and nucleotide 618 of SEQ ID NO:32), these clones are predicted to encode the same protein. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the fj283 protein corresponding to the foregoing nucleotide sequences is reported in SEQ ID NO:4. Amino acids 8 to 20 of SEQ ID NO:4 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 21. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the fj283 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone fj283_11 should be approximately 3350 bp. The EcoRI/NotI restriction fragment obtainable from the deposit containing clone fj283_6 should be approximately 2700 bp.

The nucleotide sequences disclosed herein for fj283_11 and fj283_6 were searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. fj283_11 and/or fj283_6 demonstrated at least some similarity with sequences identified as AA052962 (zl70c02.s1 Stratagene colon (#937204) Homo sapiens cDNA clone 509954 3' similar to gb D14531 60S RIBOSOMAL PROTEIN L9 (HUMAN)), AA080949 (zn04d12.r1 Stratagene hNT), AA160948 (zq40e12.r1 Stratagene hNT neuron (#937233) Homo sapiens cDNA clone 632206 5'), AA195089 (zr34c02.r1 Soares NhHMPu S1 Homo sapiens cDNA clone 665282 5', mRNA sequence), AA258887 (zs32b02.r1 NCI_CGAP_GCB1 Homo sapiens cDNA clone IMAGE:686859 5'), H97993 (yw06e03.s1 Homo sapiens cDNA clone 251452 3'), R19768 (yg40g06.r1 Homo sapiens cDNA clone 34951 5'), U09953 (Human ribosomal protein L9 mRNA, complete cds), Z73639 (Human DNA sequence from cosmid V389H8 on chromosome X; Contains mRNA near btk gene involved in a-gamma-globulinemia, ESTs, STS), and Z73901 (Human DNA sequence from cosmid V389H8, between markers DDX366 and DDX87 on chromosome X contains pseudogene, mRNA near btk gene involved in a-gamma-globulinemia, ESTs, STSs). The predicted amino acid sequence

disclosed herein for the fj283 protein was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted fj283 protein demonstrated at least some similarity to sequences identified as AB011084 (KIAA0512 protein [Homo sapiens]) and U09953 (ribosomal protein L9 [Homo sapiens]).

5 Based upon sequence similarity, fj283 proteins and each similar protein or peptide may share at least some activity. Profile hidden markov model analysis has revealed the presence of an Armadillo/beta-catenin-like domain within the predicted fj283 protein sequence. The armadillo multigene family comprises many proteins widely differing in sizes and functions which have in common a variable number of tandemly repeated arm

10 sequences of about 42 amino acids in length. Many, but not all, armadillo-repeat-containing proteins are nuclear in localization. The predicted fj283 protein does not appear to be of the nuclear variety, but rather appears to be an extracellular protein.

Clone "fk317_3"

15 A polynucleotide of the present invention has been identified as clone "fk317_3". fk317_3 was isolated from a human adult kidney cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. fk317_3 is a full-length clone,

20 including the entire coding sequence of a secreted protein (also referred to herein as "fk317_3 protein").

The nucleotide sequence of fk317_3 as presently determined is reported in SEQ ID NO:5, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the fk317_3 protein

25 corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:6.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone fk317_3 should be approximately 1400 bp.

The nucleotide sequence disclosed herein for fk317_3 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and

30 FASTA search protocols. fk317_3 demonstrated at least some similarity with sequences identified as AA568588 (nm21b11.s1 NCI_CGAP_Co10 Homo sapiens cDNA clone IMAGE:1060797), AC002326 (Genomic sequence from Human 6, complete sequence), H48562 (yq78g07.s1 Homo sapiens cDNA clone 201948 3' similar to contains Alu repetitive element; contains MER30 repetitive element), T67164 (Human alpha-N-

acetylglucosaminidase gene), and Z46941 (H.sapiens DNA for alu repeats). The predicted amino acid sequence disclosed herein for fk317_3 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted fk317_3 protein demonstrated at least some similarity to sequences identified 5 as X55777 (put. ORF [Homo sapiens]). Based upon sequence similarity, fk317_3 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts a potential transmembrane domain within the fk317_3 protein sequence centered around amino acid 42 of SEQ ID NO:6. The nucleotide sequence of fk317_3 indicates that it may contain an Alu repetitive element.

10

Clone "k213_2x"

A polynucleotide of the present invention has been identified as clone "k213_2x". Secreted cDNA clones were first isolated from a murine adult bone marrow (stromal cell line FCM-4) cDNA library using methods which are selective for cDNAs encoding 15 secreted proteins (see U.S. Pat. No. 5,536,637), or were identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. These murine cDNAs were then used to isolate k213_2x, a full-length human cDNA clone, including the entire coding sequence of a secreted protein (also referred to herein as "k213_2x protein").

20 The nucleotide sequence of k213_2x as presently determined is reported in SEQ ID NO:7, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the k213_2x protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:8. Amino acids 26 to 38 are a predicted leader/signal sequence, with the predicted mature amino 25 acid sequence beginning at amino acid 39. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the k213_2x protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone k213_2x should be approximately 1900 bp.

30 The nucleotide sequence disclosed herein for k213_2x was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. k213_2x demonstrated at least some similarity with sequences identified as AA123852 (mp96e08.r1 Soares 2NbMT Mus musculus cDNA clone 577094 5'), AA362005 (EST71348 T-cell lymphoma Homo sapiens cDNA 5' end), AA436477

(zv08f05.s1 Soares NhHMPu S1 Homo sapiens cDNA clone 753057 3'), AA436528
(zv08f05.r1 Soares NhHMPu S1 Homo sapiens cDNA clone 753057 5'), AA643506
(nq86f04.s1 NCI_CGAP_Co9 Homo sapiens cDNA clone IMAGE:1159231, mRNA
sequence), F13485 (H. sapiens partial cDNA sequence; clone c-3dh08), and T19502
5 (Human gene signature HUMGS00560). Based upon sequence similarity, k213_2x
proteins and each similar protein or peptide may share at least some activity.

Clone "na316_1"

A polynucleotide of the present invention has been identified as clone "na316_1".
10 na316_1 was isolated from a human adult brain (corpus callosum) cDNA library using
methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No.
5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis
of computer analysis of the amino acid sequence of the encoded protein. na316_1 is a full-
length clone, including the entire coding sequence of a secreted protein (also referred to
15 herein as "na316_1 protein").

The nucleotide sequence of na316_1 as presently determined is reported in SEQ
ID NO:9, and includes a poly(A) tail. What applicants presently believe to be the proper
reading frame and the predicted amino acid sequence of the na316_1 protein
corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:10. Amino
20 acids 30 to 42 are a predicted leader/signal sequence, with the predicted mature amino
acid sequence beginning at amino acid 43. Due to the hydrophobic nature of the predicted
leader/signal sequence, it is likely to act as a transmembrane domain should the predicted
leader/signal sequence not be separated from the remainder of the na316_1 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone
25 na316_1 should be approximately 900 bp.

The nucleotide sequence disclosed herein for na316_1 was searched against the
GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and
FASTA search protocols. No hits were found in the database. The TopPredII computer
program predicts two potential transmembrane domains within the na316_1 protein
30 sequence, centered around amino acids 31 and 66 of SEQ ID NO:10, respectively.

Clone "nf93_20"

A polynucleotide of the present invention has been identified as clone "nf93_20".
nf93_20 was isolated from a human adult brain (substantia nigra) cDNA library using

methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. nf93_20 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to 5 herein as "nf93_20 protein").

The nucleotide sequence of nf93_20 as presently determined is reported in SEQ ID NO:11, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the nf93_20 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:12. Amino 10 acids 6 to 18 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 19. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the nf93_20 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone 15 nf93_20 should be approximately 2000 bp.

The nucleotide sequence disclosed herein for nf93_20 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. nf93_20 demonstrated at least some similarity with sequences identified as AA063620 (ze87g07.s1 Soares fetal heart NbHH19W Homo sapiens cDNA 20 clone 366012 3'), AA317410 (EST19337 Retina II Homo sapiens cDNA 5' end), H29417 (ym60e07.r1 Homo sapiens cDNA clone 52631 5'), and N41425 (yw93e08.r1 Homo sapiens cDNA clone 259814 5'). Based upon sequence similarity, nf93_20 proteins and each similar protein or peptide may share at least some activity.

25 Clone "np164_1"

A polynucleotide of the present invention has been identified as clone "np164_1". np164_1 was isolated from a human fetal kidney (293 cell line) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis 30 of computer analysis of the amino acid sequence of the encoded protein. np164_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "np164_1 protein").

The nucleotide sequence of np164_1 as presently determined is reported in SEQ ID NO:13, and includes a poly(A) tail. What applicants presently believe to be the proper

reading frame and the predicted amino acid sequence of the np164_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:14. Amino acids 348 to 360 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 361. Due to the hydrophobic nature of the 5 predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the np164_1 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone np164_1 should be approximately 2100 bp.

10 The nucleotide sequence disclosed herein for np164_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. np164_1 demonstrated at least some similarity with sequences identified as N63143 (yz37c12.s1 Homo sapiens cDNA clone 285238 3'), T19992 (Human gene signature HUMGS01129), Z46676 (Caenorhabditis elegans cosmid C08B11, complete 15 sequence), and Z74910 (S.cerevisiae chromosome XV reading frame ORF YOR002w). The predicted amino acid sequence disclosed herein for np164_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted np164_1 protein demonstrated at least some similarity to sequences identified as Z46676 (C08B11.8 [Caenorhabditis elegans]) and Z74910 (ORF YOR002w 20 [Saccharomyces cerevisiae]). Based upon sequence similarity, np164_1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts ten potential transmembrane domains within the np164_1 protein sequence, centered around amino acids 4, 114, 165, 229, 293, 322, 360, 386, 436, and 465 of SEQ ID NO:14, respectively.

25

Clone "pe204_1"

A polynucleotide of the present invention has been identified as clone "pe204_1". pe204_1 was isolated from a human adult blood (chronic myelogenous leukemia K5) cDNA library using methods which are selective for cDNAs encoding secreted proteins 30 (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. pe204_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "pe204_1 protein").

The nucleotide sequence of pe204_1 as presently determined is reported in SEQ ID NO:15, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the pe204_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:16. Amino acids 116 to 128 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 129. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the pe204_1 protein.

10 The EcoRI/NotI restriction fragment obtainable from the deposit containing clone pe204_1 should be approximately 1100 bp.

The nucleotide sequence disclosed herein for pe204_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. pe204_1 demonstrated at least some similarity with sequences 15 identified as AA279961 (zs92h08.s1 NCI_CGAP_GCB1 Homo sapiens cDNA clone 704991 3'), AA306911 (EST178043 Colon carcinoma (HCC) cell line Homo sapiens cDNA 5' end), AC002086 (Human PAC clone DJ525N14), AC002094 (Genomic sequence from Human 17, complete sequence), T97749 (ye58c04.s1 Homo sapiens cDNA clone), Z74696 (Human DNA sequence from cosmid 203C2, between markers DXS6791 and DXS8038 on 20 chromosome X contains ESTs), Z80901 (Human DNA sequence from cosmid N119A7 on chromosome 22q12-qter), and Z82245 (Human DNA sequence *** SEQUENCING IN PROGRESS *** from clone 799F10; HTGS phase 1). The predicted amino acid sequence disclosed herein for pe204_1 was searched against the GenPept and GeneSeq amino acid 25 sequence databases using the BLASTX search protocol. The predicted pe204_1 protein demonstrated at least some similarity to sequences identified as K02113 (Gallus gallus vitellogenin [Gallus gallus]). Based upon sequence similarity, pe204_1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts two additional potential transmembrane domains within the pe204_1 protein sequence, one centered around amino acid 50 and another around amino acid 90 30 of SEQ ID NO:16.

Clone "ya1_1"

A polynucleotide of the present invention has been identified as clone "ya1_1". ya1_1 was isolated from a human adult testes cDNA library and was identified as

encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. ya1_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "ya1_1 protein").

The nucleotide sequence of ya1_1 as presently determined is reported in SEQ ID NO:17, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the ya1_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:18. Amino acids 330 to 342 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 343. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the ya1_1 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone ya1_1 should be approximately 1400 bp.

The nucleotide sequence disclosed herein for ya1_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. ya1_1 demonstrated at least some similarity with sequences identified as AA431507 (zw76e05.r1 Soares testis NHT Homo sapiens cDNA clone 782144 5') and F03332 (H. sapiens partial cDNA sequence; clone c-1tg07). Based upon sequence similarity, ya1_1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts two potential transmembrane domains within the ya1_1 protein sequence centered around amino acid 156 and around amino acid 332 of SEQ ID NO:18, respectively. The nucleotide sequence of ya1_1 indicates that it may contain an Alu repetitive element.

25 Clone "yb8_1"

A polynucleotide of the present invention has been identified as clone "yb8_1". yb8_1 was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. yb8_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "yb8_1 protein").

The nucleotide sequence of yb8_1 as presently determined is reported in SEQ ID NO:19, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the yb8_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:20. Amino acids 69 to 81

are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 82. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the yb8_1 protein.

5 The EcoRI/NotI restriction fragment obtainable from the deposit containing clone yb8_1 should be approximately 1800 bp.

The nucleotide sequence disclosed herein for yb8_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. yb8_1 demonstrated at least some similarity with sequences 10 identified as AA418057 (zv97a06.r1 Soares NhHMPu S1 Homo sapiens cDNA clone 767698 5' similar to TR:G1143719 G1143719 RS-REX-B), L10334 (Homo sapiens neuroendocrine-specific protein B (NSP) mRNA, complete cds), U17603 (Rattus norvegicus rS-Rex-s mRNA, complete cds), and W19986 (zb38e09.r1 Soares parathyroid tumor NbHPA Homo sapiens cDNA clone 305896 5', mRNA sequence). The predicted 15 amino acid sequence disclosed herein for yb8_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted yb8_1 protein demonstrated at least some similarity to sequences identified as L10334 (neuroendocrine-specific proteins B and C [Homo sapiens]) and U17603 (rS-Rex-s [Rattus norvegicus]). Based upon sequence similarity, yb8_1 proteins and each similar 20 protein or peptide may share at least some activity. The predicted yb8_1 protein shows significant (60% identity) amino acid similarity to the neuro-endocrine specific protein (NSP) family of proteins. Roebroek *et al.* (1993, *J. Biol. Chem.* 268: 13439, which is incorporated by reference herein) report observing three transcripts from this gene family: NSP-A (3.4 kb), -B (2.3 kb), and -C (1.8 kb); they encode proteins of 776, 356, and 208 25 amino acids, respectively. Roebroek *et al.* also observe that these three transcripts are identical at the 3' end and only differ over a short portion near their 5' ends, and are thus possible splice variants. NSP-A and NSP-C were found in neural and endocrine tissues while NSP-B was found only in a lung carcinoma cell line (Roebrek *et al.* state that NSP-B is "aberrant" suggesting that it might be an artifact). The C-terminal portions of the protein 30 sequences from all three transcripts are identical. The predicted yb8_1 protein shows strong amino acid similarity within this region and is about as long as NSP-C. Thus the predicted yb8_1 protein appears to be related to NSP-C. The TopPredII computer program predicts two potential transmembrane domains within the yb8_1 protein sequence, centered around amino acids 82 and 174 of SEQ ID NO:20, respectively.

Deposit of Clones

Clones bd306_7, fj283_11, fk317_3, k213_2x, na316_1, nf93_20, np164_1, pe204_1, ya1_1, and yb8_1 were deposited on November 26, 1997 with the American Type Culture Collection (10801 University Boulevard, Manassas, Virginia 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and were given the accession number ATCC 98599, from which each clone comprising a particular polynucleotide is obtainable. Clone fj283_6 was deposited on 17 November, 1998 with the American Type Culture Collection (10801 University Boulevard, Manassas, Virginia 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and was given the accession number ATCC xxxx. All restrictions on the availability to the public of the deposited material will be irrevocably removed upon the granting of the patent, except for the requirements specified in 37 C.F.R. § 1.808(b), and the term of the deposit will comply with 37 C.F.R. § 1.806.

Each clone has been transfected into separate bacterial cells (*E. coli*) in the accession number ATCC 98599 composite deposit. Each clone can be removed from the vector in which it was deposited by performing an EcoRI/NotI digestion (5' site, EcoRI; 3' site, NotI) to produce the appropriate fragment for such clone. Each clone was deposited in either the pED6 or pNOTs vector depicted in Figures 1A and 1B, respectively. The pED6dpc2 vector ("pED6") was derived from pED6dpc1 by insertion of a new polylinker to facilitate cDNA cloning (Kaufman *et al.*, 1991, *Nucleic Acids Res.* 19: 4485-4490); the pNOTs vector was derived from pMT2 (Kaufman *et al.*, 1989, *Mol. Cell. Biol.* 9: 946-958) by deletion of the DHFR sequences, insertion of a new polylinker, and insertion of the M13 origin of replication in the ClaI site. In some instances, the deposited clone can become "flipped" (i.e., in the reverse orientation) in the deposited isolate. In such instances, the cDNA insert can still be isolated by digestion with EcoRI and NotI. However, NotI will then produce the 5' site and EcoRI will produce the 3' site for placement of the cDNA in proper orientation for expression in a suitable vector. The cDNA may also be expressed from the vectors in which they were deposited.

Bacterial cells containing a particular clone can be obtained from the composite deposit as follows:

An oligonucleotide probe or probes should be designed to the sequence that is known for that particular clone. This sequence can be derived from the sequences provided herein, or from a combination of those sequences. The sequence of an

oligonucleotide probe that was used to isolate or to sequence each full-length clone is identified below, and should be most reliable in isolating the clone of interest.

<u>Clone</u>	<u>Probe Sequence</u>
5 bd306_7	SEQ ID NO:21
fj283_11	SEQ ID NO:22
fj283_6	SEQ ID NO:31
fk317_3	SEQ ID NO:23
k213_2x	SEQ ID NO:24
10 na316_1	SEQ ID NO:25
nf93_20	SEQ ID NO:26
np164_1	SEQ ID NO:27
pe204_1	SEQ ID NO:28
ya1_1	SEQ ID NO:29
15 yb8_1	SEQ ID NO:30

In the sequences listed above which include an N at position 2, that position is occupied in preferred probes/primers by a biotinylated phosphoaramidite residue rather than a nucleotide (such as, for example, that produced by use of biotin phosphoramidite (1-dimethoxytrityloxy-2-(N-biotinyl-4-aminobutyl)-propyl-3-O-(2-cyanoethyl)-(N,N-diisopropyl)-phosphoramidite) (Glen Research, cat. no. 10-1953)).

The design of the oligonucleotide probe should preferably follow these parameters:

- 25 (a) It should be designed to an area of the sequence which has the fewest ambiguous bases ("N's"), if any;

(b) It should be designed to have a T_m of approx. 80 ° C (assuming 2° for each A or T and 4 degrees for each G or C).

The oligonucleotide should preferably be labeled with γ -³²P ATP (specific activity 6000 Ci/mmole) and T4 polynucleotide kinase using commonly employed techniques for labeling oligonucleotides. Other labeling techniques can also be used. Unincorporated label should preferably be removed by gel filtration chromatography or other established methods. The amount of radioactivity incorporated into the probe should be quantitated by measurement in a scintillation counter. Preferably, specific activity of the resulting probe should be approximately 4e+6 dpm/pmole.

The bacterial culture containing the pool of full-length clones should preferably be thawed and 100 μ l of the stock used to inoculate a sterile culture flask containing 25 ml of sterile L-broth containing ampicillin at 100 μ g/ml. The culture should preferably be grown to saturation at 37°C, and the saturated culture should preferably be diluted in 5 fresh L-broth. Aliquots of these dilutions should preferably be plated to determine the dilution and volume which will yield approximately 5000 distinct and well-separated colonies on solid bacteriological media containing L-broth containing ampicillin at 100 μ g/ml and agar at 1.5% in a 150 mm petri dish when grown overnight at 37°C. Other known methods of obtaining distinct, well-separated colonies can also be employed.

10 Standard colony hybridization procedures should then be used to transfer the colonies to nitrocellulose filters and lyse, denature and bake them.

15 The filter is then preferably incubated at 65°C for 1 hour with gentle agitation in 6X SSC (20X stock is 175.3 g NaCl/liter, 88.2 g Na citrate/liter, adjusted to pH 7.0 with NaOH) containing 0.5% SDS, 100 μ g/ml of yeast RNA, and 10 mM EDTA (approximately 10 mL per 150 mm filter). Preferably, the probe is then added to the hybridization mix at a concentration greater than or equal to 1e+6 dpm/mL. The filter is then preferably incubated at 65°C with gentle agitation overnight. The filter is then preferably washed in 500 mL of 2X SSC/0.5% SDS at room temperature without agitation, preferably followed by 500 mL of 2X SSC/0.1% SDS at room temperature with gentle shaking for 15 minutes.

20 A third wash with 0.1X SSC/0.5% SDS at 65°C for 30 minutes to 1 hour is optional. The filter is then preferably dried and subjected to autoradiography for sufficient time to visualize the positives on the X-ray film. Other known hybridization methods can also be employed.

25 The positive colonies are picked, grown in culture, and plasmid DNA isolated using standard procedures. The clones can then be verified by restriction analysis, hybridization analysis, or DNA sequencing.

30 Fragments of the proteins of the present invention which are capable of exhibiting biological activity are also encompassed by the present invention. Fragments of the protein may be in linear form or they may be cyclized using known methods, for example, as described in H.U. Saragovi, *et al.*, Bio/Technology 10, 773-778 (1992) and in R.S. McDowell, *et al.*, J. Amer. Chem. Soc. 114, 9245-9253 (1992), both of which are incorporated herein by reference. Such fragments may be fused to carrier molecules such as immunoglobulins for many purposes, including increasing the valency of protein binding sites. For example, fragments of the protein may be fused through "linker" sequences to

the Fc portion of an immunoglobulin. For a bivalent form of the protein, such a fusion could be to the Fc portion of an IgG molecule. Other immunoglobulin isotypes may also be used to generate such fusions. For example, a protein - IgM fusion would generate a decavalent form of the protein of the invention.

5 The present invention also provides both full-length and mature forms of the disclosed proteins. The full-length form of the such proteins is identified in the sequence listing by translation of the nucleotide sequence of each disclosed clone. The mature form(s) of such protein may be obtained by expression of the disclosed full-length polynucleotide (preferably those deposited with ATCC) in a suitable mammalian cell or
10 other host cell. The sequence(s) of the mature form(s) of the protein may also be determinable from the amino acid sequence of the full-length form.

The present invention also provides genes corresponding to the polynucleotide sequences disclosed herein. "Corresponding genes" are the regions of the genome that are transcribed to produce the mRNAs from which cDNA polynucleotide sequences are
15 derived and may include contiguous regions of the genome necessary for the regulated expression of such genes. Corresponding genes may therefore include but are not limited to coding sequences, 5' and 3' untranslated regions, alternatively spliced exons, introns, promoters, enhancers, and silencer or suppressor elements. The corresponding genes can be isolated in accordance with known methods using the sequence information disclosed
20 herein. Such methods include the preparation of probes or primers from the disclosed sequence information for identification and/or amplification of genes in appropriate genomic libraries or other sources of genomic materials. An "isolated gene" is a gene that has been separated from the adjacent coding sequences, if any, present in the genome of the organism from which the gene was isolated.

25 The chromosomal location corresponding to the polynucleotide sequences disclosed herein may also be determined, for example by hybridizing appropriately labeled polynucleotides of the present invention to chromosomes *in situ*. It may also be possible to determine the corresponding chromosomal location for a disclosed polynucleotide by identifying significantly similar nucleotide sequences in public
30 databases, such as expressed sequence tags (ESTs), that have already been mapped to particular chromosomal locations. For at least some of the polynucleotide sequences disclosed herein, public database sequences having at least some similarity to the polynucleotide of the present invention have been listed by database accession number. Searches using the GenBank accession numbers of these public database sequences can

then be performed at an Internet site provided by the National Center for Biotechnology Information having the address <http://www.ncbi.nlm.nih.gov/UniGene/>, in order to identify "UniGene clusters" of overlapping sequences. Many of the "UniGene clusters" so identified will already have been mapped to particular chromosomal sites.

- 5 Organisms that have enhanced, reduced, or modified expression of the gene(s) corresponding to the polynucleotide sequences disclosed herein are provided. The desired change in gene expression can be achieved through the use of antisense polynucleotides or ribozymes that bind and/or cleave the mRNA transcribed from the gene (Albert and Morris, 1994, *Trends Pharmacol. Sci.* **15**(7): 250-254; Lavarosky *et al.*, 1997, *Biochem. Mol. Med.* **62**(1): 11-22; and Hampel, 1998, *Prog. Nucleic Acid Res. Mol. Biol.* **58**: 1-39; all of which are incorporated by reference herein). Transgenic animals that have multiple copies of the gene(s) corresponding to the polynucleotide sequences disclosed herein, preferably produced by transformation of cells with genetic constructs that are stably maintained within the transformed cells and their progeny, are provided.
- 10 Transgenic animals that have modified genetic control regions that increase or reduce gene expression levels, or that change temporal or spatial patterns of gene expression, are also provided (see European Patent No. 0 649 464 B1, incorporated by reference herein). In addition, organisms are provided in which the gene(s) corresponding to the polynucleotide sequences disclosed herein have been partially or completely inactivated,
- 15 20 through insertion of extraneous sequences into the corresponding gene(s) or through deletion of all or part of the corresponding gene(s). Partial or complete gene inactivation can be accomplished through insertion, preferably followed by imprecise excision, of transposable elements (Plasterk, 1992, *Bioessays* **14**(9): 629-633; Zwaal *et al.*, 1993, *Proc. Natl. Acad. Sci. USA* **90**(16): 7431-7435; Clark *et al.*, 1994, *Proc. Natl. Acad. Sci. USA* **91**(2): 719-722;
- 25 25 all of which are incorporated by reference herein), or through homologous recombination, preferably detected by positive/negative genetic selection strategies (Mansour *et al.*, 1988, *Nature* **336**: 348-352; U.S. Patent Nos. 5,464,764; 5,487,992; 5,627,059; 5,631,153; 5,614,396; 5,616,491; and 5,679,523; all of which are incorporated by reference herein). These organisms with altered gene expression are preferably eukaryotes and more preferably are mammals. Such organisms are useful for the development of non-human models for the study of disorders involving the corresponding gene(s), and for the development of assay systems for the identification of molecules that interact with the protein product(s)
- 30 30 of the corresponding gene(s).

Where the protein of the present invention is membrane-bound (e.g., is a receptor), the present invention also provides for soluble forms of such protein. In such forms, part or all of the intracellular and transmembrane domains of the protein are deleted such that the protein is fully secreted from the cell in which it is expressed. The intracellular and 5 transmembrane domains of proteins of the invention can be identified in accordance with known techniques for determination of such domains from sequence information. For example, the TopPredII computer program can be used to predict the location of transmembrane domains in an amino acid sequence, domains which are described by the location of the center of the transmsmbrane domain, with at least ten transmembrane 10 amino acids on each side of the reported central residue(s).

Proteins and protein fragments of the present invention include proteins with amino acid sequence lengths that are at least 25% (more preferably at least 50%, and most preferably at least 75%) of the length of a disclosed protein and have at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90% or 95% 15 identity) with that disclosed protein, where sequence identity is determined by comparing the amino acid sequences of the proteins when aligned so as to maximize overlap and identity while minimizing sequence gaps. Also included in the present invention are proteins and protein fragments that contain a segment preferably comprising 8 or more (more preferably 20 or more, most preferably 30 or more) contiguous amino acids that 20 shares at least 75% sequence identity (more preferably, at least 85% identity; most preferably at least 95% identity) with any such segment of any of the disclosed proteins.

In particular, sequence identity may be determined using WU-BLAST (Washington University BLAST) version 2.0 software, which builds upon WU-BLAST version 1.4, which in turn is based on the public domain NCBI-BLAST version 1.4 25 (Altschul and Gish, 1996, Local alignment statistics, Doolittle *ed.*, *Methods in Enzymology* 266: 460-480; Altschul *et al.*, 1990, Basic local alignment search tool, *Journal of Molecular Biology* 215: 403-410; Gish and States, 1993, Identification of protein coding regions by database similarity search, *Nature Genetics* 3: 266-272; Karlin and Altschul, 1993, Applications and statistics for multiple high-scoring segments in molecular 30 sequences, *Proc. Natl. Acad. Sci. USA* 90: 5873-5877; all of which are incorporated by reference herein). WU-BLAST version 2.0 executable programs for several UNIX platforms can be downloaded from <ftp://blast.wustl.edu/blast/executables>. The complete suite of search programs (BLASTP, BLASTN, BLASTX, TBLASTN, and TBLASTX) is

provided at that site, in addition to several support programs. WU-BLAST 2.0 is copyrighted and may not be sold or redistributed in any form or manner without the express written consent of the author; but the posted executables may otherwise be freely used for commercial, nonprofit, or academic purposes. In all search programs in the suite
5 -- BLASTP, BLASTN, BLASTX, TBLASTN and TBLASTX -- the gapped alignment routines are integral to the database search itself, and thus yield much better sensitivity and selectivity while producing the more easily interpreted output. Gapping can optionally be turned off in all of these programs, if desired. The default penalty (Q) for a gap of length one is Q=9 for proteins and BLASTP, and Q=10 for BLASTN, but may be changed to any
10 integer value including zero, one through eight, nine, ten, eleven, twelve through twenty, twenty-one through fifty, fifty-one through one hundred, etc. The default per-residue penalty for extending a gap (R) is R=2 for proteins and BLASTP, and R=10 for BLASTN, but may be changed to any integer value including zero, one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve through twenty, twenty-one through fifty, fifty-one
15 through one hundred, etc. Any combination of values for Q and R can be used in order to align sequences so as to maximize overlap and identity while minimizing sequence gaps. The default amino acid comparison matrix is BLOSUM62, but other amino acid comparison matrices such as PAM can be utilized.

Species homologues of the disclosed polynucleotides and proteins are also
20 provided by the present invention. As used herein, a "species homologue" is a protein or polynucleotide with a different species of origin from that of a given protein or polynucleotide, but with significant sequence similarity to the given protein or polynucleotide. Preferably, polynucleotide species homologues have at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90% identity) with
25 the given polynucleotide, and protein species homologues have at least 30% sequence identity (more preferably, at least 45% identity; most preferably at least 60% identity) with the given protein, where sequence identity is determined by comparing the nucleotide sequences of the polynucleotides or the amino acid sequences of the proteins when aligned so as to maximize overlap and identity while minimizing sequence gaps. Species
30 homologues may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source from the desired species. Preferably, species homologues are those isolated from mammalian

species. Most preferably, species homologues are those isolated from certain mammalian species such as, for example, *Pan troglodytes*, *Gorilla gorilla*, *Pongo pygmaeus*, *Hylobates concolor*, *Macaca mulatta*, *Papio papio*, *Papio hamadryas*, *Cercopithecus aethiops*, *Cebus capucinus*, *Aotus trivirgatus*, *Sanguinus oedipus*, *Microcebus murinus*, *Mus musculus*, *Rattus norvegicus*, 5 *Cricetulus griseus*, *Felis catus*, *Mustela vison*, *Canis familiaris*, *Oryctolagus cuniculus*, *Bos taurus*, *Ovis aries*, *Sus scrofa*, and *Equus caballus*, for which genetic maps have been created allowing the identification of syntenic relationships between the genomic organization of genes in one species and the genomic organization of the related genes in another species (O'Brien and Seuánez, 1988, *Ann. Rev. Genet.* 22: 323-351; O'Brien *et al.*, 1993, *Nature Genetics* 3:103-112; Johansson *et al.*, 1995, *Genomics* 25: 682-690; Lyons *et al.*, 1997, *Nature Genetics* 15: 47-56; O'Brien *et al.*, 1997, *Trends in Genetics* 13(10): 393-399; Carver and Stubbs, 10 1997, *Genome Research* 7:1123-1137; all of which are incorporated by reference herein).

The invention also encompasses allelic variants of the disclosed polynucleotides or proteins; that is, naturally-occurring alternative forms of the isolated polynucleotides 15 which also encode proteins which are identical or have significantly similar sequences to those encoded by the disclosed polynucleotides. Preferably, allelic variants have at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90% identity) with the given polynucleotide, where sequence identity is determined by comparing the nucleotide sequences of the polynucleotides when aligned so as to maximize 20 overlap and identity while minimizing sequence gaps. Allelic variants may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source from individuals of the appropriate species.

The invention also includes polynucleotides with sequences complementary to those of the polynucleotides disclosed herein.

25 The present invention also includes polynucleotides that hybridize under reduced stringency conditions, more preferably stringent conditions, and most preferably highly stringent conditions, to polynucleotides described herein. Examples of stringency conditions are shown in the table below: highly stringent conditions are those that are at least as stringent as, for example, conditions A-F; stringent conditions are at least as 30 stringent as, for example, conditions G-L; and reduced stringency conditions are at least as stringent as, for example, conditions M-R.

Stringency Condition	Polynucleotide Hybrid	Hybrid Length (bp) ^a	Hybridization Temperature and Buffer ^b	Wash Temperature and Buffer ^b
5	A	≥ 50	65°C; 1xSSC -or- 42°C; 1xSSC, 50% formamide	65°C; 0.3xSSC
	B	<50	T _s *; 1xSSC	T _s *; 1xSSC
	C	≤ 50	67°C; 1xSSC -or- 45°C; 1xSSC, 50% formamide	67°C, 0.3xSSC
	D	<50	T _D *; 1xSSC	T _D *; 1xSSC
10	E	≤ 50	70°C; 1xSSC -or- 50°C; 1xSSC, 50% formamide	70°C; 0.3xSSC
	F	<50	T _F *; 1xSSC	T _F *; 1xSSC
	G	≥ 50	65°C; 4xSSC -or- 42°C; 4xSSC, 50% formamide	65°C; 1xSSC
	H	<50	T _H *; 4xSSC	T _H *; 4xSSC
15	I	≤ 50	67°C; 4xSSC -or- 45°C; 4xSSC, 50% formamide	67°C; 1xSSC
	J	<50	T _J *; 4xSSC	T _J *; 4xSSC
	K	≤ 50	70°C; 4xSSC -or- 50°C; 4xSSC, 50% formamide	67°C; 1xSSC
	L	<50	T _L *; 2xSSC	T _L *; 2xSSC
20	M	≤ 50	50°C; 4xSSC -or- 40°C; 6xSSC, 50% formamide	50°C; 2xSSC
	N	<50	T _N *; 6xSSC	T _N *; 6xSSC
	O	≤ 50	55°C; 4xSSC -or- 42°C; 6xSSC, 50% formamide	55°C; 2xSSC
	P	<50	T _P *; 6xSSC	T _P *; 6xSSC
25	Q	≤ 50	60°C; 4xSSC -or- 45°C; 6xSSC, 50% formamide	60°C; 2xSSC
	R	<50	T _R *; 4xSSC	T _R *; 4xSSC

^a: The hybrid length is that anticipated for the hybridized region(s) of the hybridizing polynucleotides. When hybridizing a polynucleotide to a target polynucleotide of unknown sequence, the hybrid length is assumed to be that of the hybridizing polynucleotide. When polynucleotides of known sequence are hybridized, the hybrid length can be determined by aligning the sequences of the polynucleotides and identifying the region or regions of optimal sequence complementarity.

^b: SSPE (1xSSPE is 0.15M NaCl, 10mM NaH₂PO₄, and 1.25mM EDTA, pH 7.4) can be substituted for SSC (1xSSC is 0.15M NaCl and 15mM sodium citrate) in the hybridization and wash buffers; washes are performed for 15 minutes after hybridization is complete.

30 ^cT_D-T_R: The hybridization temperature for hybrids anticipated to be less than 50 base pairs in length should be 5-10°C less than the melting temperature (T_m) of the hybrid, where T_m is determined according to the following equations. For hybrids less than 18 base pairs in length, T_m(°C) = 2(# of A + T bases) + 4(# of G + C bases). For hybrids between 18 and 49 base pairs in length, T_m(°C) = 81.5 + 16.6(log₁₀[Na⁺]) + 0.41(%G+C) - (600/N), where N is the number of bases in the hybrid, and [Na⁺] is the concentration of sodium ions in the hybridization buffer ([Na⁺] for 1xSSC = 0.165 M).

Additional examples of stringency conditions for polynucleotide hybridization are provided in Sambrook, J., E.F. Fritsch, and T. Maniatis, 1989, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, chapters 9 and 11, and *Current Protocols in Molecular Biology*, 1995, F.M. Ausubel et al., eds., 5 John Wiley & Sons, Inc., sections 2.10 and 6.3-6.4, incorporated herein by reference.

Preferably, each such hybridizing polynucleotide has a length that is at least 25% (more preferably at least 50%, and most preferably at least 75%) of the length of the polynucleotide of the present invention to which it hybridizes, and has at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90% or 10 95% identity) with the polynucleotide of the present invention to which it hybridizes, where sequence identity is determined by comparing the sequences of the hybridizing polynucleotides when aligned so as to maximize overlap and identity while minimizing sequence gaps.

The isolated polynucleotide of the invention may be operably linked to an 15 expression control sequence such as the pMT2 or pED expression vectors disclosed in Kaufman et al., *Nucleic Acids Res.* 19, 4485-4490 (1991), in order to produce the protein recombinantly. Many suitable expression control sequences are known in the art. General methods of expressing recombinant proteins are also known and are exemplified in R. Kaufman, *Methods in Enzymology* 185, 537-566 (1990). As defined herein "operably 20 linked" means that the isolated polynucleotide of the invention and an expression control sequence are situated within a vector or cell in such a way that the protein is expressed by a host cell which has been transformed (transfected) with the ligated polynucleotide/expression control sequence.

A number of types of cells may act as suitable host cells for expression of the 25 protein. Mammalian host cells include, for example, monkey COS cells, Chinese Hamster Ovary (CHO) cells, human kidney 293 cells, human epidermal A431 cells, human Colo205 cells, 3T3 cells, CV-1 cells, other transformed primate cell lines, normal diploid cells, cell strains derived from *in vitro* culture of primary tissue, primary explants, HeLa cells, mouse L cells, BHK, HL-60, U937, HaK or Jurkat cells.

30 Alternatively, it may be possible to produce the protein in lower eukaryotes such as yeast or in prokaryotes such as bacteria. Potentially suitable yeast strains include *Saccharomyces cerevisiae*, *Schizosaccharomyces pombe*, *Kluyveromyces* strains, *Candida*, or any yeast strain capable of expressing heterologous proteins. Potentially suitable bacterial strains include *Escherichia coli*, *Bacillus subtilis*, *Salmonella typhimurium*, or any bacterial

strain capable of expressing heterologous proteins. If the protein is made in yeast or bacteria, it may be necessary to modify the protein produced therein, for example by phosphorylation or glycosylation of the appropriate sites, in order to obtain the functional protein. Such covalent attachments may be accomplished using known chemical or 5 enzymatic methods.

The protein may also be produced by operably linking the isolated polynucleotide of the invention to suitable control sequences in one or more insect expression vectors, and employing an insect expression system. Materials and methods for baculovirus/insect cell expression systems are commercially available in kit form from, 10 e.g., Invitrogen, San Diego, California, U.S.A. (the MaxBac® kit), and such methods are well known in the art, as described in Summers and Smith, Texas Agricultural Experiment Station Bulletin No. 1555 (1987), incorporated herein by reference. As used herein, an insect cell capable of expressing a polynucleotide of the present invention is "transformed."

15 The protein of the invention may be prepared by culturing transformed host cells under culture conditions suitable to express the recombinant protein. The resulting expressed protein may then be purified from such culture (i.e., from culture medium or cell extracts) using known purification processes, such as gel filtration and ion exchange chromatography. The purification of the protein may also include an affinity column 20 containing agents which will bind to the protein; one or more column steps over such affinity resins as concanavalin A-agarose, heparin-toyopearl® or Cibacrom blue 3GA Sepharose®; one or more steps involving hydrophobic interaction chromatography using such resins as phenyl ether, butyl ether, or propyl ether; or immunoaffinity chromatography.

25 Alternatively, the protein of the invention may also be expressed in a form which will facilitate purification. For example, it may be expressed as a fusion protein, such as those of maltose binding protein (MBP), glutathione-S-transferase (GST) or thioredoxin (TRX). Kits for expression and purification of such fusion proteins are commercially 30 available from New England BioLabs (Beverly, MA), Pharmacia (Piscataway, NJ) and Invitrogen Corporation (Carlsbad, CA), respectively. The protein can also be tagged with an epitope and subsequently purified by using a specific antibody directed to such epitope. One such epitope ("Flag") is commercially available from the Eastman Kodak Company (New Haven, CT).

Finally, one or more reverse-phase high performance liquid chromatography (RP-HPLC) steps employing hydrophobic RP-HPLC media, e.g., silica gel having pendant methyl or other aliphatic groups, can be employed to further purify the protein. Some or all of the foregoing purification steps, in various combinations, can also be employed to 5 provide a substantially homogeneous isolated recombinant protein. The protein thus purified is substantially free of other mammalian proteins and is defined in accordance with the present invention as an "isolated protein."

The protein of the invention may also be expressed as a product of transgenic animals, e.g., as a component of the milk of transgenic cows, goats, pigs, or sheep which 10 are characterized by somatic or germ cells containing a nucleotide sequence encoding the protein.

The protein may also be produced by known conventional chemical synthesis. Methods for constructing the proteins of the present invention by synthetic means are known to those skilled in the art. The synthetically-constructed protein sequences, by 15 virtue of sharing primary, secondary or tertiary structural and/or conformational characteristics with proteins may possess biological properties in common therewith, including protein activity. Thus, they may be employed as biologically active or immunological substitutes for natural, purified proteins in screening of therapeutic compounds and in immunological processes for the development of antibodies.

20 The proteins provided herein also include proteins characterized by amino acid sequences similar to those of purified proteins but into which modification are naturally provided or deliberately engineered. For example, modifications in the peptide or DNA sequences can be made by those skilled in the art using known techniques. Modifications of interest in the protein sequences may include the alteration, substitution, replacement, 25 insertion or deletion of a selected amino acid residue in the coding sequence. For example, one or more of the cysteine residues may be deleted or replaced with another amino acid to alter the conformation of the molecule. Techniques for such alteration, substitution, replacement, insertion or deletion are well known to those skilled in the art (see, e.g., U.S. Patent No. 4,518,584). Preferably, such alteration, substitution, replacement, 30 insertion or deletion retains the desired activity of the protein.

Other fragments and derivatives of the sequences of proteins which would be expected to retain protein activity in whole or in part and may thus be useful for screening or other immunological methodologies may also be easily made by those skilled in the art

given the disclosures herein. Such modifications are believed to be encompassed by the present invention.

5 USES AND BIOLOGICAL ACTIVITY

The polynucleotides and proteins of the present invention are expected to exhibit one or more of the uses or biological activities (including those associated with assays cited herein) identified below. Uses or activities described for proteins of the present invention may be provided by administration or use of such proteins or by administration 10 or use of polynucleotides encoding such proteins (such as, for example, in gene therapies or vectors suitable for introduction of DNA).

Research Uses and Utilities

The polynucleotides provided by the present invention can be used by the research 15 community for various purposes. The polynucleotides can be used to express recombinant protein for analysis, characterization or therapeutic use; as markers for tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in disease states); as molecular weight markers on Southern gels; as chromosome markers or tags 20 (when labeled) to identify chromosomes or to map related gene positions; to compare with endogenous DNA sequences in patients to identify potential genetic disorders; as probes to hybridize and thus discover novel, related DNA sequences; as a source of information to derive PCR primers for genetic fingerprinting; as a probe to "subtract-out" known sequences in the process of discovering other novel polynucleotides; for selecting 25 and making oligomers for attachment to a "gene chip" or other support, including for examination of expression patterns; to raise anti-protein antibodies using DNA immunization techniques; and as an antigen to raise anti-DNA antibodies or elicit another immune response. Where the polynucleotide encodes a protein which binds or potentially binds to another protein (such as, for example, in a receptor-ligand interaction), the 30 polynucleotide can also be used in interaction trap assays (such as, for example, those described in Gyuris *et al.*, 1993, *Cell* 75: 791-803 and in Rossi *et al.*, 1997, *Proc. Natl. Acad. Sci. USA* 94: 8405-8410, all of which are incorporated by reference herein) to identify polynucleotides encoding the other protein with which binding occurs or to identify inhibitors of the binding interaction.

The proteins provided by the present invention can similarly be used in assay to determine biological activity, including in a panel of multiple proteins for high-throughput screening; to raise antibodies or to elicit another immune response; as a reagent (including the labeled reagent) in assays designed to quantitatively determine 5 levels of the protein (or its receptor) in biological fluids; as markers for tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in a disease state); and, of course, to isolate correlative receptors or ligands. Where the protein binds or potentially binds to another protein (such as, for example, in a receptor-ligand interaction), the 10 protein can be used to identify the other protein with which binding occurs or to identify inhibitors of the binding interaction. Proteins involved in these binding interactions can also be used to screen for peptide or small molecule inhibitors or agonists of the binding interaction.

Any or all of these research utilities are capable of being developed into reagent 15 grade or kit format for commercialization as research products.

Methods for performing the uses listed above are well known to those skilled in the art. References disclosing such methods include without limitation "Molecular Cloning: A Laboratory Manual", 2d ed., Cold Spring Harbor Laboratory Press, Sambrook, J., E.F. Fritsch and T. Maniatis eds., 1989, and "Methods in Enzymology: Guide to 20 Molecular Cloning Techniques", Academic Press, Berger, S.L. and A.R. Kimmel eds., 1987.

Nutritional Uses

Polynucleotides and proteins of the present invention can also be used as nutritional sources or supplements. Such uses include without limitation use as a protein 25 or amino acid supplement, use as a carbon source, use as a nitrogen source and use as a source of carbohydrate. In such cases the protein or polynucleotide of the invention can be added to the feed of a particular organism or can be administered as a separate solid or liquid preparation, such as in the form of powder, pills, solutions, suspensions or capsules. In the case of microorganisms, the protein or polynucleotide of the invention 30 can be added to the medium in or on which the microorganism is cultured.

Cytokine and Cell Proliferation/Differentiation Activity

A protein of the present invention may exhibit cytokine, cell proliferation (either inducing or inhibiting) or cell differentiation (either inducing or inhibiting) activity or may

induce production of other cytokines in certain cell populations. Many protein factors discovered to date, including all known cytokines, have exhibited activity in one or more factor-dependent cell proliferation assays, and hence the assays serve as a convenient confirmation of cytokine activity. The activity of a protein of the present invention is 5 evidenced by any one of a number of routine factor dependent cell proliferation assays for cell lines including, without limitation, 32D, DA2, DA1G, T10, B9, B9/11, BaF3, MC9/G, M+ (preB M+), 2E8, RB5, DA1, 123, T1165, HT2, CTLL2, TF-1, Mo7e and CMK.

The activity of a protein of the invention may, among other means, be measured 10 by the following methods:

Assays for T-cell or thymocyte proliferation include without limitation those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 15 7, Immunologic studies in Humans); Takai et al., J. Immunol. 137:3494-3500, 1986; Bertagnolli et al., J. Immunol. 145:1706-1712, 1990; Bertagnolli et al., Cellular Immunology 133:327-341, 1991; Bertagnolli, et al., J. Immunol. 149:3778-3783, 1992; Bowman et al., J. Immunol. 152: 1756-1761, 1994.

Assays for cytokine production and/or proliferation of spleen cells, lymph node 20 cells or thymocytes include, without limitation, those described in: Polyclonal T cell stimulation, Kruisbeek, A.M. and Shevach, E.M. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 3.12.1-3.12.14, John Wiley and Sons, Toronto. 1994; and Measurement of mouse and human Interferon γ , Schreiber, R.D. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 6.8.1-6.8.8, John Wiley and Sons, Toronto. 1994.

Assays for proliferation and differentiation of hematopoietic and lymphopoietic 25 cells include, without limitation, those described in: Measurement of Human and Murine Interleukin 2 and Interleukin 4, Bottomly, K., Davis, L.S. and Lipsky, P.E. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 6.3.1-6.3.12, John Wiley and Sons, Toronto. 1991; DeVries et al., J. Exp. Med. 173:1205-1211, 1991; Moreau et al., Nature 30 336:690-692, 1988; Greenberger et al., Proc. Natl. Acad. Sci. U.S.A. 80:2931-2938, 1983; Measurement of mouse and human interleukin 6 - Nordan, R. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 6.6.1-6.6.5, John Wiley and Sons, Toronto. 1991; Smith et al., Proc. Natl. Acad. Sci. U.S.A. 83:1857-1861, 1986; Measurement of human Interleukin 11 - Bennett, F., Giannotti, J., Clark, S.C. and Turner, K. J. In *Current Protocols*

in Immunology. J.E.e.a. Coligan eds. Vol 1 pp. 6.15.1 John Wiley and Sons, Toronto. 1991; Measurement of mouse and human Interleukin 9 - Ciarletta, A., Giannotti, J., Clark, S.C. and Turner, K.J. In *Current Protocols in Immunology.* J.E.e.a. Coligan eds. Vol 1 pp. 6.13.1, John Wiley and Sons, Toronto. 1991.

5 Assays for T-cell clone responses to antigens (which will identify, among others, proteins that affect APC-T cell interactions as well as direct T-cell effects by measuring proliferation and cytokine production) include, without limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience
10 (Chapter 3, In Vitro assays for Mouse Lymphocyte Function; Chapter 6, Cytokines and their cellular receptors; Chapter 7, Immunologic studies in Humans); Weinberger et al., Proc. Natl. Acad. Sci. USA 77:6091-6095, 1980; Weinberger et al., Eur. J. Immun. 11:405-411, 1981; Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988.

15

Immune Stimulating or Suppressing Activity

A protein of the present invention may also exhibit immune stimulating or immune suppressing activity, including without limitation the activities for which assays are described herein. A protein may be useful in the treatment of various immune 20 deficiencies and disorders (including severe combined immunodeficiency (SCID)), e.g., in regulating (up or down) growth and proliferation of T and/or B lymphocytes, as well as effecting the cytolytic activity of NK cells and other cell populations. These immune deficiencies may be genetic or be caused by viral (e.g., HIV) as well as bacterial or fungal infections, or may result from autoimmune disorders. More specifically, infectious 25 diseases causes by viral, bacterial, fungal or other infection may be treatable using a protein of the present invention, including infections by HIV, hepatitis viruses, herpesviruses, mycobacteria, Leishmania spp., malaria spp. and various fungal infections such as candidiasis. Of course, in this regard, a protein of the present invention may also be useful where a boost to the immune system generally may be desirable, i.e., in the 30 treatment of cancer.

Autoimmune disorders which may be treated using a protein of the present invention include, for example, connective tissue disease, multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes mellitus,

myasthenia gravis, graft-versus-host disease and autoimmune inflammatory eye disease. Such a protein of the present invention may also be useful in the treatment of allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems. Other conditions, in which immune suppression is desired (including, for 5 example, organ transplantation), may also be treatable using a protein of the present invention.

Using the proteins of the invention it may also be possible to regulate immune responses in a number of ways. Down regulation may be in the form of inhibiting or blocking an immune response already in progress or may involve preventing the 10 induction of an immune response. The functions of activated T cells may be inhibited by suppressing T cell responses or by inducing specific tolerance in T cells, or both. Immunosuppression of T cell responses is generally an active, non-antigen-specific, process which requires continuous exposure of the T cells to the suppressive agent. Tolerance, which involves inducing non-responsiveness or anergy in T cells, is 15 distinguishable from immunosuppression in that it is generally antigen-specific and persists after exposure to the tolerizing agent has ceased. Operationally, tolerance can be demonstrated by the lack of a T cell response upon reexposure to specific antigen in the absence of the tolerizing agent.

Down regulating or preventing one or more antigen functions (including without 20 limitation B lymphocyte antigen functions (such as, for example, B7)), e.g., preventing high level lymphokine synthesis by activated T cells, will be useful in situations of tissue, skin and organ transplantation and in graft-versus-host disease (GVHD). For example, blockage of T cell function should result in reduced tissue destruction in tissue transplantation. Typically, in tissue transplants, rejection of the transplant is initiated 25 through its recognition as foreign by T cells, followed by an immune reaction that destroys the transplant. The administration of a molecule which inhibits or blocks interaction of a B7 lymphocyte antigen with its natural ligand(s) on immune cells (such as a soluble, monomeric form of a peptide having B7-2 activity alone or in conjunction with a monomeric form of a peptide having an activity of another B lymphocyte antigen (e.g., B7- 30 1, B7-3) or blocking antibody), prior to transplantation can lead to the binding of the molecule to the natural ligand(s) on the immune cells without transmitting the corresponding costimulatory signal. Blocking B lymphocyte antigen function in this matter prevents cytokine synthesis by immune cells, such as T cells, and thus acts as an immunosuppressant. Moreover, the lack of costimulation may also be sufficient to

anergize the T cells, thereby inducing tolerance in a subject. Induction of long-term tolerance by B lymphocyte antigen-blocking reagents may avoid the necessity of repeated administration of these blocking reagents. To achieve sufficient immunosuppression or tolerance in a subject, it may also be necessary to block the function of a combination of 5 B lymphocyte antigens.

The efficacy of particular blocking reagents in preventing organ transplant rejection or GVHD can be assessed using animal models that are predictive of efficacy in humans. Examples of appropriate systems which can be used include allogeneic cardiac grafts in rats and xenogeneic pancreatic islet cell grafts in mice, both of which have been 10 used to examine the immunosuppressive effects of CTLA4Ig fusion proteins *in vivo* as described in Lenschow *et al.*, Science 257:789-792 (1992) and Turka *et al.*, Proc. Natl. Acad. Sci USA, 89:11102-11105 (1992). In addition, murine models of GVHD (see Paul ed., Fundamental Immunology, Raven Press, New York, 1989, pp. 846-847) can be used to determine the effect of blocking B lymphocyte antigen function *in vivo* on the development 15 of that disease.

Blocking antigen function may also be therapeutically useful for treating autoimmune diseases. Many autoimmune disorders are the result of inappropriate activation of T cells that are reactive against self tissue and which promote the production of cytokines and autoantibodies involved in the pathology of the diseases. Preventing the 20 activation of autoreactive T cells may reduce or eliminate disease symptoms. Administration of reagents which block costimulation of T cells by disrupting receptor:ligand interactions of B lymphocyte antigens can be used to inhibit T cell activation and prevent production of autoantibodies or T cell-derived cytokines which may be involved in the disease process. Additionally, blocking reagents may induce 25 antigen-specific tolerance of autoreactive T cells which could lead to long-term relief from the disease. The efficacy of blocking reagents in preventing or alleviating autoimmune disorders can be determined using a number of well-characterized animal models of human autoimmune diseases. Examples include murine experimental autoimmune encephalitis, systemic lupus erythematosis in MRL/*lpr/lpr* mice or NZB hybrid mice, 30 murine autoimmune collagen arthritis, diabetes mellitus in NOD mice and BB rats, and murine experimental myasthenia gravis (see Paul ed., Fundamental Immunology, Raven Press, New York, 1989, pp. 840-856).

Upregulation of an antigen function (preferably a B lymphocyte antigen function), as a means of up regulating immune responses, may also be useful in therapy.

Upregulation of immune responses may be in the form of enhancing an existing immune response or eliciting an initial immune response. For example, enhancing an immune response through stimulating B lymphocyte antigen function may be useful in cases of viral infection. In addition, systemic viral diseases such as influenza, the common cold, 5 and encephalitis might be alleviated by the administration of stimulatory forms of B lymphocyte antigens systemically.

Alternatively, anti-viral immune responses may be enhanced in an infected patient by removing T cells from the patient, costimulating the T cells *in vitro* with viral antigen-pulsed APCs either expressing a peptide of the present invention or together with a 10 stimulatory form of a soluble peptide of the present invention and reintroducing the *in vitro* activated T cells into the patient. Another method of enhancing anti-viral immune responses would be to isolate infected cells from a patient, transfet them with a nucleic acid encoding a protein of the present invention as described herein such that the cells express all or a portion of the protein on their surface, and reintroduce the transfected 15 cells into the patient. The infected cells would now be capable of delivering a costimulatory signal to, and thereby activate, T cells *in vivo*.

In another application, up regulation or enhancement of antigen function (preferably B lymphocyte antigen function) may be useful in the induction of tumor immunity. Tumor cells (*e.g.*, sarcoma, melanoma, lymphoma, leukemia, neuroblastoma, 20 carcinoma) transfected with a nucleic acid encoding at least one peptide of the present invention can be administered to a subject to overcome tumor-specific tolerance in the subject. If desired, the tumor cell can be transfected to express a combination of peptides. For example, tumor cells obtained from a patient can be transfected *ex vivo* with an expression vector directing the expression of a peptide having B7-2-like activity alone, or 25 in conjunction with a peptide having B7-1-like activity and/or B7-3-like activity. The transfected tumor cells are returned to the patient to result in expression of the peptides on the surface of the transfected cell. Alternatively, gene therapy techniques can be used to target a tumor cell for transfection *in vivo*.

The presence of the peptide of the present invention having the activity of a B 30 lymphocyte antigen(s) on the surface of the tumor cell provides the necessary costimulation signal to T cells to induce a T cell mediated immune response against the transfected tumor cells. In addition, tumor cells which lack MHC class I or MHC class II molecules, or which fail to reexpress sufficient amounts of MHC class I or MHC class II molecules, can be transfected with nucleic acid encoding all or a portion of (*e.g.*, a

cytoplasmic-domain truncated portion) of an MHC class I α chain protein and β_2 microglobulin protein or an MHC class II α chain protein and an MHC class II β chain protein to thereby express MHC class I or MHC class II proteins on the cell surface. Expression of the appropriate class I or class II MHC in conjunction with a peptide having 5 the activity of a B lymphocyte antigen (e.g., B7-1, B7-2, B7-3) induces a T cell mediated immune response against the transfected tumor cell. Optionally, a gene encoding an antisense construct which blocks expression of an MHC class II associated protein, such as the invariant chain, can also be cotransfected with a DNA encoding a peptide having the activity of a B lymphocyte antigen to promote presentation of tumor associated 10 antigens and induce tumor specific immunity. Thus, the induction of a T cell mediated immune response in a human subject may be sufficient to overcome tumor-specific tolerance in the subject.

The activity of a protein of the invention may, among other means, be measured by the following methods:

15 Suitable assays for thymocyte or splenocyte cytotoxicity include, without limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Herrmann et al., Proc. Natl. Acad. Sci. 20 USA 78:2488-2492, 1981; Herrmann et al., J. Immunol. 128:1968-1974, 1982; Handa et al., J. Immunol. 135:1564-1572, 1985; Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988; Herrmann et al., Proc. Natl. Acad. Sci. USA 78:2488-2492, 1981; Herrmann et al., J. Immunol. 128:1968-1974, 1982; Handa et al., J. Immunol. 135:1564-1572, 1985; Takai et al., J. Immunol. 137:3494-3500, 1986; Bowman et al., J. 25 Virology 61:1992-1998; Takai et al., J. Immunol. 140:508-512, 1988; Bertagnolli et al., Cellular Immunology 133:327-341, 1991; Brown et al., J. Immunol. 153:3079-3092, 1994.

Assays for T-cell-dependent immunoglobulin responses and isotype switching (which will identify, among others, proteins that modulate T-cell dependent antibody responses and that affect Th1/Th2 profiles) include, without limitation, those described 30 in: Maliszewski, J. Immunol. 144:3028-3033, 1990; and Assays for B cell function: *In vitro* antibody production, Mond, J.J. and Brunswick, M. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 3.8.1-3.8.16, John Wiley and Sons, Toronto. 1994.

Mixed lymphocyte reaction (MLR) assays (which will identify, among others, proteins that generate predominantly Th1 and CTL responses) include, without limitation,

those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988; Bertagnolli et al., J. Immunol. 149:3778-3783, 1992.

Dendritic cell-dependent assays (which will identify, among others, proteins expressed by dendritic cells that activate naive T-cells) include, without limitation, those described in: Guery et al., J. Immunol. 134:536-544, 1995; Inaba et al., Journal of Experimental Medicine 173:549-559, 1991; Macatonia et al., Journal of Immunology 154:5071-5079, 1995; Porgador et al., Journal of Experimental Medicine 182:255-260, 1995; Nair et al., Journal of Virology 67:4062-4069, 1993; Huang et al., Science 264:961-965, 1994; Macatonia et al., Journal of Experimental Medicine 169:1255-1264, 1989; Bhardwaj et al., Journal of Clinical Investigation 94:797-807, 1994; and Inaba et al., Journal of Experimental Medicine 172:631-640, 1990.

Assays for lymphocyte survival/apoptosis (which will identify, among others, proteins that prevent apoptosis after superantigen induction and proteins that regulate lymphocyte homeostasis) include, without limitation, those described in: Darzynkiewicz et al., Cytometry 13:795-808, 1992; Gorczyca et al., Leukemia 7:659-670, 1993; Gorczyca et al., Cancer Research 53:1945-1951, 1993; Itoh et al., Cell 66:233-243, 1991; Zacharchuk, Journal of Immunology 145:4037-4045, 1990; Zamai et al., Cytometry 14:891-897, 1993; Gorczyca et al., International Journal of Oncology 1:639-648, 1992.

Assays for proteins that influence early steps of T-cell commitment and development include, without limitation, those described in: Antica et al., Blood 84:111-117, 1994; Fine et al., Cellular Immunology 155:111-122, 1994; Galy et al., Blood 85:2770-2778, 1995; Toki et al., Proc. Nat. Acad. Sci. USA 88:7548-7551, 1991.

Hematopoiesis Regulating Activity

A protein of the present invention may be useful in regulation of hematopoiesis and, consequently, in the treatment of myeloid or lymphoid cell deficiencies. Even marginal biological activity in support of colony forming cells or of factor-dependent cell lines indicates involvement in regulating hematopoiesis, e.g. in supporting the growth and proliferation of erythroid progenitor cells alone or in combination with other cytokines, thereby indicating utility, for example, in treating various anemias or for use in conjunction with irradiation/chemotherapy to stimulate the production of erythroid

precursors and/or erythroid cells; in supporting the growth and proliferation of myeloid cells such as granulocytes and monocytes/macrophages (i.e., traditional CSF activity) useful, for example, in conjunction with chemotherapy to prevent or treat consequent myelo-suppression; in supporting the growth and proliferation of megakaryocytes and 5 consequently of platelets thereby allowing prevention or treatment of various platelet disorders such as thrombocytopenia, and generally for use in place of or complimentary to platelet transfusions; and/or in supporting the growth and proliferation of hematopoietic stem cells which are capable of maturing to any and all of the above-mentioned hematopoietic cells and therefore find therapeutic utility in various stem cell 10 disorders (such as those usually treated with transplantation, including, without limitation, aplastic anemia and paroxysmal nocturnal hemoglobinuria), as well as in repopulating the stem cell compartment post irradiation/chemotherapy, either *in-vivo* or *ex-vivo* (i.e., in conjunction with bone marrow transplantation or with peripheral progenitor cell transplantation (homologous or heterologous)) as normal cells or 15 genetically manipulated for gene therapy.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Suitable assays for proliferation and differentiation of various hematopoietic lines are cited above.

20 Assays for embryonic stem cell differentiation (which will identify, among others, proteins that influence embryonic differentiation hematopoiesis) include, without limitation, those described in: Johansson et al. *Cellular Biology* 15:141-151, 1995; Keller et al., *Molecular and Cellular Biology* 13:473-486, 1993; McClanahan et al., *Blood* 81:2903-2915, 1993.

25 Assays for stem cell survival and differentiation (which will identify, among others, proteins that regulate lympho-hematopoiesis) include, without limitation, those described in: Methylcellulose colony forming assays, Freshney, M.G. In *Culture of Hematopoietic Cells*. R.I. Freshney, et al. eds. Vol pp. 265-268, Wiley-Liss, Inc., New York, NY. 1994; Hirayama et al., *Proc. Natl. Acad. Sci. USA* 89:5907-5911, 1992; Primitive 30 hematopoietic colony forming celis with high proliferative potential, McNiece, I.K. and Briddell, R.A. In *Culture of Hematopoietic Cells*. R.I. Freshney, et al. eds. Vol pp. 23-39, Wiley-Liss, Inc., New York, NY. 1994; Neben et al., *Experimental Hematology* 22:353-359, 1994; Cobblestone area forming cell assay, Ploemacher, R.E. In *Culture of Hematopoietic Cells*. R.I. Freshney, et al. eds. Vol pp. 1-21, Wiley-Liss, Inc., New York, NY. 1994; Long

term bone marrow cultures in the presence of stromal cells, Spooncer, E., Dexter, M. and Allen, T. In *Culture of Hematopoietic Cells*. R.I. Freshney, et al. eds. Vol pp. 163-179, Wiley-Liss, Inc., New York, NY. 1994; Long term culture initiating cell assay, Sutherland, H.J. In *Culture of Hematopoietic Cells*. R.I. Freshney, et al. eds. Vol pp. 139-162, Wiley-Liss, Inc., New York, NY. 1994.

Tissue Growth Activity

A protein of the present invention also may have utility in compositions used for bone, cartilage, tendon, ligament and/or nerve tissue growth or regeneration, as well as 10 for wound healing and tissue repair and replacement, and in the treatment of burns, incisions and ulcers.

A protein of the present invention, which induces cartilage and/or bone growth in circumstances where bone is not normally formed, has application in the healing of bone fractures and cartilage damage or defects in humans and other animals. Such a 15 preparation employing a protein of the invention may have prophylactic use in closed as well as open fracture reduction and also in the improved fixation of artificial joints. *De novo* bone formation induced by an osteogenic agent contributes to the repair of congenital, trauma induced, or oncologic resection induced craniofacial defects, and also is useful in cosmetic plastic surgery.

20 A protein of this invention may also be used in the treatment of periodontal disease, and in other tooth repair processes. Such agents may provide an environment to attract bone-forming cells, stimulate growth of bone-forming cells or induce differentiation of progenitors of bone-forming cells. A protein of the invention may also be useful in the treatment of osteoporosis or osteoarthritis, such as through stimulation 25 of bone and/or cartilage repair or by blocking inflammation or processes of tissue destruction (collagenase activity, osteoclast activity, etc.) mediated by inflammatory processes.

Another category of tissue regeneration activity that may be attributable to the 30 protein of the present invention is tendon/ligament formation. A protein of the present invention, which induces tendon/ligament-like tissue or other tissue formation in circumstances where such tissue is not normally formed, has application in the healing of tendon or ligament tears, deformities and other tendon or ligament defects in humans and other animals. Such a preparation employing a tendon/ligament-like tissue inducing protein may have prophylactic use in preventing damage to tendon or ligament tissue, as

well as use in the improved fixation of tendon or ligament to bone or other tissues, and in repairing defects to tendon or ligament tissue. De novo tendon/ligament-like tissue formation induced by a composition of the present invention contributes to the repair of congenital, trauma induced, or other tendon or ligament defects of other origin, and is also
5 useful in cosmetic plastic surgery for attachment or repair of tendons or ligaments. The compositions of the present invention may provide an environment to attract tendon- or ligament-forming cells, stimulate growth of tendon- or ligament-forming cells, induce differentiation of progenitors of tendon- or ligament-forming cells, or induce growth of tendon/ligament cells or progenitors *ex vivo* for return *in vivo* to effect tissue repair. The
10 compositions of the invention may also be useful in the treatment of tendinitis, carpal tunnel syndrome and other tendon or ligament defects. The compositions may also include an appropriate matrix and/or sequestering agent as a carrier as is well known in the art.

The protein of the present invention may also be useful for proliferation of neural
15 cells and for regeneration of nerve and brain tissue, *i.e.* for the treatment of central and peripheral nervous system diseases and neuropathies, as well as mechanical and traumatic disorders, which involve degeneration, death or trauma to neural cells or nerve tissue. More specifically, a protein may be used in the treatment of diseases of the peripheral nervous system, such as peripheral nerve injuries, peripheral neuropathy and
20 localized neuropathies, and central nervous system diseases, such as Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome. Further conditions which may be treated in accordance with the present invention include mechanical and traumatic disorders, such as spinal cord disorders, head trauma and cerebrovascular diseases such as stroke. Peripheral neuropathies resulting
25 from chemotherapy or other medical therapies may also be treatable using a protein of the invention.

Proteins of the invention may also be useful to promote better or faster closure of non-healing wounds, including without limitation pressure ulcers, ulcers associated with vascular insufficiency, surgical and traumatic wounds, and the like.

30 It is expected that a protein of the present invention may also exhibit activity for generation or regeneration of other tissues, such as organs (including, for example, pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac) and vascular (including vascular endothelium) tissue, or for promoting the growth of cells comprising such tissues. Part of the desired effects may be by inhibition or modulation

of fibrotic scarring to allow normal tissue to regenerate. A protein of the invention may also exhibit angiogenic activity.

A protein of the present invention may also be useful for gut protection or regeneration and treatment of lung or liver fibrosis, reperfusion injury in various tissues, 5 and conditions resulting from systemic cytokine damage.

A protein of the present invention may also be useful for promoting or inhibiting differentiation of tissues described above from precursor tissues or cells; or for inhibiting the growth of tissues described above.

The activity of a protein of the invention may, among other means, be measured 10 by the following methods:

Assays for tissue generation activity include, without limitation, those described in: International Patent Publication No. WO95/16035 (bone, cartilage, tendon); International Patent Publication No. WO95/05846 (nerve, neuronal); International Patent Publication No. WO91/07491 (skin, endothelium).

15 Assays for wound healing activity include, without limitation, those described in: Winter, Epidermal Wound Healing, pps. 71-112 (Maibach, HI and Rovee, DT, eds.), Year Book Medical Publishers, Inc., Chicago, as modified by Eaglstein and Mertz, J. Invest. Dermatol 71:382-84 (1978).

20 Activin/Inhibin Activity

A protein of the present invention may also exhibit activin- or inhibin-related activities. Inhibins are characterized by their ability to inhibit the release of follicle stimulating hormone (FSH), while activins and are characterized by their ability to stimulate the release of follicle stimulating hormone (FSH). Thus, a protein of the present 25 invention, alone or in heterodimers with a member of the inhibin α family, may be useful as a contraceptive based on the ability of inhibins to decrease fertility in female mammals and decrease spermatogenesis in male mammals. Administration of sufficient amounts of other inhibins can induce infertility in these mammals. Alternatively, the protein of the invention, as a homodimer or as a heterodimer with other protein subunits of the inhibin- 30 β group, may be useful as a fertility inducing therapeutic, based upon the ability of activin molecules in stimulating FSH release from cells of the anterior pituitary. See, for example, United States Patent 4,798,885. A protein of the invention may also be useful for advancement of the onset of fertility in sexually immature mammals, so as to increase the lifetime reproductive performance of domestic animals such as cows, sheep and pigs.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Assays for activin/inhibin activity include, without limitation, those described in: Vale et al., Endocrinology 91:562-572, 1972; Ling et al., Nature 321:779-782, 1986; Vale et 5 al., Nature 321:776-779, 1986; Mason et al., Nature 318:659-663, 1985; Forage et al., Proc. Natl. Acad. Sci. USA 83:3091-3095, 1986.

Chemotactic/Chemokinetic Activity

A protein of the present invention may have chemotactic or chemokinetic activity 10 (e.g., act as a chemokine) for mammalian cells, including, for example, monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells. Chemotactic and chemokinetic proteins can be used to mobilize or attract a desired cell population to a desired site of action. Chemotactic or chemokinetic proteins provide particular advantages in treatment of wounds and other trauma to tissues, as well as in 15 treatment of localized infections. For example, attraction of lymphocytes, monocytes or neutrophils to tumors or sites of infection may result in improved immune responses against the tumor or infecting agent.

A protein or peptide has chemotactic activity for a particular cell population if it 20 can stimulate, directly or indirectly, the directed orientation or movement of such cell population. Preferably, the protein or peptide has the ability to directly stimulate directed movement of cells. Whether a particular protein has chemotactic activity for a population of cells can be readily determined by employing such protein or peptide in any known assay for cell chemotaxis.

The activity of a protein of the invention may, among other means, be measured 25 by the following methods:

Assays for chemotactic activity (which will identify proteins that induce or prevent chemotaxis) consist of assays that measure the ability of a protein to induce the migration of cells across a membrane as well as the ability of a protein to induce the adhesion of one cell population to another cell population. Suitable assays for movement and adhesion 30 include, without limitation, those described in: Current Protocols in Immunology, Ed by J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W. Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 6.12, Measurement of alpha and beta Chemokines 6.12.1-6.12.28; Taub et al. J. Clin. Invest. 95:1370-1376, 1995; Lind et al.

APMIS 103:140-146, 1995; Muller et al Eur. J. Immunol. 25: 1744-1748; Gruber et al. J. of Immunol. 152:5860-5867, 1994; Johnston et al. J. of Immunol. 153: 1762-1768, 1994.

Hemostatic and Thrombolytic Activity

5 A protein of the invention may also exhibit hemostatic or thrombolytic activity. As a result, such a protein is expected to be useful in treatment of various coagulation disorders (including hereditary disorders, such as hemophilias) or to enhance coagulation and other hemostatic events in treating wounds resulting from trauma, surgery or other causes. A protein of the invention may also be useful for dissolving or inhibiting 10 formation of thromboses and for treatment and prevention of conditions resulting therefrom (such as, for example, infarction of cardiac and central nervous system vessels (e.g., stroke).

The activity of a protein of the invention may, among other means, be measured by the following methods:

15 Assay for hemostatic and thrombolytic activity include, without limitation, those described in: Linet et al., J. Clin. Pharmacol. 26:131-140, 1986; Burdick et al., Thrombosis Res. 45:413-419, 1987; Humphrey et al., Fibrinolysis 5:71-79 (1991); Schaub, Prostaglandins 35:467-474, 1988.

20 Receptor/Ligand Activity

A protein of the present invention may also demonstrate activity as receptors, receptor ligands or inhibitors or agonists of receptor/ligand interactions. Examples of such receptors and ligands include, without limitation, cytokine receptors and their ligands, receptor kinases and their ligands, receptor phosphatases and their ligands, 25 receptors involved in cell-cell interactions and their ligands (including without limitation, cellular adhesion molecules (such as selectins, integrins and their ligands) and receptor/ligand pairs involved in antigen presentation, antigen recognition and development of cellular and humoral immune responses). Receptors and ligands are also useful for screening of potential peptide or small molecule inhibitors of the relevant 30 receptor/ligand interaction. A protein of the present invention (including, without limitation, fragments of receptors and ligands) may themselves be useful as inhibitors of receptor/ligand interactions.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Suitable assays for receptor-ligand activity include without limitation those described in: Current Protocols in Immunology, Ed by J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W. Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 7.28, Measurement of Cellular Adhesion under static conditions 7.28.1-7.28.22), Takai et al., Proc. Natl. Acad. Sci. USA 84:6864-6868, 1987; Bierer et al., J. Exp. Med. 168:1145-1156, 1988; Rosenstein et al., J. Exp. Med. 169:149-160 1989; Stoltenborg et al., J. Immunol. Methods 175:59-68, 1994; Stitt et al., Cell 80:661-670, 1995.

10 Anti-Inflammatory Activity

Proteins of the present invention may also exhibit anti-inflammatory activity. The anti-inflammatory activity may be achieved by providing a stimulus to cells involved in the inflammatory response, by inhibiting or promoting cell-cell interactions (such as, for example, cell adhesion), by inhibiting or promoting chemotaxis of cells involved in the inflammatory process, inhibiting or promoting cell extravasation, or by stimulating or suppressing production of other factors which more directly inhibit or promote an inflammatory response. Proteins exhibiting such activities can be used to treat inflammatory conditions including chronic or acute conditions), including without limitation inflammation associated with infection (such as septic shock, sepsis or systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine-induced lung injury, inflammatory bowel disease, Crohn's disease or resulting from over production of cytokines such as TNF or IL-1. Proteins of the invention may also be useful to treat anaphylaxis and hypersensitivity to an antigenic substance or material.

25

Cadherin/Tumor Invasion Suppressor Activity

Cadherins are calcium-dependent adhesion molecules that appear to play major roles during development, particularly in defining specific cell types. Loss or alteration of normal cadherin expression can lead to changes in cell adhesion properties linked to tumor growth and metastasis. Cadherin malfunction is also implicated in other human diseases, such as pemphigus vulgaris and pemphigus foliaceus (auto-immune blistering skin diseases), Crohn's disease, and some developmental abnormalities.

The cadherin superfamily includes well over forty members, each with a distinct pattern of expression. All members of the superfamily have in common conserved

extracellular repeats (cadherin domains), but structural differences are found in other parts of the molecule. The cadherin domains bind calcium to form their tertiary structure and thus calcium is required to mediate their adhesion. Only a few amino acids in the first cadherin domain provide the basis for homophilic adhesion; modification of this 5 recognition site can change the specificity of a cadherin so that instead of recognizing only itself, the mutant molecule can now also bind to a different cadherin. In addition, some cadherins engage in heterophilic adhesion with other cadherins.

E-cadherin, one member of the cadherin superfamily, is expressed in epithelial cell types. Pathologically, if E-cadherin expression is lost in a tumor, the malignant cells 10 become invasive and the cancer metastasizes. Transfection of cancer cell lines with polynucleotides expressing E-cadherin has reversed cancer-associated changes by returning altered cell shapes to normal, restoring cells' adhesiveness to each other and to their substrate, decreasing the cell growth rate, and drastically reducing anchorage-independent cell growth. Thus, reintroducing E-cadherin expression reverts carcinomas 15 to a less advanced stage. It is likely that other cadherins have the same invasion suppressor role in carcinomas derived from other tissue types. Therefore, proteins of the present invention with cadherin activity, and polynucleotides of the present invention encoding such proteins, can be used to treat cancer. Introducing such proteins or polynucleotides into cancer cells can reduce or eliminate the cancerous changes observed 20 in these cells by providing normal cadherin expression.

Cancer cells have also been shown to express cadherins of a different tissue type than their origin, thus allowing these cells to invade and metastasize in a different tissue in the body. Proteins of the present invention with cadherin activity, and polynucleotides of the present invention encoding such proteins, can be substituted in these cells for the 25 inappropriately expressed cadherins, restoring normal cell adhesive properties and reducing or eliminating the tendency of the cells to metastasize.

Additionally, proteins of the present invention with cadherin activity, and polynucleotides of the present invention encoding such proteins, can be used to generate antibodies recognizing and binding to cadherins. Such antibodies can be used to block 30 the adhesion of inappropriately expressed tumor-cell cadherins, preventing the cells from forming a tumor elsewhere. Such an anti-cadherin antibody can also be used as a marker for the grade, pathological type, and prognosis of a cancer, i.e. the more progressed the cancer, the less cadherin expression there will be, and this decrease in cadherin expression can be detected by the use of a cadherin-binding antibody.

Fragments of proteins of the present invention with cadherin activity, preferably a polypeptide comprising a decapeptide of the cadherin recognition site, and polynucleotides of the present invention encoding such protein fragments, can also be used to block cadherin function by binding to cadherins and preventing them from binding in 5 ways that produce undesirable effects. Additionally, fragments of proteins of the present invention with cadherin activity, preferably truncated soluble cadherin fragments which have been found to be stable in the circulation of cancer patients, and polynucleotides encoding such protein fragments, can be used to disturb proper cell-cell adhesion.

Assays for cadherin adhesive and invasive suppressor activity include, without 10 limitation, those described in: Hortsch et al. J Biol Chem 270 (32): 18809-18817, 1995; Miyaki et al. Oncogene 11: 2547-2552, 1995; Ozawa et al. Cell 63: 1033-1038, 1990.

Tumor Inhibition Activity

In addition to the activities described above for immunological treatment or 15 prevention of tumors, a protein of the invention may exhibit other anti-tumor activities. A protein may inhibit tumor growth directly or indirectly (such as, for example, via antibody-dependent cell-mediated cytotoxicity (ADCC)). A protein may exhibit its tumor inhibitory activity by acting on tumor tissue or tumor precursor tissue, by inhibiting formation of tissues necessary to support tumor growth (such as, for example, by 20 inhibiting angiogenesis), by causing production of other factors, agents or cell types which inhibit tumor growth, or by suppressing, eliminating or inhibiting factors, agents or cell types which promote tumor growth.

Other Activities

25 A protein of the invention may also exhibit one or more of the following additional activities or effects: inhibiting the growth, infection or function of, or killing, infectious agents, including, without limitation, bacteria, viruses, fungi and other parasites; effecting (suppressing or enhancing) bodily characteristics, including, without limitation, height, weight, hair color, eye color, skin, fat to lean ratio or other tissue pigmentation, or organ 30 or body part size or shape (such as, for example, breast augmentation or diminution, change in bone form or shape); effecting biorhythms or circadian cycles or rhythms; effecting the fertility of male or female subjects; effecting the metabolism, catabolism, anabolism, processing, utilization, storage or elimination of dietary fat, lipid, protein, carbohydrate, vitamins, minerals, cofactors or other nutritional factors or component(s);

effecting behavioral characteristics, including, without limitation, appetite, libido, stress, cognition (including cognitive disorders), depression (including depressive disorders) and violent behaviors; providing analgesic effects or other pain reducing effects; promoting differentiation and growth of embryonic stem cells in lineages other than hematopoietic
5 lineages; hormonal or endocrine activity; in the case of enzymes, correcting deficiencies of the enzyme and treating deficiency-related diseases; treatment of hyperproliferative disorders (such as, for example, psoriasis); immunoglobulin-like activity (such as, for example, the ability to bind antigens or complement); and the ability to act as an antigen in a vaccine composition to raise an immune response against such protein or another
10 material or entity which is cross-reactive with such protein.

ADMINISTRATION AND DOSING

A protein of the present invention (from whatever source derived, including
15 without limitation from recombinant and non-recombinant sources) may be used in a pharmaceutical composition when combined with a pharmaceutically acceptable carrier. Such a composition may also contain (in addition to protein and a carrier) diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials well known in the art. The term "pharmaceutically acceptable" means a non-toxic material that does not interfere with the
20 effectiveness of the biological activity of the active ingredient(s). The characteristics of the carrier will depend on the route of administration. The pharmaceutical composition of the invention may also contain cytokines, lymphokines, or other hematopoietic factors such as M-CSF, GM-CSF, TNF, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IFN, TNF0, TNF1, TNF2, G-CSF, Meg-CSF, thrombopoietin, stem
25 cell factor, and erythropoietin. The pharmaceutical composition may further contain other agents which either enhance the activity of the protein or compliment its activity or use in treatment. Such additional factors and/or agents may be included in the pharmaceutical composition to produce a synergistic effect with protein of the invention, or to minimize side effects. Conversely, protein of the present invention may be included
30 in formulations of the particular cytokine, lymphokine, other hematopoietic factor, thrombolytic or anti-thrombotic factor, or anti-inflammatory agent to minimize side effects of the cytokine, lymphokine, other hematopoietic factor, thrombolytic or anti-thrombotic factor, or anti-inflammatory agent.

A protein of the present invention may be active in multimers (e.g., heterodimers or homodimers) or complexes with itself or other proteins. As a result, pharmaceutical compositions of the invention may comprise a protein of the invention in such multimeric or complexed form.

5 The pharmaceutical composition of the invention may be in the form of a complex of the protein(s) of present invention along with protein or peptide antigens. The protein and/or peptide antigen will deliver a stimulatory signal to both B and T lymphocytes. B lymphocytes will respond to antigen through their surface immunoglobulin receptor. T lymphocytes will respond to antigen through the T cell receptor (TCR) following 10 presentation of the antigen by MHC proteins. MHC and structurally related proteins including those encoded by class I and class II MHC genes on host cells will serve to present the peptide antigen(s) to T lymphocytes. The antigen components could also be supplied as purified MHC-peptide complexes alone or with co-stimulatory molecules that can directly signal T cells. Alternatively antibodies able to bind surface immunoglobulin 15 and other molecules on B cells as well as antibodies able to bind the TCR and other molecules on T cells can be combined with the pharmaceutical composition of the invention.

The pharmaceutical composition of the invention may be in the form of a liposome in which protein of the present invention is combined, in addition to other 20 pharmaceutically acceptable carriers, with amphipathic agents such as lipids which exist in aggregated form as micelles, insoluble monolayers, liquid crystals, or lamellar layers in aqueous solution. Suitable lipids for liposomal formulation include, without limitation, monoglycerides, diglycerides, sulfatides, lysolecithin, phospholipids, saponin, bile acids, and the like. Preparation of such liposomal formulations is within the level of skill in the 25 art, as disclosed, for example, in U.S. Patent No. 4,235,871; U.S. Patent No. 4,501,728; U.S. Patent No. 4,837,028; and U.S. Patent No. 4,737,323, all of which are incorporated herein by reference.

As used herein, the term "therapeutically effective amount" means the total amount of each active component of the pharmaceutical composition or method that is 30 sufficient to show a meaningful patient benefit, i.e., treatment, healing, prevention or amelioration of the relevant medical condition, or an increase in rate of treatment, healing, prevention or amelioration of such conditions. When applied to an individual active ingredient, administered alone, the term refers to that ingredient alone. When applied to

a combination, the term refers to combined amounts of the active ingredients that result in the therapeutic effect, whether administered in combination, serially or simultaneously.

In practicing the method of treatment or use of the present invention, a therapeutically effective amount of protein of the present invention is administered to a mammal having a condition to be treated. Protein of the present invention may be administered in accordance with the method of the invention either alone or in combination with other therapies such as treatments employing cytokines, lymphokines or other hematopoietic factors. When co-administered with one or more cytokines, lymphokines or other hematopoietic factors, protein of the present invention may be administered either simultaneously with the cytokine(s), lymphokine(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors, or sequentially. If administered sequentially, the attending physician will decide on the appropriate sequence of administering protein of the present invention in combination with cytokine(s), lymphokine(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors.

Administration of protein of the present invention used in the pharmaceutical composition or to practice the method of the present invention can be carried out in a variety of conventional ways, such as oral ingestion, inhalation, topical application or cutaneous, subcutaneous, intraperitoneal, parenteral or intravenous injection.

20 Intravenous administration to the patient is preferred.

When a therapeutically effective amount of protein of the present invention is administered orally, protein of the present invention will be in the form of a tablet, capsule, powder, solution or elixir. When administered in tablet form, the pharmaceutical composition of the invention may additionally contain a solid carrier such as a gelatin or an adjuvant. The tablet, capsule, and powder contain from about 5 to 95% protein of the present invention, and preferably from about 25 to 90% protein of the present invention. When administered in liquid form, a liquid carrier such as water, petroleum, oils of animal or plant origin such as peanut oil, mineral oil, soybean oil, or sesame oil, or synthetic oils may be added. The liquid form of the pharmaceutical composition may further contain physiological saline solution, dextrose or other saccharide solution, or glycols such as ethylene glycol, propylene glycol or polyethylene glycol. When administered in liquid form, the pharmaceutical composition contains from about 0.5 to 90% by weight of protein of the present invention, and preferably from about 1 to 50% protein of the present invention.

When a therapeutically effective amount of protein of the present invention is administered by intravenous, cutaneous or subcutaneous injection, protein of the present invention will be in the form of a pyrogen-free, parenterally acceptable aqueous solution. The preparation of such parenterally acceptable protein solutions, having due regard to 5 pH, isotonicity, stability, and the like, is within the skill in the art. A preferred pharmaceutical composition for intravenous, cutaneous, or subcutaneous injection should contain, in addition to protein of the present invention, an isotonic vehicle such as Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, Lactated Ringer's Injection, or other vehicle as known in the art. The 10 pharmaceutical composition of the present invention may also contain stabilizers, preservatives, buffers, antioxidants, or other additives known to those of skill in the art.

The amount of protein of the present invention in the pharmaceutical composition of the present invention will depend upon the nature and severity of the condition being treated, and on the nature of prior treatments which the patient has undergone. 15 Ultimately, the attending physician will decide the amount of protein of the present invention with which to treat each individual patient. Initially, the attending physician will administer low doses of protein of the present invention and observe the patient's response. Larger doses of protein of the present invention may be administered until the optimal therapeutic effect is obtained for the patient, and at that point the dosage is not 20 increased further. It is contemplated that the various pharmaceutical compositions used to practice the method of the present invention should contain about 0.01 µg to about 100 mg (preferably about 0.1ng to about 10 mg, more preferably about 0.1 µg to about 1 mg) of protein of the present invention per kg body weight.

The duration of intravenous therapy using the pharmaceutical composition of the 25 present invention will vary, depending on the severity of the disease being treated and the condition and potential idiosyncratic response of each individual patient. It is contemplated that the duration of each application of the protein of the present invention will be in the range of 12 to 24 hours of continuous intravenous administration. Ultimately the attending physician will decide on the appropriate duration of intravenous 30 therapy using the pharmaceutical composition of the present invention.

Protein of the invention may also be used to immunize animals to obtain polyclonal and monoclonal antibodies which specifically react with the protein. Such antibodies may be obtained using either the entire protein or fragments thereof as an immunogen. The peptide immunogens additionally may contain a cysteine residue at the

carboxyl terminus, and are conjugated to a haptent such as keyhole limpet hemocyanin (KLH). Methods for synthesizing such peptides are known in the art, for example, as in R.P. Merrifield, J. Amer. Chem. Soc. 85, 2149-2154 (1963); J.L. Krstenansky, *et al.*, FEBS Lett. 211, 10 (1987). Monoclonal antibodies binding to the protein of the invention may be 5 useful diagnostic agents for the immunodetection of the protein. Neutralizing monoclonal antibodies binding to the protein may also be useful therapeutics for both conditions associated with the protein and also in the treatment of some forms of cancer where abnormal expression of the protein is involved. In the case of cancerous cells or leukemic cells, neutralizing monoclonal antibodies against the protein may be useful in detecting 10 and preventing the metastatic spread of the cancerous cells, which may be mediated by the protein.

For compositions of the present invention which are useful for bone, cartilage, tendon or ligament regeneration, the therapeutic method includes administering the composition topically, systematically, or locally as an implant or device. When 15 administered, the therapeutic composition for use in this invention is, of course, in a pyrogen-free, physiologically acceptable form. Further, the composition may desirably be encapsulated or injected in a viscous form for delivery to the site of bone, cartilage or tissue damage. Topical administration may be suitable for wound healing and tissue repair. Therapeutically useful agents other than a protein of the invention which may also 20 optionally be included in the composition as described above, may alternatively or additionally, be administered simultaneously or sequentially with the composition in the methods of the invention. Preferably for bone and/or cartilage formation, the composition would include a matrix capable of delivering the protein-containing composition to the site of bone and/or cartilage damage, providing a structure for the 25 developing bone and cartilage and optimally capable of being resorbed into the body. Such matrices may be formed of materials presently in use for other implanted medical applications.

The choice of matrix material is based on biocompatibility, biodegradability, mechanical properties, cosmetic appearance and interface properties. The particular 30 application of the compositions will define the appropriate formulation. Potential matrices for the compositions may be biodegradable and chemically defined calcium sulfate, tricalciumphosphate, hydroxyapatite, polylactic acid, polyglycolic acid and polyanhydrides. Other potential materials are biodegradable and biologically well-defined, such as bone or dermal collagen. Further matrices are comprised of pure proteins

or extracellular matrix components. Other potential matrices are nonbiodegradable and chemically defined, such as sintered hydroxapatite, bioglass, aluminates, or other ceramics. Matrices may be comprised of combinations of any of the above mentioned types of material, such as polylactic acid and hydroxyapatite or collagen and tricalciumphosphate. The bioceramics may be altered in composition, such as in calcium-aluminate-phosphate and processing to alter pore size, particle size, particle shape, and biodegradability.

Presently preferred is a 50:50 (mole weight) copolymer of lactic acid and glycolic acid in the form of porous particles having diameters ranging from 150 to 800 microns. 10 In some applications, it will be useful to utilize a sequestering agent, such as carboxymethyl cellulose or autologous blood clot, to prevent the protein compositions from disassociating from the matrix.

A preferred family of sequestering agents is cellulosic materials such as alkylcelluloses (including hydroxyalkylcelluloses), including methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropyl-methylcellulose, and carboxymethylcellulose, the most preferred being cationic salts of carboxymethylcellulose (CMC). Other preferred sequestering agents include hyaluronic acid, sodium alginate, poly(ethylene glycol), polyoxyethylene oxide, carboxyvinyl polymer and poly(vinyl alcohol). The amount of sequestering agent useful herein is 0.5-20 20 wt%, preferably 1-10 wt% based on total formulation weight, which represents the amount necessary to prevent desorption of the protein from the polymer matrix and to provide appropriate handling of the composition, yet not so much that the progenitor cells are prevented from infiltrating the matrix, thereby providing the protein the opportunity to assist the osteogenic activity of the progenitor cells.

25 In further compositions, proteins of the invention may be combined with other agents beneficial to the treatment of the bone and/or cartilage defect, wound, or tissue in question. These agents include various growth factors such as epidermal growth factor (EGF), platelet derived growth factor (PDGF), transforming growth factors (TGF- α and TGF- β), and insulin-like growth factor (IGF).

30 The therapeutic compositions are also presently valuable for veterinary applications. Particularly domestic animals and thoroughbred horses, in addition to humans, are desired patients for such treatment with proteins of the present invention.

The dosage regimen of a protein-containing pharmaceutical composition to be used in tissue regeneration will be determined by the attending physician considering

various factors which modify the action of the proteins, e.g., amount of tissue weight desired to be formed, the site of damage, the condition of the damaged tissue, the size of a wound, type of damaged tissue (e.g., bone), the patient's age, sex, and diet, the severity of any infection, time of administration and other clinical factors. The dosage may vary
5 with the type of matrix used in the reconstitution and with inclusion of other proteins in the pharmaceutical composition. For example, the addition of other known growth factors, such as IGF I (insulin like growth factor I), to the final composition, may also effect the dosage. Progress can be monitored by periodic assessment of tissue/bone growth and/or repair, for example, X-rays, histomorphometric determinations and tetracycline
10 labeling.

Polynucleotides of the present invention can also be used for gene therapy. Such polynucleotides can be introduced either *in vivo* or *ex vivo* into cells for expression in a mammalian subject. Polynucleotides of the invention may also be administered by other known methods for introduction of nucleic acid into a cell or organism (including, without limitation, in the form of viral vectors or naked DNA).
15

Cells may also be cultured *ex vivo* in the presence of proteins of the present invention in order to proliferate or to produce a desired effect on or activity in such cells. Treated cells can then be introduced *in vivo* for therapeutic purposes.

20 Patent and literature references cited herein are incorporated by reference as if fully set forth.

What is claimed is:

1. An isolated polynucleotide selected from the group consisting of:
 - (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1;
 - (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide 63 to nucleotide 1265;
 - (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide 132 to nucleotide 1265;
 - (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone bd306_7 deposited under accession number ATCC 98599;
 - (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone bd306_7 deposited under accession number ATCC 98599;
 - (f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone bd306_7 deposited under accession number ATCC 98599;
 - (g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone bd306_7 deposited under accession number ATCC 98599;
 - (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:2;
 - (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:2;
 - (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above; and
 - (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i).

2. The polynucleotide of claim 1 wherein said polynucleotide is operably linked to at least one expression control sequence.
3. A host cell transformed with the polynucleotide of claim 2.
4. The host cell of claim 3, wherein said cell is a mammalian cell.
5. A process for producing a protein encoded by the polynucleotide of claim 2, which process comprises:
 - (a) growing a culture of the host cell of claim 3 in a suitable culture medium; and

(b) purifying said protein from the culture.

6. A protein produced according to the process of claim 5.

7. An isolated polynucleotide encoding the protein of claim 6.

8. The polynucleotide of claim 7, wherein the polynucleotide comprises the cDNA insert of clone bd306_7 deposited under accession number ATCC 98599.

9. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:2;

(b) the amino acid sequence of SEQ ID NO:2 from amino acid 148 to amino acid 189;

(c) fragments of the amino acid sequence of SEQ ID NO:2 comprising eight consecutive amino acids of SEQ ID NO:2; and

(d) the amino acid sequence encoded by the cDNA insert of clone bd306_7 deposited under accession number ATCC 98599;

the protein being substantially free from other mammalian proteins.

10. The protein of claim 9, wherein said protein comprises the amino acid sequence of SEQ ID NO:2.

11. The protein of claim 9, wherein said protein comprises the amino acid sequence of SEQ ID NO:2 from amino acid 148 to amino acid 189.

12. A composition comprising the protein of claim 9 and a pharmaceutically acceptable carrier.

13. A process for producing an isolated polynucleotide, wherein the process is selected from the group consisting of:

(a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:1, but excluding the poly(A) tail at the 3' end of SEQ ID NO:1; and

(ab) the nucleotide sequence of the cDNA insert of clone bd306_7 deposited under accession number ATCC 98599; and

- .
 - (ii) hybridizing said probe(s) to human DNA; and
 - (iii) isolating the DNA polynucleotide detected with the probe(s);

and

- (b) a process comprising the steps of:
 - (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:1, but excluding the poly(A) tail at the 3' end of SEQ ID NO:1; and

(bb) the nucleotide sequence of the cDNA insert of clone bd306_7 deposited under accession number ATCC 98599; and

(ii) hybridizing said primer(s) to human DNA;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide product of step (b)(iii);

wherein the isolated polynucleotide comprises a nucleotide sequence selected from the group consisting of:

(v) a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:1, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:1 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:1 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:1,

(w) a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:1 from nucleotide 63 to nucleotide 1265, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:1 from nucleotide 63 to nucleotide 1265, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:1 from nucleotide 63 to nucleotide 1265; and

(x) a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:1 from nucleotide 132 to nucleotide 1265, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:1 from nucleotide 132 to nucleotide 1265, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:1 from nucleotide 132 to nucleotide 1265.

14. An isolated polynucleotide produced according to the process of claim 13.

15. An isolated polynucleotide comprising the polynucleotide of claim 14.

16. An isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:32;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:32 from nucleotide 982 to nucleotide 2118;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:32 from nucleotide 1042 to nucleotide 2118;
- (d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:32 from nucleotide 621 to nucleotide 1248;
- (e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone fj283_6 deposited under accession number ATCC xxxx;
- (f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone fj283_6 deposited under accession number ATCC xxxx;
- (g) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone fj283_6 deposited under accession number ATCC xxxx;
- (h) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone fj283_6 deposited under accession number ATCC xxxx;
- (i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:4;
- (j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:4; and
- (k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above.

17. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:4;
- (b) fragments of the amino acid sequence of SEQ ID NO:4 comprising eight consecutive amino acids of SEQ ID NO:4; and
- (c) the amino acid sequence encoded by the cDNA insert of clone fj283_6 deposited under accession number ATCC xxxx;

the protein being substantially free from other mammalian proteins.

18. An isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:5;

- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:5 from nucleotide 259 to nucleotide 624;
- (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone fk317_3 deposited under accession number ATCC 98599;
- (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone fk317_3 deposited under accession number ATCC 98599;
- (e) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:6;
- (f) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:6;
- (g) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above; and
- (h) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(f).

19. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:6;
- (b) the amino acid sequence of SEQ ID NO:6 from amino acid 1 to amino acid 72;
- (c) fragments of the amino acid sequence of SEQ ID NO:6 comprising eight consecutive amino acids of SEQ ID NO:6; and
- (d) the amino acid sequence encoded by the cDNA insert of clone fk317_3 deposited under accession number ATCC 98599;

the protein being substantially free from other mammalian proteins.

20. A process for producing an isolated polynucleotide, wherein the process is selected from the group consisting of:

- (a) a process comprising the steps of:
 - (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - (aa) SEQ ID NO:5, but excluding the poly(A) tail at the 3' end of SEQ ID NO:5; and
 - (ab) the nucleotide sequence of the cDNA insert of clone fk317_3 deposited under accession number ATCC 98599; and
 - (ii) hybridizing said probe(s) to human DNA; and

(iii) isolating the DNA polynucleotide detected with the probe(s);

and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:5, but excluding the poly(A) tail at the 3' end of SEQ ID NO:5; and

(bb) the nucleotide sequence of the cDNA insert of clone fk317_3 deposited under accession number ATCC 98599; and

(ii) hybridizing said primer(s) to human DNA;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide product of step (b)(iii);

wherein the isolated polynucleotide comprises a nucleotide sequence selected from the group consisting of:

(v) a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:5, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:5 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:5 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:5; and

(w) a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:5 from nucleotide 259 to nucleotide 624, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:5 from nucleotide 259 to nucleotide 624, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:5 from nucleotide 259 to nucleotide 624.

21. An isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:7;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:7 from nucleotide 357 to nucleotide 578;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:7 from nucleotide 471 to nucleotide 578;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone k213_2x deposited under accession number ATCC 98599;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone k213_2x deposited under accession number ATCC 98599;

- (f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone k213_2x deposited under accession number ATCC 98599;
- (g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone k213_2x deposited under accession number ATCC 98599;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:8;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:8;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above; and
- (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i).

22. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:8;
- (b) fragments of the amino acid sequence of SEQ ID NO:8 comprising eight consecutive amino acids of SEQ ID NO:8; and
- (c) the amino acid sequence encoded by the cDNA insert of clone k213_2x deposited under accession number ATCC 98599;

the protein being substantially free from other mammalian proteins.

23. A process for producing an isolated polynucleotide, wherein the process is selected from the group consisting of:

- (a) a process comprising the steps of:
 - (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - (aa) SEQ ID NO:7, but excluding the poly(A) tail at the 3' end of SEQ ID NO:7; and
 - (ab) the nucleotide sequence of the cDNA insert of clone k213_2x deposited under accession number ATCC 98599; and
 - (ii) hybridizing said probe(s) to human DNA; and
 - (iii) isolating the DNA polynucleotide detected with the probe(s);

and

- (b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:7, but excluding the poly(A) tail at the 3' end of SEQ ID NO:7; and

(bb) the nucleotide sequence of the cDNA insert of clone k213_2x deposited under accession number ATCC 98599; and

(ii) hybridizing said primer(s) to human DNA;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide product of step (b)(iii);

wherein the isolated polynucleotide comprises a nucleotide sequence selected from the group consisting of:

(v) a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:7, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:7 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:7 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:7;

(w) a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:7 from nucleotide 357 to nucleotide 578, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:7 from nucleotide 357 to nucleotide 578, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:7 from nucleotide 357 to nucleotide 578; and

(x) a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:7 from nucleotide 471 to nucleotide 578, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:7 from nucleotide 471 to nucleotide 578, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:7 from nucleotide 471 to nucleotide 578.

24. An isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:9;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:9 from nucleotide 332 to nucleotide 598;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:9 from nucleotide 458 to nucleotide 598;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone na316_1 deposited under accession number ATCC 98599;

- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone na316_1 deposited under accession number ATCC 98599;
- (f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone na316_1 deposited under accession number ATCC 98599;
- (g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone na316_1 deposited under accession number ATCC 98599;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:10;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:10;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above; and
- (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i).

25. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:10;
- (b) fragments of the amino acid sequence of SEQ ID NO:10 comprising eight consecutive amino acids of SEQ ID NO:10; and
- (c) the amino acid sequence encoded by the cDNA insert of clone na316_1 deposited under accession number ATCC 98599;

the protein being substantially free from other mammalian proteins.

26. A process for producing an isolated polynucleotide, wherein the process is selected from the group consisting of:

- (a) a process comprising the steps of:
 - (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - (aa) SEQ ID NO:9, but excluding the poly(A) tail at the 3' end of SEQ ID NO:9; and
 - (ab) the nucleotide sequence of the cDNA insert of clone na316_1 deposited under accession number ATCC 98599; and
 - (ii) hybridizing said probe(s) to human DNA; and
 - (iii) isolating the DNA polynucleotide detected with the probe(s);

and

- (b) a process comprising the steps of:
 - (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - (ba) SEQ ID NO:9, but excluding the poly(A) tail at the 3' end of SEQ ID NO:9; and
 - (bb) the nucleotide sequence of the cDNA insert of clone na316_1 deposited under accession number ATCC 98599; and
 - (ii) hybridizing said primer(s) to human DNA;
 - (iii) amplifying human DNA sequences; and
 - (iv) isolating the polynucleotide product of step (b)(iii);
- wherein the isolated polynucleotide comprises a nucleotide sequence selected from the group consisting of:
 - (v) a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:9, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:9 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:9 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:9;
 - (w) a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:9 from nucleotide 332 to nucleotide 598, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:9 from nucleotide 332 to nucleotide 598, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:9 from nucleotide 332 to nucleotide 598; and
 - (x) a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:9 from nucleotide 458 to nucleotide 598, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:9 from nucleotide 458 to nucleotide 598, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:9 from nucleotide 458 to nucleotide 598.

27. An isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:11;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:11 from nucleotide 354 to nucleotide 986;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:11 from nucleotide 408 to nucleotide 986;

- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone nf93_20 deposited under accession number ATCC 98599;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone nf93_20 deposited under accession number ATCC 98599;
- (f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone nf93_20 deposited under accession number ATCC 98599;
- (g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone nf93_20 deposited under accession number ATCC 98599;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:12;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:12;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above; and
- (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i).

28. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:12;
- (b) fragments of the amino acid sequence of SEQ ID NO:12 comprising eight consecutive amino acids of SEQ ID NO:12; and
- (c) the amino acid sequence encoded by the cDNA insert of clone nf93_20 deposited under accession number ATCC 98599;

the protein being substantially free from other mammalian proteins.

29. A process for producing an isolated polynucleotide, wherein the process is selected from the group consisting of:

- (a) a process comprising the steps of:
 - (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - (aa) SEQ ID NO:11, but excluding the poly(A) tail at the 3' end of SEQ ID NO:11; and
 - (ab) the nucleotide sequence of the cDNA insert of clone nf93_20 deposited under accession number ATCC 98599; and

- (ii) hybridizing said probe(s) to human DNA; and
- (iii) isolating the DNA polynucleotide detected with the probe(s);

and

- (b) a process comprising the steps of:
 - (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:11, but excluding the poly(A) tail at the 3' end of SEQ ID NO:11; and

(bb) the nucleotide sequence of the cDNA insert of clone nf93_20 deposited under accession number ATCC 98599; and

(ii) hybridizing said primer(s) to human DNA;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide product of step (b)(iii);

wherein the isolated polynucleotide comprises a nucleotide sequence selected from the group consisting of:

(v) a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:11, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:11 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:11 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:11;

(w) a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:11 from nucleotide 354 to nucleotide 986, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:11 from nucleotide 354 to nucleotide 986, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:11 from nucleotide 354 to nucleotide 986; and

(x) a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:11 from nucleotide 408 to nucleotide 986, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:11 from nucleotide 408 to nucleotide 986, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:11 from nucleotide 408 to nucleotide 986.

30. An isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:13;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:13 from nucleotide 301 to nucleotide 1821;

- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:13 from nucleotide 1381 to nucleotide 1821;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone np164_1 deposited under accession number ATCC 98599;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone np164_1 deposited under accession number ATCC 98599;
- (f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone np164_1 deposited under accession number ATCC 98599;
- (g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone np164_1 deposited under accession number ATCC 98599;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:14;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:14 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:14;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above; and
- (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i).

31. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:14;
- (b) fragments of the amino acid sequence of SEQ ID NO:14 comprising eight consecutive amino acids of SEQ ID NO:14; and
- (c) the amino acid sequence encoded by the cDNA insert of clone np164_1 deposited under accession number ATCC 98599;

the protein being substantially free from other mammalian proteins.

32. A process for producing an isolated polynucleotide, wherein the process is selected from the group consisting of:

- (a) a process comprising the steps of:
 - (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - (aa) SEQ ID NO:13, but excluding the poly(A) tail at the 3' end of SEQ ID NO:13; and

- (ab) the nucleotide sequence of the cDNA insert of clone np164_1 deposited under accession number ATCC 98599; and
- (ii) hybridizing said probe(s) to human DNA; and
- (iii) isolating the DNA polynucleotide detected with the probe(s);
- and
- (b) a process comprising the steps of:
- (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
- (ba) SEQ ID NO:13, but excluding the poly(A) tail at the 3' end of SEQ ID NO:13; and
- (bb) the nucleotide sequence of the cDNA insert of clone np164_1 deposited under accession number ATCC 98599; and
- (ii) hybridizing said primer(s) to human DNA;
- (iii) amplifying human DNA sequences; and
- (iv) isolating the polynucleotide product of step (b)(iii);
- wherein the isolated polynucleotide comprises a nucleotide sequence selected from the group consisting of:
- (v) a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:13, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:13 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:13 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:13;
- (w) a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:13 from nucleotide 301 to nucleotide 1821, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:13 from nucleotide 301 to nucleotide 1821, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:13 from nucleotide 301 to nucleotide 1821; and
- (x) a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:13 from nucleotide 1381 to nucleotide 1821, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:13 from nucleotide 1381 to nucleotide 1821, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:13 from nucleotide 1381 to nucleotide 1821.

33. An isolated polynucleotide selected from the group consisting of:
- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:15;

- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:15 from nucleotide 148 to nucleotide 537;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:15 from nucleotide 532 to nucleotide 537;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone pe204_1 deposited under accession number ATCC 98599;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone pe204_1 deposited under accession number ATCC 98599;
- (f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone pe204_1 deposited under accession number ATCC 98599;
- (g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone pe204_1 deposited under accession number ATCC 98599;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:16;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:16 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:16;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above; and
- (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i).

34. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:16;
- (b) fragments of the amino acid sequence of SEQ ID NO:16 comprising eight consecutive amino acids of SEQ ID NO:16; and
- (c) the amino acid sequence encoded by the cDNA insert of clone pe204_1 deposited under accession number ATCC 98599;

the protein being substantially free from other mammalian proteins.

35. A process for producing an isolated polynucleotide, wherein the process is selected from the group consisting of:

- (a) a process comprising the steps of:
 - (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:15, but excluding the poly(A) tail at the 3' end of SEQ ID NO:15; and

(ab) the nucleotide sequence of the cDNA insert of clone pe204_1 deposited under accession number ATCC 98599; and

(ii) hybridizing said probe(s) to human DNA; and

(iii) isolating the DNA polynucleotide detected with the probe(s);

and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:15, but excluding the poly(A) tail at the 3' end of SEQ ID NO:15; and

(bb) the nucleotide sequence of the cDNA insert of clone pe204_1 deposited under accession number ATCC 98599; and

(ii) hybridizing said primer(s) to human DNA;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide product of step (b)(iii);

wherein the isolated polynucleotide comprises a nucleotide sequence selected from the group consisting of:

(v) a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:15, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:15 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:15 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:15; and

(w) a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:15 from nucleotide 148 to nucleotide 537, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:15 from nucleotide 148 to nucleotide 537, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:15 from nucleotide 148 to nucleotide 537.

36. An isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:17;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:17 from nucleotide 24 to nucleotide 1109;

- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:17 from nucleotide 1050 to nucleotide 1109;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone ya1_1 deposited under accession number ATCC 98599;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone ya1_1 deposited under accession number ATCC 98599;
- (f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone ya1_1 deposited under accession number ATCC 98599;
- (g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone ya1_1 deposited under accession number ATCC 98599;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:18;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:18 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:18;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above; and
- (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i).

37. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:18;
- (b) fragments of the amino acid sequence of SEQ ID NO:18 comprising eight consecutive amino acids of SEQ ID NO:18; and
- (c) the amino acid sequence encoded by the cDNA insert of clone ya1_1 deposited under accession number ATCC 98599;

the protein being substantially free from other mammalian proteins.

38. A process for producing an isolated polynucleotide, wherein the process is selected from the group consisting of:

- (a) a process comprising the steps of:
 - (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - (aa) SEQ ID NO:17, but excluding the poly(A) tail at the 3' end of SEQ ID NO:17; and

(ab) the nucleotide sequence of the cDNA insert of clone ya1_1 deposited under accession number ATCC 98599; and
(ii) hybridizing said probe(s) to human DNA; and
(iii) isolating the DNA polynucleotide detected with the probe(s);

and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:17, but excluding the poly(A) tail at the 3' end of SEQ ID NO:17; and

(bb) the nucleotide sequence of the cDNA insert of clone ya1_1 deposited under accession number ATCC 98599; and

(ii) hybridizing said primer(s) to human DNA;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide product of step (b)(iii);

wherein the isolated polynucleotide comprises a nucleotide sequence selected from the group consisting of:

(v) a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:17, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:17 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:17, but excluding the poly(A) tail at the 3' end of SEQ ID NO:17;

(w) a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:17 from nucleotide 24 to nucleotide 1109, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:17 from nucleotide 24 to nucleotide 1109, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:17 from nucleotide 24 to nucleotide 1109; and

(x) a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:17 from nucleotide 1050 to nucleotide 1109, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:17 from nucleotide 1050 to nucleotide 1109, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:17 from nucleotide 1050 to nucleotide 1109.

39. An isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:19;

- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:19 from nucleotide 27 to nucleotide 734;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:19 from nucleotide 270 to nucleotide 734;
- (d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:19 from nucleotide 85 to nucleotide 1604;
- (e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone yb8_1 deposited under accession number ATCC 98599;
- (f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone yb8_1 deposited under accession number ATCC 98599;
- (g) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone yb8_1 deposited under accession number ATCC 98599;
- (h) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone yb8_1 deposited under accession number ATCC 98599;
- (i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:20;
- (j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:20 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:20;
- (k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above; and
- (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j).

40. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:20;
- (b) the amino acid sequence of SEQ ID NO:20 from amino acid 70 to amino acid 236;
- (c) fragments of the amino acid sequence of SEQ ID NO:20 comprising eight consecutive amino acids of SEQ ID NO:20; and
- (d) the amino acid sequence encoded by the cDNA insert of clone yb8_1 deposited under accession number ATCC 98599;

the protein being substantially free from other mammalian proteins.

41. A process for producing an isolated polynucleotide, wherein the process is selected from the group consisting of:

(a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:19, but excluding the poly(A) tail at the 3' end of SEQ ID NO:19; and

(ab) the nucleotide sequence of the cDNA insert of clone yb8_1 deposited under accession number ATCC 98599; and

(ii) hybridizing said probe(s) to human DNA; and

(iii) isolating the DNA polynucleotide detected with the probe(s);

and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:19, but excluding the poly(A) tail at the 3' end of SEQ ID NO:19; and

(bb) the nucleotide sequence of the cDNA insert of clone yb8_1 deposited under accession number ATCC 98599; and

(ii) hybridizing said primer(s) to human DNA;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide product of step (b)(iii);

wherein the isolated polynucleotide comprises a nucleotide sequence selected from the group consisting of:

(v) a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:19, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:19 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:19 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:19;

(w) a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:19 from nucleotide 27 to nucleotide 734, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:19 from nucleotide 27 to nucleotide 734, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:19 from nucleotide 27 to nucleotide 734;

(x) a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:19 from nucleotide 270 to nucleotide 734, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:19 from nucleotide 270 to nucleotide 734, to a nucleotide sequence corresponding to

the 3' end of said sequence of SEQ ID NO:19 from nucleotide 270 to nucleotide 734; and

(y) a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:19 from nucleotide 85 to nucleotide 1604, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:19 from nucleotide 85 to nucleotide 1604, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:19 from nucleotide 85 to nucleotide 1604.

FIGURE 1A





FIGURE 1B



SEQUENCE LISTING

<110> Jacobs, Kenneth
McCoy, John M.
LaVallie, Edward R.
Collins-Racie, Lisa A.
Evans, Cheryl
Merberg, David
Treacy, Maurice
Agostino, Michael J.
Steininger II, Robert J.
Wong, Gordon G.
Clark, Hilary
Fechtel, Kim
Genetics Institute, Inc.

<120> SECRETED PROTEINS AND POLYNUCLEOTIDES ENCODING THEM

<130> 6055A

<140>
<141>

<160> 32

<170> PatentIn Ver. 2.0

<210> 1

<211> 3871

<212> DNA

<213> Homo sapiens

tgtgccacca cgcccggtctt attttgtatt ttttagtagag acggggtttt gccatgttgg 1680
 ccaggcgtgt ctgcactct tgacttcaga tgatccatct gccttggct cccacagtgc 1740
 tgggattaca ggcgtgagcc accatgcggc gccttcttctt cacccttata cctgtcttctt 1800
 tatacctcaca tctgtttca caccttcate cctgtcttcc tcatgttac actgttcttc 1860
 cccatgttca tagctgcctt tcttaccatt ttgggttgaa gggcagtcctt ctctggcttg 1920
 tttttttgtt ttcccagaa aatcgttattttaaaa taagaaaaac attccttagaa 1980
 gatgataattt gtgaaaacct cctttggctt atttgtttt ccagatttta gtccttc 2040
 tccccatccg ggaagatgg tggaagacat aggctaaattt tctccagctt cacaatggc 2100
 ttcaacttggt ctgacttgc ccaattcttag cacccactga aaaacaagtt gaggtagagag 2160
 tgttagagtgc agaaaatgtgg cttttggccc actttgcatttcccaaaaatataa caacgggttgg 2220
 cccatccat ttgaggacaa tgcttagtta taagtctccg agttggaaaa ggaagaaaagc 2280
 cagagctgtc tagtttcattt catttttca gtaaaatattt attgagttacc tactgtgtgc 2340
 taggcattga cctggaaactt agagataactt cacagaataa cagggaaagt tccctgtgt 2400
 catggagctt acatttctaca gggagaaaaga gatagccaat acataggaat aaatatatac 2460
 aaggtatcat gtatgtataa ttgtgtgttggaa gaaaaataaa gcaggggagg gagaagaaa 2520
 tcctggagat gaggctgcag ttttaaatgg ggcctcaactg ggaatgtgc gttgagcaga 2580
 gacgttaggg aagtggatcc tggacaaggc attccaggca gaggacaacaaatgtgcactg 2640
 ccccaaagtg agaacttgcctt acatgtggcaggcaggaaagagc agggagacca agcagagtcg 2700
 tgggcaggg tagaatggaa ggagaggcgg ctggggagga caggtgggtgg agggccttgg 2760
 cttctgtttaa gtgagatggg aaccacttggaa gggtttgaac agaggagtgc cttgattgt 2820
 ttatatttttca caagggtcat tctagctgcataatgttggaa aaacttttagt ggacaaggc 2880
 agaaggaaga gggagacct gtttaggaagc tactgcacagg ttccaggctt gggcctgggc 2940
 cacagcaaca gcagtggtca aataatctaga ttatatttga aaagagccaa taggatttgc 3000
 tgagagtttgc aatgtggagt gtaagagaag gaagagttaa tgatgcattt aaggttttttgc 3060
 gcctgaatag cagggaaagat ggagttacca gttactgtaaa taggaaagga tgggtgggtt 3120
 aagtaagggaa ttgtgtgcaaa agcaggctgt ctgtgtttgg aatggggaggt tctggctgc 3180
 aatcaaagtg gagattctctt caggccaggctt ctgcacgcaga gctcgagaca gggatctgaa 3240
 tgcacttggt ttatgtttgg ggggtgttctc agaaggaacc tggaaagcc ttatctgtc 3300
 atttatttgc tggagaaatgtt gttactgttggat tgggtgttaca ttgtgttggca agtgcatttca 3360
 gttgagggca agtctcttggaa aagaggctgt taggcacatctg gcagctacca tgcgtggtag 3420
 tgggtgttggg gttgggttctc tgggtgttgg ctgtgtgttgg aatggggaggtt tgggtggca 3480
 gggcccccata ctgaaccatc agcatgttca gggatcttgcag ctggagggggc 3540
 cactgagatt gtctctgtgttattactgaga agcaacacaa aagagccatc gatggagccc 3600
 ttgggtcttc tggggaaatgg gaaaatcagcc aaaggactga gaaggagttt ctttaagggtc 3660
 agagaaaaacc aagagagttt ggtgttcttgg aagctgatgtt ttcttttatttcc aaccttcatc 3720
 cttcttccaa ataagccact tggtagtttgg gggcccttcca ggggttggaaagg caagaggaga 3780
 aaggcacacgc gtttggggaaa caagactttt cctgcacatag cttggggagg aataaaaggaa 3840
 tagagtgttta aaataaaaaaaa aaaaaaaaaaaa a 3871

<210> 2
 <211> 401
 <212> PRT
 <213> Homo sapiens

<220>
 <221> UNSURE
 <222> (64)

<400> 2
 Met Glu Pro Gly Arg Arg Gly Ala Ala Ala Leu Leu Ala Leu Leu Cys
 1 5 10 15

Val Ala Cys Ala Leu Arg Ala Gly Arg Ala Gln Tyr Glu Arg Tyr Ser
 20 25 30

Phe Arg Ser Phe Pro Arg Asp Glu Leu Met Pro Leu Glu Ser Ala Tyr
 35 40 45

Arg His Ala Leu Asp Lys Tyr Ser Gly Glu His Trp Ala Glu Ser Xaa
 50 55 60

Gly Tyr Leu Glu Ile Ser Leu Arg Leu His Arg Leu Leu Arg Asp Ser
 65 70 75 80
 Glu Ala Phe Cys His Arg Asn Cys Ser Ala Ala Pro Gln Pro Glu Pro
 85 90 95
 Ala Ala Gly Leu Ala Ser Tyr Pro Glu Leu Arg Leu Phe Gly Gly Leu
 100 105 110
 Leu Arg Arg Ala His Cys Leu Lys Arg Cys Lys Gln Gly Leu Pro Ala
 115 120 125
 Phe Arg Gln Ser Gln Pro Ser Arg Glu Val Leu Ala Asp Phe Gln Arg
 130 135 140
 Arg Glu Pro Tyr Lys Phe Leu Gln Phe Ala Tyr Phe Lys Ala Asn Asn
 145 150 155 160
 Leu Pro Lys Ala Ile Ala Ala Ala His Thr Phe Leu Leu Lys His Pro
 165 170 175
 Asp Asp Glu Met Met Lys Arg Asn Met Ala Tyr Tyr Lys Ser Leu Pro
 180 185 190
 Gly Ala Glu Asp Tyr Ile Lys Asp Leu Glu Thr Lys Ser Tyr Glu Ser
 195 200 205
 Leu Phe Ile Arg Ala Val Arg Ala Tyr Asn Gly Glu Asn Trp Arg Thr
 210 215 220
 Ser Ile Thr Asp Met Glu Leu Ala Leu Pro Asp Phe Phe Lys Ala Phe
 225 230 235 240
 Tyr Glu Cys Leu Ala Ala Cys Glu Gly Ser Arg Glu Ile Lys Asp Phe
 245 250 255
 Lys Asp Phe Tyr Leu Ser Ile Ala Asp His Tyr Val Glu Val Leu Glu
 260 265 270
 Cys Lys Ile Gln Cys Glu Glu Asn Leu Thr Pro Val Ile Gly Gly Tyr
 275 280 285
 Pro Val Glu Lys Phe Val Ala Thr Met Tyr His Tyr Leu Gln Phe Ala
 290 295 300
 Tyr Tyr Lys Leu Asn Asp Leu Lys Asn Ala Ala Pro Cys Ala Val Ser
 305 310 315 320
 Tyr Leu Leu Phe Asp Gln Asn Asp Lys Val Met Gln Gln Asn Leu Val
 325 330 335
 Tyr Tyr Gln Tyr His Arg Asp Thr Trp Gly Leu Ser Asp Glu His Phe
 340 345 350
 Gln Pro Arg Pro Glu Ala Val Gln Phe Phe Asn Val Thr Thr Leu Gln
 355 360 365
 Lys Glu Leu Tyr Asp Phe Ala Lys Glu Asn Ile Met Asp Asp Asp Glu
 370 375 380

Gly Glu Val Val Glu Tyr Val Asp Asp Leu Leu Glu Leu Glu Thr
 385 390 395 400

Ser

<210> 3
 <211> 3637
 <212> DNA
 <213> Homo sapiens

<220>
 <221> unsure
 <222> (1582)

<400> 3
 tttttttttt tttttttta agaagaagg ccaaataat aggtcttttta ttgcattcatt 60
 taaatatcac aagttaggtct taagtgtcat ctggcatctt ctttctgttag ccaggttaact 120
 cttagatctt attcatcagc ctgctgaaca gttccctttt cagagacata gataccatcc 180
 aaaaatttcc tgatatcctt gtttttaact gttgtggctt gctgaatcaa agccgctgaa 240
 tttgaaacaa gctcaatgtc atcccattt agtaccagct cccactgccc ctgagggcgg 300
 gccggcctgc ggcggaggaa aaaaggaga ggagaaggaa attgtcccga atccctgcag 360
 tctttctgtt gtttgcggca caacgccagg caaaagaaga ggaaggaaatt taatcctaatt 420
 cggtgaggt cgatttgggg gtctgctgtt gcagggtggct ccgttgaag cgagggaggaa 480
 agtttcctcc gatcagtaga gattggaaag attgtggggta gtggcacacc actaggaa 540
 agaagaagg gcgaaactgtc tgtcttgagg aggtcaaccc ccagaatcag ctcttgcgc 600
 cttgaagtgg ctgaagacga tcaccctcca caggcttgag cccagtttcca cagccttcct 660
 cccccagcct gagtactac tctattcctt ggtccctgtt attgtcgggg acgattgtat 720
 gggctaccc agggaaatgg tagtgggtgac cgcaggccctg gtgattgggg ctggcgccctg 780
 ctatttgcatt tataactgtt ctagggggaa aaaaacagaac aaggaaaaaa tgggtgaggaa 840
 tggatctggg gatgtggatg atgtctggggta ctgttctggg gccaggtata atgactggc 900
 tgatgtatgat gatgacagca atgagagcaa gagtatagta tggtaaccac ctggggctcg 960
 gattggact gaagctggaa ccagaacttag ggcaggcggca agggccagg ctacccgggc 1020
 acgtctgtc gtccagaaac gggcttcccc caattcagat gataccgttt tgccttcctca 1080
 agagctacaa aaggttctt gcttgggttga gatgtctgaa aaggcttata ttcttgaagc 1140
 agctttaatt gctctggta acaatgtc ttatgcattt aacagagata ttattctgtt 1200
 tctgggttgtt ctcccaattt tcgaaagat tctcaataact cgggatccca tagttaagga 1260
 aaaggcttta attgtccctga ataactttagt tgtgaatgtt gaaaatcagc gcaggctta 1320
 agtatacatg aatcaagtgt gtgatgacac aatcacttct cgttgaact catctgtgca 1380
 gcttgcgttga ctgagattgc ttacaaatat gactgtact aatgaggtatc agcacatgt 1440
 tgctaattcc atttctgtt ttttctgtttt atttcagcg gaaatgaag aaaccaaact 1500
 tcaggttctg aaacctttt tgaatttggc tggaaatcca gccatgacta gggactgtct 1560
 caggcccaa gtaccatctt cnctggctc ccttttaat aagaaggaga acaaagaagt 1620
 tatttttaaa cttctggta tatttgagaa cataaatgtt aatttcaat gggaaagaaaa 1680
 tgaacctact cagaatcaat tgggtgaagg ttcactttt ttctttttta aagaatttca 1740
 agtgtgtgtc gataagggttcc tgggaataga aagtccat gatttttgg tggaaagtaaa 1800
 agttggaaaa ttcatggcca aacttgcgtt acatatgttcc ccaaagagcc aggaataaca 1860
 ccttgattttt gtaattttaga agcaacacac attgttactt attcattttc tccaccttgt 1920
 ttatatgttta aaggaatccct ttcagctgccc agttttgtt aatgaatatac atattgtatc 1980
 atcaatgttgc atatttaact gagttggctt tttagtttaa gatggataaa tgaatatcac 2040
 tacttgttct gaaaacatgt ttgttgcattt ttatctcgct gccttagattt aatattttt 2100
 ctatttcctc tgcataagtgc acagtgttgc acc aattcatcat gagaatgtc ccttctgtca 2160
 ttttcatgtt tttatgtt gatcatcaat taaaattgtt tggtaatgtt gggaaagaaaa 2220
 aaagaagaaaa gaaagaaaacc atccctgtcc ttcagttt aatctgttgc gagagataag 2280
 aaacgtacaa accaaaagat aacagaatat ctgaagcatg tactcattgt cagatgttcc 2340
 ctctgagagc acagaggagg caaaagcttc tgggtatgtt gctagtcggc taaagcttca 2400
 cagaggaggt ggcaattgaa aatgagtcctt gaatgggtt ggggtttag ggaattccat 2460
 gagacaagac aaggggggca tgggtgtgaga aaggcatgga agtaggaacc ctcttcctat 2520

gacaggagat cattctgctt agagtggaga gtgtggagag tggagtaga taatttgga 2580
 aagctgggtg aagccagttg tggagaattt tttgaatatt atcccattga ataccagag 2640
 ccactaaatc ttttttact agaaaataat tggggtccat atgaaagtct ctattactga 2700
 gtagtgtcaa tgagggtgtg gcaaaatgga gccttcaca tcctagtggt ggcatttgg 2760
 taatacagat ataagccta aactatgtaa acccttgtcc taaggaagta attgaataat 2820
 tgcccaaaga ttgtatgtat gaggctgttc atcccagcac tgtctaagct agtaaaaatt 2880
 ggaaacaatt taagtatcta gcacattgga ttggttataa agcaaggaat gttcacacag 2940
 taggatatta taagtatgtct gatggaaatc tatattgcca ggaaaagcta ttcattatgc 3000
 gttgtgaagt cagaaagtaa aaaaggtag atagaagttt tcaagttt gttccatttt 3060
 ttgagactaa taaaacatat gtttaaaagg acactaaaaa ctggagttt agatatccag 3120
 atagaaacag tagttatctt tggtagaaag aataatgagt gatctttact tttttacttt 3180
 ttattcatct ttgtgtttt atttatctaa aatgggtatt gatttttagg acgggtttga 3240
 aaaagaaaag tggggaaat gaagcaagtg attgatgga aaacatactg aatggaagaa 3300
 atattnagat taaaatgag gtaggttcaa gtttcttc tgaatgata gataaatgtt 3360
 gaagataagg cttattgtga ggattcagtg aggttaatata tgcaaagtac ttacaatgtt 3420
 ctggcacata gtaattaaatt aagaaaatcg agcaccctta attacctaga atgcagggtt 3480
 gttagttttt tggtgactt ttgtttgc ggggcattct gccatgtttt agtgcatttt 3540
 aataaataat agtaacaata aaggttaaca tttattaagt gaaaaaaaaaaaaaaa 3600
 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 3637

<210> 4

<211> 379

<212> PRT

<213> Homo sapiens

<400> 4

Met	Gly	Tyr	Ala	Arg	Lys	Val	Gly	Trp	Val	Thr	Ala	Gly	Leu	Val	Ile
1															15

Gly	Ala	Gly	Ala	Cys	Tyr	Cys	Ile	Tyr	Arg	Leu	Thr	Arg	Gly	Arg	Lys
															30
							20								25

Gln	Asn	Lys	Glu	Lys	Met	Ala	Glu	Gly	Gly	Ser	Gly	Asp	Val	Asp	Asp
															45
							35								40

Ala	Gly	Asp	Cys	Ser	Gly	Ala	Arg	Tyr	Asn	Asp	Trp	Ser	Asp	Asp	Asp
															50
															55
															60

Asp	Asp	Ser	Asn	Glu	Ser	Lys	Ser	Ile	Val	Trp	Tyr	Pro	Pro	Trp	Ala
															65
															70
															75
															80

Arg	Ile	Gly	Thr	Glu	Ala	Gly	Thr	Arg	Thr	Arg	Ala	Arg	Ala	Arg	Ala
															85
															90

Arg	Ala	Thr	Arg	Ala	Arg	Leu	Ala	Val	Gln	Lys	Arg	Ala	Ser	Pro	Asn
															100
															105
															110

Ser	Asp	Asp	Thr	Val	Leu	Ser	Pro	Gln	Glu	Leu	Gln	Lys	Val	Leu	Cys
															115
															120
															125

Leu	Val	Glu	Met	Ser	Glu	Lys	Pro	Tyr	Ile	Leu	Glu	Ala	Ala	Leu	Ile
															130
															135
															140

Ala	Leu	Gly	Asn	Asn	Ala	Ala	Tyr	Ala	Phe	Asn	Arg	Asp	Ile	Ile	Arg
															145
															150
															155
															160

Asp	Leu	Gly	Gly	Leu	Pro	Ile	Val	Ala	Lys	Ile	Leu	Asn	Thr	Arg	Asp
															165
															170
															175

Pro	Ile	Val	Lys	Glu	Lys	Ala	Leu	Ile	Val	Leu	Asn	Asn	Leu	Ser	Val
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

180	185	190
Asn Ala Glu Asn Gln Arg Arg Leu Lys Val Tyr Met Asn Gln Val Cys		
195	200	205
Asp Asp Thr Ile Thr Ser Arg Leu Asn Ser Ser Val Gln Leu Ala Gly		
210	215	220
Leu Arg Leu Leu Thr Asn Met Thr Val Thr Asn Glu Tyr Gln His Met		
225	230	235
240		
Leu Ala Asn Ser Ile Ser Asp Phe Phe Arg Leu Phe Ser Ala Gly Asn		
245	250	255
Glu Glu Thr Lys Leu Gln Val Leu Lys Leu Leu Asn Leu Ala Glu		
260	265	270
Asn Pro Ala Met Thr Arg Glu Leu Leu Arg Ala Gln Val Pro Ser Ser		
275	280	285
Leu Gly Ser Leu Phe Asn Lys Lys Glu Asn Lys Glu Val Ile Leu Lys		
290	295	300
Leu Leu Val Ile Phe Glu Asn Ile Asn Asp Asn Phe Lys Trp Glu Glu		
305	310	315
320		
Asn Glu Pro Thr Gln Asn Gln Phe Gly Glu Gly Ser Leu Phe Phe Phe		
325	330	335
Leu Lys Glu Phe Gln Val Cys Ala Asp Lys Val Leu Gly Ile Glu Ser		
340	345	350
His His Asp Phe Leu Val Lys Val Lys Val Gly Lys Phe Met Ala Lys		
355	360	365
Leu Ala Glu His Met Phe Pro Lys Ser Gln Glu		
370	375	

<210> 5

<211> 1608

<212> DNA

<213> Homo sapiens

<400> 5

gtatccgtt gcatagactt aacactgtat tttaacttag gtaatgtatg gctttttgt 60
 ttatTTTTT cctgcatttt tgggggggtgt tgaataagt aaactggaa ggtgcagggg 120
 aattctaaaa ttcaatgcaa ggagtTTTTG ctgagttatct gcagcattca aggaattaat 180
 attagtcact gagaacaaaa agcggaaattta gaaaatttca agtcacttct aggctttag 240
 gggagaagac gtgttagtcat gaaatttctatc atttatgaag tacccactgg atccccacaca 300
 ctgtgcaaga ctttttagatc aggcccttcc ctgggtttt ttcaccctgt gcagcagggt 360
 ctgttatttc ctTTTTaaaa ttatttattta ttatttattat ttttgagac aggtatctccc 420
 ttgtcactc aggctggaaat gcagaggcat gatcaactgt cactgcagct tcgaccaccc 480
 aggctcaaag gagtctccca cctcggtgc tgccacacctt ggccaacttt tttgtatTTT 540
 tttggtagag accggggTTT caccatgttg cccaggctgg ttttgaactt ttggactcca 600
 gcgatctgcc tgcctccgccc tccctaagtgt ctgggattac agacatgagc cattgtgcc 660
 gtcctgttgt ttccctgttt agtggggagg aagggttaga taacttggcc agtcggTTGT 720
 aggaccagca ctagtacagt gttgggcacg tagtaggtgt ttaatacatg accgatgagc 780
 aaatggctcc agatgtctct ggttccatag gcagccttga atagggtctt acacacctga 840
 tgagaatgac agcctgtgtt gactgagccc tgacttgggt ccaaccctgc catagtgcc 900

gtgccttgca tgaattcaat aattttaggcc tagcagcaac cttaagagg aggtactgtt 960
 acctcccggt ttataaatga gaagacaggc gcagttaggc ccaagattga agagcttgg 1020
 gccaagaaga tggagttgca ggtgggttgg ccatagagct gatgtttgtt aaatgtgtt 1080
 tatctgtat ggtcattttt ggttaataaa agctctgtt ttagattgt aattctaagg 1140
 gtttatcatc aagggtgtatc agaagggtgag ggagccctg tggtagcgc agcaactctg 1200
 gccttcgttga cagtaggtag gcattgtgatc actgttgtca ctaaacctgg gaaatgattc 1260
 ctgggtcagg gttcatatat tgccaaatga ttaaagtaat aaagctgaca ctggaaacct 1320
 atctaacttc atttcttttcc ttgatttac aaagatagtc aatacatttt cctaccaaaa 1380
 agaactggcc agccgtggtg gctcatgcct gtaatcctag cagtttagga agccgagggt 1440
 ggccgatcgc ttgaggtcag gagttcgaga ccagtctggc caacatgggtt gaaatcctgt 1500
 ctctactgaa aataaaaaaa ttatctgggc atagtgggt gtgcctgtaa ttgcagcctg 1560
 ggcaacggag tgagagactg tctcaggaaa aaaaaaaaaa aaaaaaaaaa 1608

<210> 6

<211> 122

<212> PRT

<213> Homo sapiens

<400> 6

Met	Asn	Ser	Ile	Ile	Tyr	Glu	Val	Pro	Thr	Gly	Ser	His	Thr	Leu	Cys
1															

		5				10									15
--	--	---	--	--	--	----	--	--	--	--	--	--	--	--	----

Lys	Thr	Phe	Arg	Ser	Gly	Ala	Ser	Leu	Gly	Phe	Leu	His	Pro	Val	Gln
		20					25								30

Gln	Val	Leu	Leu	Phe	Pro	Phe	Leu	Asn	Tyr	Tyr	Leu	Leu	Leu	Phe	
		35				40									45

Phe	Glu	Thr	Gly	Ser	Pro	Phe	Val	Thr	Gln	Ala	Gly	Met	Gln	Arg	His
	50				55							60			

Asp	His	Cys	Ser	Leu	Cln	Leu	Arg	Pro	Pro	Arg	Leu	Lys	Gly	Val	Ser
	65			70				75					80		

His	Leu	Gly	Cys	Cys	His	Thr	Trp	Pro	Thr	Phe	Leu	Tyr	Phe	Phe	Gly
		85					90						95		

Arg	Asp	Arg	Gly	Phe	Thr	Met	Leu	Pro	Arg	Leu	Val	Leu	Asn	Phe	Trp
		100				105							110		

Thr	Pro	Ala	Ile	Cys	Leu	Pro	Pro	Pro	Pro						
		115				120									

<210> 7

<211> 1969

<212> DNA

<213> Homo sapiens

<400> 7

ggaagtttgtt ggctgcagct gccgtgggtt tctcttgggt tccagcagaa acggcggcgg 60
 cgcaagggtgt ggctgggcca acccaggatc tcccaggacc ctccgcctcg cgccacaagg 120
 ggcccgcgct tgccaaaggcc gacgggcagg agtgaacgtg gcctccgtgg gtctgcagcc 180
 ccgataggcc aattgtacag aatttaaacc gtctctcaga tggatgggt cactaataac accaggacaa 240
 aagacagact accaagggtc atctgaagtc gtgatgggt cactaataac accaggacaa 300
 agttaagggta tcactactca agcataagcc ccagtttca taagactgt gtgaagatgt 360
 ttgatataaa ggcttgggtt gaggatgtt tggaatgggc tgcaaaggac ccctatggct 420
 tccttacaac cgatattttt gcccctactc cactgttccct agcaagtgt gtactgtctt 480
 ggaaattggc caagatgatt gaggccaggg agaaggagca aaagaagaag caaaaacgcc 540
 aaaaaaacat tgcaaaaagct aaacgactaa aaaaggattg aaggactgaa caggcttgc 600

aaccagagga aaatcatttg gaaaattaca cagcttggaa agaatccact aaagtttctt 660
 ctttggattt cttgacagta tgattnatgt aatgaaattt gaccaaattgg aagaatcatg 720
 ttagttctga cctcaataact atagtaactt ttagggcggtt gtgtagaagt ttataggttt 780
 ctattgacag ttattgtaaa ttagcatatc ctgtggtaca aattctttat aactgactta 840
 gtcatttgcg gettagcagt ttatatactg aaatgaaaac atcttgtggg gaaaagtgac 900
 tttagattat gaactcaatt caaatgaact ctattnaaaa tgggtgccta ttttggacaa 960
 aggaattnaa gaatgtaaa gtcagaacag tcttgagta aaaagtgtgc tttggcttaa 1020
 aagggataca gtatattat tacatctttt attattattt tttattnctt agaatcattt 1080
 ctggctttct caaaacaaaa taatattat gagtacttctt atttgtgcata ttttcttta 1140
 tacagcctt gagacagctg gtaattataa gtcatttcc attttttaaa acataatttt 1200
 ataaagaatt ctcttatctc gactatgttag aataccacct actggacaga acaatttttg 1260
 tactcacaaa cactgccatt ttcttagaga tggcttgaga ggagtaacac tatggtttaa 1320
 agcttgcagt aaaaatgcca aacactgttag taccttgaa cccagtttat tcttgcata 1380
 agcagaactg taaaatgtttt aaaaatgtctt atcaagtaat tcgcccatta caaagacacc 1440
 atttgtttt tatttcattc ttgttttaa ctcatgtgtt agtgcataat tatactttct 1500
 gatcaaacag gttcaagta aaacgtttaa ttccacatctt cttttaaaga actctttaaag 1560
 tgtaacagtt acgcataact tcataagtgg taaagaaagg tataaaattt gaaaacattt 1620
 tggggcat agtagtgatt gggtaaaaag gataaattat atcaaaatga gaatgtgctg 1680
 taatttggaaag tagggagcta aaggatgttt ctccatgtt agtgcatactg gaacgtttta 1740
 ctattaaaca tggcttttat aatgcatacg tccataattt ttattcactg ttagtattta 1800
 attcaactgtc agcttattaa ttgtttctgt acccattaat gaattttaaa ttacmaaaaa 1860
 ttgtctwgca gctacagttt aaaaatgaaa ctagacatca aaataaaattt gataattttt 1920
 tttaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1969

<210> 8

<211> 74

<212> PRT

<213> Homo sapiens

<400> 8

Met	Phe	Asp	Ile	Lys	Ala	Trp	Ala	Glu	Tyr	Val	Val	Glu	Trp	Ala	Ala
1															15

Lys	Asp	Pro	Tyr	Gly	Phe	Leu	Thr	Val	Ile	Leu	Ala	Leu	Thr	Pro
														20
														30

Leu	Phe	Leu	Ala	Ser	Ala	Val	Leu	Ser	Trp	Lys	Leu	Ala	Lys	Met	Ile
														35	45

Glu	Ala	Arg	Glu	Lys	Glu	Gln	Lys	Lys	Lys	Gln	Lys	Arg	Gln	Glu	Asn
														50	55
															60

Ile	Ala	Lys	Ala	Lys	Arg	Leu	Lys	Lys	Asp
									65
									70

<210> 9

<211> 819

<212> DNA

<213> Homo sapiens

<400> 9

tgacttttta	tatatatctc	agaggcaaac	attcctagtg	aagggttgtt	ttcttcttgc	60
accttggagg	ggtctttca	tctgctcagg	caccttcgca	tccccgtgga	tcagggctca	120
gagcagagga	gagtcaagcag	tctctaaatt	atcatcatct	cctacctgca	catgtacaca	180
aaaataagcc	tgaatgtttt	ttctttagtat	gcaatttgct	gtctattnntt	aacttgcata	240
cagagggcca	aaaagaaaaat	tccatgagga	catgagagtg	cattgaggtt	gcaggtatac	300
agtcaccaaa	gaacctgaaa	taattgcccgg	aatgataatcc	tctaaaagat	gtgagcctct	360
cagagagaga	gagagagggt	tcccttgcata	acaggcatcg	tgtgtgtgtt	ttatgtccct	420
tctcttctgc	tgctgtgcac	ttaattcggt	tcagggagac	tcgagaaaaaa		480

aatcccacca taaaagacat gctttttgtt ttttcaatct gtgaccccg caatctttt 540
 agcaaggccat ggttcagtga actggcacac aycagccgtt cggcagtggaa aaaaatcata 600
 aaacagatgg aagcttaca tttttttta gtttttaaga gcagttttta taacatcgct 650
 taagaccatt ctgatgcata atactgttttta cactcaaagc ttgttagctta agatgtttac 720
 agtatggaga atgttttaag atatttataa gttttgatat ttagataatt ggcaaaaaaaaaa 780
 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 819

<210> 10
 <211> 89
 <212> PRT
 <213> Homo sapiens

<400> 10
 Met Ile Ser Ser Lys Arg Cys Glu Pro Leu Arg Glu Arg Gly
 1 5 10 15

Phe Leu Leu Gln Gln Ala Ser Cys Val Cys Phe Met Ser Leu Leu Phe
 20 25 30

Cys Cys Cys Ala Leu Asn Ser Val Pro Ala Val Ser Gly Arg Leu Glu
 35 40 45

Lys Lys Ile Pro Pro Leu Lys Thr Cys Ser Leu Phe Phe Gln Ser Val
 50 55 60

Thr Pro Ala Ile Ser Leu Ala Ser His Gly Ser Val Asn Trp His Thr
 65 70 75 80

Ala Ala Val Arg Gln Trp Lys Lys Ser
 85

<210> 11
 <211> 1969
 <212> DNA
 <213> Homo sapiens

<400> 11
 acactccatc tccccggagc aaggggaaac tccgagagga gggcaacaga gccagcatct 60
 tgccaggggcc ccggaggagg ggttccccgc tacgcctgtt cccggaggagt tccagtcacc 120
 gagcggagggg cgcaagggtt ggtgcatactt ggcgtgcggc gggcgcgctt cccagacgct 180
 ggtgtgcaga gccacatgaa gcttgcgtgg gactgggggc cagggagcag caagccagct 240
 gggactgagg cggacgcgtt ctcagggaga cgctgactcg caaagacact cccttccttg 300
 tgcctgggtt aaaagtctcc tccctgggtt cctggccatc ctgaatatcc agaatgggtt 360
 ttctgaagtt ctctgcata gttttcttctt gccacctgtt tcaaggctac ttgcgtggcc 420
 ccctctaccc agagatgtcc aatgggactc tgcaccaactt cttcgatggcc gatggggact 480
 atgaggagaa cgtatgacccc gagaagtgcc agctgcgtttt cagggtgagt gaccacaggg 540
 gctgtccca gggggaggggg agccagggtt gcagcctgtt gagecctcacc ctgcggggagg 600
 agttcacccgt gctggggccgc caggtggagg atgctggggc cgtgctggag ggcacatcagca 660
 aaagcatctc ctacgaccta gacggggaaag agagatctgg caagttactt cggcggggagt 720
 cccaccagat cggggatgcc tactccaact cggacaaatc cctcacttgag ctggagagca 780
 agttcaagca gggccaggaa caggacagcc ggcaggagag caggctcaac gaggactttc 840
 tgggaatgtt ggtccacacc agttccctgc tgaaggagac actggacatc tctgtggggc 900
 tcagggacaa atacgagctg ctggccctca ccattaggag ccattgggacc cggacttaggtc 960
 ggctgaaaaaa tgattatctt aaagtatagg tggaggata caaatgttag aaagagggaa 1020
 tcaaattcagc cccgttttgg aggggggggg acagaagatg gggctacatt tccccccatac 1080
 ctactatttt ttatataccc gattgcact ttgagaatac atctaaggtc atctttcaaa 1140
 agagaaaaat tggacacttg agtgcatttg ttttttagttt tgtttttgta cattatttat 1200
 gtgattgtta tggattgtc acctggaaaag aacaatttttta agcaatgtca tttcttagatg 1260
 gttttctaat tctgcagaga cacccgtttc agccacatct aaaaagacac agtttatgtg 1320

gtgcggatt aaactcccc atcctgcaga ttatgtggaa atacccaaag ataatagtgc 1380
 atagctcctt tcagcctcta gccttcactc ctgggctcca aaagctatcc cagttgcctg 1440
 ttttcaaat gaggttcaag gtgctgttt gcatgcctgc caacccatgg aagttgtttc 1500
 ttacttcttt tctcttttat ttattaacca tggtctgaga gttgttttg ttctatgtaa 1560
 cagtattgcc aaaaaactat aggcaaatcg tggggcagg gagatttctg atgccttgt 1620
 gggtgtgtgt aagttaaagt ggccacatcc aagaaggcca agctttagt gttgtgcaca 1680
 gtcacactga tatgctgatt tgctctttctt catgtatgt ctatgttttgc tcatcagtgc 1740
 tatagttaaat tacaaaagaaa taggttagatt gtatgaacat acccacaaat gcctatgatt 1800
 taggttacca atgtattctt tctctttgg ggtttgcctt ctgtctgtctt gtttatttgg 1860
 aacttgtact tcaaggtaggg ggaatccctaa ttcttaataac tccttagcta agtttttatta 1920
 ttcaggcaat aaacatgttt tcatgtaaaaa aaaaaaaaaa aaaaaaaaaa 1969

<210> 12
<211> 211
<212> PRT
<213> Homo sapiens

<400> 12
Met Val Phe Leu Lys Phe Phe Cys Met Ser Phe Phe Cys His Leu Cys
1 5 10 15

Gln Gly Tyr Phe Asp Gly Pro Leu Tyr Pro Glu Met Ser Asn Gly Thr
20 25 30

Leu His His Tyr Phe Val Pro Asp Gly Asp Tyr Glu Glu Asn Asp Asp
35 40 45

Pro Glu Lys Cys Gln Leu Leu Phe Arg Val Ser Asp His Arg Arg Cys
50 55 60

Ser Gln Gly Glu Gly Ser Gln Val Gly Ser Leu Leu Ser Leu Thr Leu
65 70 75 80

Arg Glu Glu Phe Thr Val Leu Gly Arg Gln Val Glu Asp Ala Gly Arg
85 90 95

Val Leu Glu Gly Ile Ser Lys Ser Ile Ser Tyr Asp Leu Asp Gly Glu
100 105 110

Glu Ser Tyr Gly Lys Tyr Leu Arg Arg Glu Ser His Gln Ile Gly Asp
115 120 125

Ala Tyr Ser Asn Ser Asp Lys Ser Leu Thr Glu Leu Glu Ser Lys Phe
130 135 140

Lys Gln Gly Gln Glu Gln Asp Ser Arg Gln Glu Ser Arg Leu Asn Glu
145 150 155 160

Asp Phe Leu Gly Met Leu Val His Thr Arg Ser Leu Leu Lys Glu Thr
165 170 175

Leu Asp Ile Ser Val Gly Leu Arg Asp Lys Tyr Glu Leu Leu Ala Leu
180 185 190

Thr Ile Arg Ser His Gly Thr Arg Leu Gly Arg Leu Lys Asn Asp Tyr
195 200 205

Leu Lys Val
210

<210> 13
<211> 2020
<212> DNA
<213> Homo sapiens

<400> 13
ggccggaggg gcagtccgccc gcgggggcga gcgcgcatgc gccttcctgg gacccacggc 60
aggcgcgaat cccaaacggcc ggccgggcgc gggataactt ctacatagac ataatcaagt 120
tttgcattt tggaaaccacaa gcatcattaa aattctctca aactctaat tgcaagaat 180
ccataacatt tcaagaagtg ataaacatttc tctgaacaag aaaagaagtg attgaccacg 240
ttttaaaagt actctggcac tggtgctgtg ttttcttccc ctccctaaat ttgaagaact 300
atggagaaaat ggtacttgtat gacagtagtg gtttaatag gactaacagt acgatggaca 360
gtgtctctta attcttattc aggtgctgtt aaaccgccta tgtttgta ttatgaagct 420
cagagacact ggcagaat aacttttaat ttaccggcata aacaatggta tttaacagc 480
agtgataaca atttacagta ttggggattt gattaccac ctcttacagc ttatcatagt 540
ctccatgttgc catatgttgc aaagtttata aatccagact ggattgtct ccatacatca 600
cgtggatatg agagtcaaggc acataagctc ttcatgcgtt caacagttt aattgtctgtat 660
ctgctgattt acataacctgc agtggtttt tactgttgtt gcttaaaga aatctcaact 720
aagaaaaaga ttgctaatttgc attatgcattc ttgctgtatc caggcattt tcttataagac 780
tatggacatt ttcaatataa ttctgtgagt ttggctttt ctttgtggg ttgttcttggg 840
atatcttgc actgcgaccc cctagggtca ctggcatttt gcttagctat aaattataaa 900
cagatggaaac tttaccacgc ctggccattt ttttgcattt tacttggcaa gtgtttaaa 960
aaaggcctca aaggaaaggg gtttgcgtkg ctgttaage tagctkgtat ttgtgtggct 1020
tccttcgttc tctgctggctt gccattttt acagaaaggg aacaaccctt gcagggttcta 1080
agaagactct tccccgggtga tcgtggatta tttgaggata aagtagccaa tattttggc 1140
agcttcaatg tttttctgaa gattaaggat attttgcac gtcacatcca attaataatg 1200
agcttttgtt ttacgtttt gagcctgtt cctgcatttca taaaattaat acttcagccc 1260
tcttccaaag gattcaatt tacactgggtt agctgtgcgca tatcattttt tttatttctt 1320
ttccaagttac atgaaaaatc catttttttgcgttactac cagtcgttgcgtt agtttaagt 1380
gaaattccctt ttatgttctac ttggtttttca cttgtgttcaat catttagtat gctaccttctt 1440
ctatttgcagg atgaacttctt aatggccctt gttgtgacaa caatggcatt ttttataatg 1500
tgtgttaactt cctttcaat atttgaaaag acttcttgcag aagaactgtca gttgaaatcc 1560
ttttccattt ctgtgaggaa atatcttca tttttwacat ttcttccag aattawacaa 1620
tattttgttcc ttatcttgcgtt catcaactatg gtgtttcttgc cgttgcgttgc ttttgcactg 1680
gatccttcctc agaaactacc ggacttgcgtt tctgttattgg ttttgcgttgc ttttgcactg 1740
aacttcctgt tcttcttgcgtt atacttttac attatttttca ttttgcgttgc ttttgcactg 1800
agaaatcaga agaaatcaga ctgtgtat ttcttgcgtt aatgttttgcgtt aacaaatgt 1860
gaaaatgtga acgtgttgcgtt aagtttttgcgtt ttttgcgttgc ttttgcactg 1920
cattttgcgtt accatggaaac cacaggaaag gaaatggcgtt aatgttgcgtt ttttgcactg 1980
maaataatg tatatggaga ccaaaaaaaaaaaaaaaa 2020

<210> 14
<211> 507
<212> PRT
<213> Homo sapiens

<220>
<221> UNSURE
<222> (230)

<220>
<221> UNSURE
<222> (236)

<220>
<221> UNSURE
<222> (432)

<220>

<221> UNSURE
 <222> (439)

<220>
 <221> UNSURE
 <222> (476)

<400> 14
 Met Glu Lys Trp Tyr Leu Met Thr Val Val Val Leu Ile Gly Leu Thr
 1 5 10 15
 Val Arg Trp Thr Val Ser Leu Asn Ser Tyr Ser Gly Ala Gly Lys Pro
 20 25 30
 Pro Met Phe Gly Asp Tyr Glu Ala Gln Arg His Trp Gln Glu Ile Thr
 35 40 45
 Phe Asn Leu Pro Val Lys Gln Trp Tyr Phe Asn Ser Ser Asp Asn Asn
 50 55 60
 Leu Gln Tyr Trp Gly Leu Asp Tyr Pro Pro Leu Thr Ala Tyr His Ser
 65 70 75 80
 Leu Leu Cys Ala Tyr Val Ala Lys Phe Ile Asn Pro Asp Trp Ile Ala
 85 90 95
 Leu His Thr Ser Arg Gly Tyr Glu Ser Gln Ala His Lys Leu Phe Met
 100 105 110
 Arg Thr Thr Val Leu Ile Ala Asp Leu Leu Ile Tyr Ile Pro Ala Val
 115 120 125
 Val Leu Tyr Cys Cys Cys Leu Lys Glu Ile Ser Thr Lys Lys Lys Ile
 130 135 140
 Ala Asn Ala Leu Cys Ile Leu Leu Tyr Pro Gly Leu Ile Leu Ile Asp
 145 150 155 160
 Tyr Gly His Phe Gln Tyr Asn Ser Val Ser Leu Gly Phe Ala Leu Trp
 165 170 175
 Gly Val Leu Gly Ile Ser Cys Asp Cys Asp Leu Leu Gly Ser Leu Ala
 180 185 190
 Phe Cys Leu Ala Ile Asn Tyr Lys Gln Met Glu Leu Tyr His Ala Leu
 195 200 205
 Pro Phe Phe Cys Phe Leu Leu Gly Lys Cys Phe Lys Lys Gly Leu Lys
 210 215 220
 Gly Lys Gly Phe Val Xaa Leu Val Lys Leu Ala Xaa Ile Val Val Ala
 225 230 235 240
 Ser Phe Val Leu Cys Trp Leu Pro Phe Phe Thr Glu Arg Glu Gln Thr
 245 250 255
 Leu Gln Val Leu Arg Arg Leu Phe Pro Val Asp Arg Gly Leu Phe Glu
 260 265 270
 Asp Lys Val Ala Asn Ile Trp Cys Ser Phe Asn Val Phe Leu Lys Ile

275	280	285
Lys Asp Ile Leu Pro Arg His Ile Gln Leu Ile Met Ser Phe Cys Phe		
290	295	300
Thr Phe Leu Ser Leu Leu Pro Ala Cys Ile Lys Leu Ile Leu Gln Pro		
305	310	315
Ser Ser Lys Gly Phe Lys Phe Thr Leu Val Ser Cys Ala Leu Ser Phe		
325	330	335
Phe Leu Phe Ser Phe Gln Val His Glu Lys Ser Ile Leu Leu Val Ser		
340	345	350
Leu Pro Val Cys Leu Val Leu Ser Glu Ile Pro Phe Met Ser Thr Trp		
355	360	365
Phe Leu Leu Val Ser Thr Phe Ser Met Leu Pro Leu Leu Leu Lys Asp		
370	375	380
Glu Leu Leu Met Pro Ser Val Val Thr Thr Met Ala Phe Phe Ile Ala		
385	390	395
Cys Val Thr Ser Phe Ser Ile Phe Glu Lys Thr Ser Glu Glu Glu Leu		
405	410	415
Gin Leu Lys Ser Phe Ser Ile Ser Val Arg Lys Tyr Leu Pro Cys Xaa		
420	425	430
Thr Phe Leu Ser Arg Ile Xaa Gln Tyr Leu Phe Leu Ile Ser Val Ile		
435	440	445
Thr Met Val Leu Leu Thr Leu Met Thr Val Thr Leu Asp Pro Pro Gln		
450	455	460
Lys Leu Pro Asp Leu Phe Ser Val Leu Val Cys Xaa Val Ser Cys Leu		
465	470	475
Asn Phe Leu Phe Phe Leu Val Tyr Phe Asn Ile Ile Ile Met Trp Asp		
485	490	495
Ser Lys Ser Gly Arg Asn Gln Lys Lys Ile Ser		
500	505	

<210> 15
<211> 940
<212> DNA
<213> Homo sapiens

<400> 15
gtttggaggt gcttgcccta gagcaaggga aacagctctc attcaaagga actagaagcc 60
tctccctcag tggtagggag acagccagga gcggtttctt gggactgtg ggatgtgcc 120
ttggggggccc gagaaaacag aaggaagatg ctccagacca gtaactacag cctggtgctc 180
tctctgcagt tcctgtgtc gtcttatgac ctctttgtca attcccttc agaactgtctc 240
caaaaagactc ctgtcatcca gcttgtgtc ttcatcatcc aggatattgc agtctcttcc 300
aacatcatca tcattttctt catgttttcc aacacccctcg tcttccaggc tggcctggtc 360
aacctcttat tccataagtt caaaggacc atcatactgaa cagctgtgta ctgtccctc 420
agcatctccc ttcatgtctg ggtcatgaac ttacgctgaa aaaactccaa cagtttcata 480
tggacagatg gacttcaa at gctgtttgta ttccagagac tagttggac cgaattctaa 540

tttttcttga ctacaagtct tcaaaataat gttttcattt tttttttctt ttttccatTTT 600
 ttttccaatt tggagtcact gaaaactaag ctgtgtttc ataaaggccc gcaaactgaa 660
 tctagacaac ttccagaagaa aaataaacgc aacctattt catacataag ccactttcat 720
 acctgcctac cgatgtatgg acttcagagt aatgtggctt atagaattt tccaggattg 780
 ttcttttgtt tgTTtgttctt ctccttctt cccccctattt tgtctttatg ggacatgaca 840
 cttcacaacc ttctaaaaat gagttttctt aataactcg gacctactcg tctagaaata 900
 aaccatcsta gccatgagag ataagataaa aaaaaaaaaa 940

<210> 16
 <211> 130
 <212> PRT
 <213> Homo sapiens

<400> 16
 Met Leu Gln Thr Ser Asn Tyr Ser Leu Val Leu Ser Leu Gln Phe Leu
 1 5 10 15

Leu Leu Ser Tyr Asp Leu Phe Val Asn Ser Phe Ser Glu Leu Leu Gln
 20 25 30

Lys Thr Pro Val Ile Gln Leu Val Leu Phe Ile Ile Gin Asp Ile Ala
 35 40 45

Val Leu Phe Asn Ile Ile Ile Phe Leu Met Phe Phe Asn Thr Phe
 50 55 60

Val Phe Gln Ala Gly Leu Val Asn Leu Leu Phe His Lys Phe Lys Gly
 65 70 75 80

Thr Ile Ile Leu Thr Ala Val Tyr Phe Ala Leu Ser Ile Ser Leu His
 85 90 95

Val Trp Val Met Asn Leu Arg Trp Lys Asn Ser Asn Ser Phe Ile Trp
 100 105 110

Thr Asp Gly Leu Gln Met Leu Phe Val Phe Gln Arg Leu Val Trp Thr
 115 120 125

Glu Phe
 130

<210> 17
 <211> 1348
 <212> DNA
 <213> Homo sapiens

<400> 17
 gctgcttgca ggaattcaac atcatggaaa agaataaagg atgggtctc ctggggaggaa 60
 aagatggcca tcttcagggc ctatTTctcc ttgcacgc attgtggaa agaaatcagc 120
 tccttgcaca gaaggtcatg tacttattag tcccttctt taaccgaggg aatgataaac 180
 ataaactcac atctgcaggg tttttgtgg agtttctccg gagtcagtg gccaagagac 240
 tgcccagcat atactctgtt gcccgctta aagactggc acaagatgaa aatcatctc 300
 ttagaattctt cggcctgagg ggactgtaca atcttgggg acaccaggag atgagagaag 360
 acatcaagag cctgttgcca tacattgttag acagcttgcg tgaaaccgt gagaagatcg 420
 ttctgtcago catccagata ctctgcac ttgtttagaaac aatggatttc actaccctgg 480
 ctgccatgat gaggaccctg ttctccttat ttgtgtatgt gagatctgat gtcatcgat 540
 tctccgtgac tctcttgaa gcccgcataa agtctgtaaa aaaccgat aagaagatg 600
 tagagaacca agtcctggac agcttggcc cactacttct gtattctcg gatgaaaatg 660
 atgcagtagc tgaggagagc aggcaagtcc taactataatg tgcccagtcc ctgaagtgg 720

agctgccccca agaagtgtac tccaaagatc cctggcacat caaacctact gaagcaggaa 780
 caatctgcag attcttgc aaagaatgtca aggggaaaat taacatccta gacacaacac 840
 tgatgtactc caagaaccca aaacttccc tcagaagatc agcagtcttg ttgttaggcc 900
 ttttatcgaa gtacatggat cacaatgagc tcaggaggat gggtaactgac tgatagagg 960
 acgatctgag agacctgctg tgtgaccctg agccctcgct gtgcatacgc gcttcccaga 1020
 ctctgttact agtccagatg gcgaggccg aaccaaaaacc taagcagaga gtgaactgg 1080
 tgcagaagct catggccagg tcctctgcct agaaacacaa ggcaagcaac atcagagaca 1140
 gaatcttgcg atgttgcg gcaagctgt cttgaactca tggcctcaag tcatccttc 1200
 gtgtcagcc cccaaagtgc tggattaca agcatgcacc acggcacca gcagaattcc 1260
 agtcttgaga aacaggtcaa ggacagctc aaaagagatt ctaaataaat gttaatgtta 1320
 caatgttaaa aaaaaaaaaaaaaaaa 1348

<210> 18
<211> 362
<212> PRT
<213> Homo sapiens

<400> 18
Met Glu Lys Asn Lys Gly Trp Ala Leu Leu Gly Gly Lys Asp Gly His
1 5 10 15
Leu Gln Gly Leu Phe Leu Leu Ala Asn Ala Leu Leu Glu Arg Asn Gln
20 25 30
Leu Leu Ala Gln Lys Val Met Tyr Leu Leu Val Pro Leu Leu Asn Arg
35 40 45
Gly Asn Asp Lys His Lys Leu Thr Ser Ala Gly Phe Phe Val Glu Leu
50 55 60
Leu Arg Ser Pro Val Ala Lys Arg Leu Pro Ser Ile Tyr Ser Val Ala
65 70 75 80
Arg Phe Lys Asp Trp Leu Gln Asp Gly Asn His Leu Phe Arg Ile Leu
85 90 95
Gly Leu Arg Gly Leu Tyr Asn Leu Val Gly His Gln Glu Met Arg Glu
100 105 110
Asp Ile Lys Ser Leu Leu Pro Tyr Ile Val Asp Ser Leu Arg Glu Thr
115 120 125
Asp Glu Lys Ile Val Leu Ser Ala Ile Gln Ile Leu Leu Gln Leu Val
130 135 140
Arg Thr Met Asp Phe Thr Thr Leu Ala Ala Met Met Arg Thr Leu Phe
145 150 155 160
Ser Leu Phe Gly Asp Val Arg Ser Asp Val His Arg Phe Ser Val Thr
165 170 175
Leu Phe Gly Ala Ala Ile Lys Ser Val Lys Asn Pro Asp Lys Lys Ser
180 185 190
Ile Glu Asn Gln Val Leu Asp Ser Leu Val Pro Leu Leu Tyr Ser
195 200 205
Gln Asp Glu Asn Asp Ala Val Ala Glu Glu Ser Arg Gln Val Leu Thr
210 215 220

Ile Cys Ala Gln Phe Leu Lys Trp Lys Leu Pro Gln Glu Val Tyr Ser
 225 230 235 240

Lys Asp Pro Trp His Ile Lys Pro Thr Glu Ala Gly Thr Ile Cys Arg
 245 250 255

Phe Phe Glu Lys Lys Cys Lys Gly Lys Ile Asn Ile Leu Glu Gln Thr
 260 265 270

Leu Met Tyr Ser Lys Asn Pro Lys Leu Pro Ile Arg Arg Ser Ala Val
 275 280 285

Leu Phe Val Gly Leu Leu Ser Lys Tyr Met Asp His Asn Glu Leu Arg
 290 295 300

Arg Met Gly Thr Asp Trp Ile Glu Asp Asp Leu Arg Asp Leu Leu Cys
 305 310 315 320

Asp Pro Glu Pro Ser Leu Cys Ile Ile Ala Ser Gln Thr Leu Leu Leu
 325 330 335

Val Gln Met Ala Arg Ala Glu Pro Lys Pro Lys Gln Arg Val Asn Trp
 340 345 350

Leu Gln Lys Leu Met Gly Arg Ser Ser Ala
 355 360

<210> 19
<211> 1656
<212> DNA
<213> Homo sapiens

<400> 19

cttctccac cctcgctcgc gtagccatgg cgagccgtc ggccggccact cagtcccatt 60
 ccattcttcgcttc gtcgtcccttc ggagccgagc cgtccgcgcc cggccggccgc gggagcccaag 120
 gagccctgcgc cgcctgggg acgaagagct gcagcttcgc ctgtcggtg cacatctga 180
 ttttctggag agatgtgaag aagactgggt ttgtcttttg caccacgctg atcatgctgc 240
 tttccctggc agctttcagt gtcatcgtg tggtttctta cctcatcctg gctttctct 300
 ctgtcaccat cagcttcagg atctacaagt ccgtcatcca agctgtacag aagtcaagaag 360
 aaggccatcc attcaaagcc tacctggacg tagacattac tctgtcctca gaagctttcc 420
 ataattacat gaatgtgcc atggcaca tcaacagggc cctgaaactc attattcgtc 480
 tctttctggt agaagatctg gttgactcct tgaagctggc tgccttcatg tggctgatga 540
 cctatgttgg tgctgtttt aacggaatca cccttctaatt ctttgcgtaa ctgctcattt 600
 tcagtgtccc gattgtctat gagaagtaca agacccagat tgatcactat gttggcatcg 660
 cccgagatca gaccaagtca atttgtaaa agatccaagc aaaactccct ggaatcgcca 720
 aaaaaaaaggc agaataagta catggaaacc agaaaatgcaaa cagttactaa aacaccattt 780
 aatagtata acgtcggttac ttgtactatg aaggaaaata ctcagtgtca gtttgagcc 840
 gcattccaag cttttttttt taatttggtg ttttctccca tcctttccct ttaaccctca 900
 gtatcaagca caaaaattga tggactgata aaagaactat cttagaactc agaagaagaa 960
 agaatcaaatt tcataggata agtcaatacc ttaatggtg tagaggccctt acctgttagct 1020
 tgaaaaggga aagattggag gtaagagaga aaatgaaaaga acacctctgg gtccttctgt 1080
 ccagtttca gcactagtct tactcagcta tccattatag ttttgcctt aagaagtcat 1140
 gattaactta tgaaaaattt atttgggac aggagtgtga taccttcctt ggtttttttt 1200
 tgcagcccttc aaatccatc ttctcgcccc acaatgtgag cagctacccc tgataactcct 1260
 tttctttaat gatttaacta tcaactttagt aaataactta taggtgatag tgataattcc 1320
 tgattccaag aatgccatct gataaaaaag aatagaaaatg gaaagtggga ctgagaggg 1380
 gtcagcaggc atgctgcgtt ggccgtcaact ccctctgcca ctatccccag ggaaggaaag 1440
 gctccgcccatttggggaaagt ggtttctacg tcaactggaca ccggttctga gcatctttt 1500
 gagaactcgt tcccgaatgt gctttccctcc ctctccctg cccaccccaa gtttaataaa 1560

taagggttgcataaaaaataaaatgtctgtaaatgcaaaaaaaaaaaaaaaaaaaaaaa 1620
 aaa 1656

<210> 20
 <211> 236
 <212> PRT
 <213> Homo sapiens

<400> 20
 Met Ala Glu Pro Ser Ala Ala Thr Gln Ser His Ser Ile Ser Ser Ser
 1 5 10 15

Ser Phe Gly Ala Glu Pro Ser Ala Pro Gly Gly Gly Ser Pro Gly
 20 25 30

Ala Cys Pro Ala Leu Gly Thr Lys Ser Cys Ser Ser Cys Ala Val
 35 40 45

His Asp Leu Ile Phe Trp Arg Asp Val Lys Lys Thr Gly Phe Val Phe
 50 55 60

Gly Thr Thr Leu Ile Met Leu Leu Ser Leu Ala Ala Phe Ser Val Ile
 65 70 75 80

Ser Val Val Ser Tyr Leu Ile Leu Ala Leu Leu Ser Val Thr Ile Ser
 85 90 95

Phe Arg Ile Tyr Lys Ser Val Ile Gln Ala Val Gln Lys Ser Glu Glu
 100 105 110

Gly His Pro Phe Lys Ala Tyr Leu Asp Val Asp Ile Thr Leu Ser Ser
 115 120 125

Glu Ala Phe His Asn Tyr Met Asn Ala Ala Met Val His Ile Asn Arg
 130 135 140

Aia Leu Lys Leu Ile Ile Arg Leu Phe Leu Val Glu Asp Leu Val Asp
 145 150 155 160

Ser Leu Lys Leu Ala Val Phe Met Trp Leu Met Thr Tyr Val Gly Ala
 165 170 175

Val Phe Asn Gly Ile Thr Leu Leu Ile Leu Ala Glu Leu Leu Ile Phe
 180 185 190

Ser Val Pro Ile Val Tyr Glu Lys Tyr Lys Thr Gln Ile Asp His Tyr
 195 200 205

Val Gly Ile Ala Arg Asp Gln Thr Lys Ser Ile Val Glu Lys Ile Gln
 210 215 220

Ala Lys Leu Pro Gly Ile Ala Lys Lys Lys Ala Glu
 225 230 235

<210> 21
 <211> 29
 <212> DNA
 <213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoaramidite residue

<400> 21
antgacttca gttgaggggca agtctctgg 29

<210> 22
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoaramidite residue

<400> 22
tnccagaaaga ctgcaggat tcgggacaa 29

<210> 23
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoaramidite residue

<400> 23
antcatcaact acacgttcttc tccccata 29

<210> 24
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoaramidite residue

<400> 24
gnctgagtat gtttgtggaat gggctgcaa 29

<210> 25

<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoamidite residue

<400> 25
tngtgactgt atacctgcaa cctcaatgc 29

<210> 26
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoamidite residue

<400> 26
tngccttgac acaggtggca gaagaaaact 29

<210> 27
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoamidite residue

<400> 27
cnngactggta gtgacacccaa gagaatgg 29

<210> 28
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoamidite residue

<400> 28	
anagcacage ttatgtttca gtgactcca	29
<210> 29	
<211> 20	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> oligonucleotide	
<400> 29	
gcataatactc tggcccccgc	20
<210> 30	
<211> 18	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> oligonucleotide	
<400> 30	
cggccactat ccccgagg	18
<210> 31	
<211> 29	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> oligonucleotide	
<220>	
<221> misc_feature	
<222> (2)	
<223> biotinylated phosphoaramidite residue	
<400> 31	
antgggtgtgc cactcccaac aatctttcc	29
<210> 32	
<211> 2505	
<212> DNA	
<213> Homo sapiens	
<400> 32	
ccagctcccc actgcccgtga gggcgccgcg gcctgcggcg gagggaaaaaa ggaagaggag 60	
aaggaaaatttgc tccccaaatcc ctgcagggtca gtacctggaa gattccataa agtcgggggtg 120	
cttgagggggg tagggccgg accgtcgccgg gtactcgagc gcctccgtcg tcttccat 180	
tccgcggcccg ctttccaaaga cataatgtccc gcttgcagcc catttcgtat ctgcgaaaacg 240	
gtgagctcgccgg ggggttttgg ggaagagctc agagactggg aaatgggaat ctgctggggag 300	
cctaggggccg caatccggaa agggagctgt ggccctgggtt ttggccctta gtccaccagg 360	
acagtgcggg aggggaatgg ctggatatgg gggcgccgggtt ggtgagatgc aacgcgatata 420	
gtcagcagaa ccccaagaga ggtaataggg gtggggaaacc tctgacaacc aggccctccga 480	
attagaaaaag agttttgtgt tctggggact agtccgtcca ccaagcgctc agtggccggca 540	
gtttcccggtc ttctgcgttgc tggctgtgtt tttactgacca tggctctgtg tcttagtgggt 600	
ccaaaggctct cccgggtggc cagtctttctt gtagggtgcg gcacaacgcc aggcaaaaaga 660	
agaggaagga atttaatcc aatcggttggaa ggtcgattttgg agggctgtctt gtagcagggtg 720	
gctcccgcttgc aagcgaggga ggaagtttcc tccgatcagt agagatttggaa aagattttgg 780	

ggagtggcac accactaggg aaaagaagaa ggggcgaact gcttgtcttg aggaggtcaa 840
cccccagaat cagctcttgt ggctctgaag tggctgaaga cgatcacccct ccacaggctt 900
gagcccagtc ccacagccctt cctcccccaag cctgagtgac tactctatttc cttgtccct 960
gttattgtcg gggacgattt catggctac gccaggaaag taggctgggt gaccgcagc 1020
ctggtgattt gggctggcgc ctgtctatttgc atttataagac tgactaggg aaaaaaacag 1080
aacaaggaaa aaatggctga ggggtggatct ggggatgtgg atgtatgttgg ggactgttct 1140
ggggccaggt ataatgactg gtctgtatgat gatgtatgaca gcaatgagag caagagtata 1200
gtatggtacc caccttggc tcggatttggg actgaagctg gaaccagagc tagggccagg 1260
gcaaggggcca gggcttacccg ggcacgtcgg gctgtccaga aacgggccttc ccccaattca 1320
gatgataccg ttttgccttca acaagagctca caaaagggttc tttgttttgt tgagatgtct 1380
gaaaaggcctt atattcttga agcagctta attgtctgtt gtaacaatgc tgcttatgca 1440
tttaacagag atattatttcg tgatctgggt ggtctcccaa ttgtcgcaaa gattctcaat 1500
actcgggatc ccatagtttaa gggaaaggct ttaattgtcc tgaataactt gagtgtgaat 1560
gctgaaaatc agcgcagggct taaagtatac atgaatcaag tgtgtgtatga cacaatcaact 1620
tctcgcttga actcatctgt gcagcttgct ggactgagat tgcttacaaa tatgactgtt 1680
actaatgagt atcagcacat gcttgcataat tccattttctg actttttctg ttttatttca 1740
gcggggaaatg aagaaaaccaa acttcagggtt ctgaaaactcc ttttgaattt ggctgaaaat 1800
ccagccatga cttagggact gctcagggcc caagtaccat cttcaactggg ctccctctt 1860
aataagaagg agaacaacaaaga agttatttctt aaacttctgg tcatatttga gaacataaaat 1920
gataatttca aatgggaaga aaatgaacct actcagaatc aattcggtga aggttcactt 1980
tttttcttt taaaagaatt tcaagtgtgt gctgataagg ttctggaaat agaaagtcac 2040
catgattttt tggtgaaaagt aaaagtttga aaattcatgg ccaaacttgc tgaacatatg 2100
ttcccaaaga gccaggaata acaccttgcat ttgttaattt agaagcaaca cacattgtaa 2160
actatttcatt ttctccacat ttgtttatatg gtaaaggaaat ctttcagct gccagttttg 2220
aataatgaat atcatatttgc atcatcaatg ctgatattta actgagttgg ttcttaggtt 2280
taagatggat aaatgaatatacactactgt tctgaaaaca tgtttgtgc tttttatctc 2340
gctgcctaga ttgaaatattt ttgtcttgcataa gtgacagtga accaattcat 2400
catgagtaag ctcccttcgt tcattttcat tgatttaattt tggttatcat caataaaaatt 2460
gtatgttaat gctggaaaga aaaaaaaaaa aaaaaaaaaa aaaaa 2505

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/25149

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :Please See Extra Sheet.

US CL :Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/69.1, 252.3, 320.1, 91.1, 91.2; 536/23.1, 23.5, 24.31; 530/350; 514/12

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
none

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Dialog and APS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Database EMBL/GenBank, Isolation and Characterization of a cDNA Encoding a Synaptonemal Complex Protein. Accessions A56822; S20742. Biochem. Cell Biol., 1992, Vol. 70, pages 1030-1038, Chen et al. 10-September-1997, see entire document.	1-15
Y	CHEN et al. Isolation and Characterization of a cDNA Encoding a Synaptonemal Complex Protein. Biochem. Cell Biol. (1992) Vol. 70, pages 1030-1038, see entire document.	1-15

Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:	*T*	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means		
"P" document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search	Date of mailing of the international search report
01 FEBRUARY 1999	08 MAR 1999

Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231	Authorized officer ENRIQUE D. LONGTON
Faximile No. 703 305-2230	Telephone No. 703 305-0106

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/25149

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos..
1-15

Remark on Protest

The additional search fees were accompanied by the applicant's protest.



No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/25149

A. CLASSIFICATION OF SUBJECT MATTER:

IPC (6):

C07H 21/04, 21/02; C12N 15/11, 15/00, 1/21, 15/63; C07K 14/00; A61K 38/00; C12P 19/34

A. CLASSIFICATION OF SUBJECT MATTER:

US CL :

435/69.1, 252.3, 320.1, 91.1, 91.2; 536/23.1, 23.5, 24.31; 530/350; 514/12

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claim(s) 1-15, drawn to isolated polynucleotides and polypeptides related to or encoding SEQ ID NOS:1 and 2 as well as processes for producing the polynucleotides and polypeptides.

Group II, claim(s) 16-17, drawn to isolated polynucleotides and polypeptides related to or encoding SEQ ID NOS:32 and 4 as well as processes for producing the polynucleotides and polypeptides.

Group III, claim(s) 18-20, drawn to isolated polynucleotides and polypeptides related to or encoding SEQ ID NOS:5 and 6 as well as processes for producing the polynucleotides and polypeptides.

Group IV, claim(s) 21-23, drawn to isolated polynucleotides and polypeptides related to or encoding SEQ ID NOS:7 and 8 as well as processes for producing the polynucleotides and polypeptides.

Group V, claim(s) 24-26, drawn to isolated polynucleotides and polypeptides related to or encoding SEQ ID NOS:9 and 10 as well as processes for producing the polynucleotides and polypeptides.

Group VI, claim(s) 27-29, drawn to isolated polynucleotides and polypeptides related to or encoding SEQ ID NOS:11 and 12 as well as processes for producing the polynucleotides and polypeptides.

Group VII, claim(s) 30-32, drawn to isolated polynucleotides and polypeptides related to or encoding SEQ ID NOS:13 and 14 as well as processes for producing the polynucleotides and polypeptides.

Group VIII, claim(s) 33-35, drawn to isolated polynucleotides and polypeptides related to or encoding SEQ ID NOS:15 and 16 as well as processes for producing the polynucleotides and polypeptides.

Group IX, claim(s) 36-38, drawn to isolated polynucleotides and polypeptides related to or encoding SEQ ID NOS:17 and 18 as well as processes for producing the polynucleotides and polypeptides.

Group X, claim(s) 39-41, drawn to isolated polynucleotides and polypeptides related to or encoding SEQ ID NOS:19 and 20 as well as processes for producing the polynucleotides and polypeptides.

The inventions listed as Groups I-X do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: The claims of each group are directed to separate and distinct polynucleotide and polypeptide sequences structurally unrelated, each to the other. Therefore, the inventions lack the same or corresponding special technical feature.